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Effect of Naphthalan on Epidermal Proliferation Activity and
CD3, CD4, and CD8 Lymphocyte Count
Pero Vrogiæ, Jasminka Jakiæ-Razumoviæ1, Aida Pašiæ2
Naftalan Special Hospital for Medical Rehabilitation, Ivaniæ Grad; 1Department of Pathology
and 2Department of Dermatology and Venerology, Zagreb University Hospital Center,
Zagreb, Croatia
SUMMARY Immunohistochemistry analysis by cell immunopheno-
typing before and after a 3-week treatment with naphthalan oil was
performed on biopsy specimens from 10 patients with psoriasis
vulgaris. For immunohistochemistry staining of 3-µm paraffin block
sections, anti-CD3, anti-CD4, anti-CD8, and Ki-67 antibodies were
used. Peroxidase reaction for T cell (CD3, CD4, and CD8) quantifica-
tion was done in the epidermis and dermis of each skin sample as to-
tal positive cell count per mm sample. Positive Ki-67 (proliferation in-
dex) was determined as percentage of positive cells per 100 cells in
the basal layer of the epidermis. Results showed naphthalan treat-
ment to decrease the mean CD3 lymphocyte count by 83% and 59%,
CD4 lymphocyte count by 81% and 73%, and CD8 lymphocyte count
by 60% and 49% in the epidermis and dermis, respectively. The
mean proliferation index also decreased with naphthalan therapy.
KEY WORDS: baths; dermatologic agents; immunohistochemistry; Ki-67
antigen; psoriasis
INTRODUCTION
Naphthalan, a natural naphthene-based earth
oil, is a thick, dark-brown liquid of a characteristic
aromatic odor. In contrast to other related oils, it has
a high specific weight (0.93-0.97) and mostly con-
tains compounds with stearic structure. Therapeu-
tic properties of naphthalan have been known since
ancient times (1). The antipsoriatic properties of
heavy naphthene oil (Naphthalan®) make the basis
of antipsoriatic treatment regimen that has been
successfully used over the last decade at the
Naftalan Special Hospital, Ivaniæ Grad, Croatia (2).
Vulgar psoriasis is a chronic relapsing skin dis-
ease affecting 1-3% of the total population world-
wide. The disease is characterized by precipitated
epidermopoiesis, with consequential formation of
scales on the skin and scalp and specific nail le-
sions. Psoriatic arthritis develops in 3-5% of psoria-
sis patients (2,3). In Croatia, 1-2% of the population
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is affected with psoriasis, whereas psoriatic pa-
tients account for 6-8% of all patients treated at de-
partments of dermatology (3). Psoriasis shows fa-
milial clustering and affects consecutive genera-
tions.
There is a novel concept in the pathogenesis of
psoriasis, demonstrating the characteristic and well
known psoriasiform epidermal hyperplasia to be a
secondary lesion in the sequence of pathogenetic
events in psoriasis, caused by migration of the in-
flammatory infiltrate cells from the dermis to the epi-
dermis, whereby T-cells (CD8) play an important
role (4,5). On entering the epidermis, these cells
produce substances that stimulate mitotic activity
within the epidermis, thus leading to psoriatic epi-
dermal hyperplasia (4). This concept has drawn at-
tention to the fact that, in addition to the known fac-
tors (genetic and other impacts), certain immune
mechanisms also have an important role in the
development of psoriatic lesion.
NAPHTHALAN – BACKGROUND
Naphthalan has long been known for its medici-
nal properties (1), and many great dermatologists
have recommend its use. In his book “Dermatologic
propedeutics”, in the chapter on ointments, Profes-
sor F. Kogoj, the greatest Croatian dermatologist,
mentions Naphthalan as a medicinal product for the
treatment of squamous dermatoses (6). Russian lit-
erature contains many data from Baku, Azerbaijan,
on the treatment of psoriasis and neurodermatitis
with naphthalan. The physicochemical analyses of
naphthalan found on the Kri oil field near Ivaniæ
Grad have shown it to be identical to naphthalan
from Baku, Azerbaijan, which has been used in the
treatment of vulgar psoriasis from the beginning of
the 20th century. The more so, naphthalan from
Ivaniæ Grad is superior to that from Baku for the
higher level of purification, which can be achieved
by the modern chemical and technological proce-
dures of naphthene oil fractionation at the Industrija
Nafte (INA) – Naftaplin chemistry laboratories (2).
Naphthalan from Ivaniæ Grad contains negligible
concentrations of cyclic compounds and light oil
fractions, which may potentially have unfavorable
toxic or carcinogenic effects.
Naphthalan is classified among so-called heavy
oils because of its high specific weight. It contains
very low concentrations of light benzine, ligroine,
and kerosene fractions, whereas condensed paraf-
fins are only found in traces or not at all. Naphthalan
also differs from other oils by its relatively high con-
centration of naphthene and cyclopentane acids.
Naphthalan oil is characterized by a high percent-
age of naphthene carbohydrates of the cyclopenta-
nohydrophenanthrene structure, the most impor-
tant of them being isoprenes, steranes, and triter-
penes.
Naphthalan therapy as a method of treatment
for vulgar psoriasis is performed in the form of
naphthalan baths. The patient spends 12-14 min
immersed up to the shoulders in the naphthalan
bath at a bath temperature of 34-36C. After the
bath, the patient takes a shower to wash the re-
maining naphthalan off the skin. During the day,
naphthalan cream is locally applied onto psoriatic
lesions for 2 hours. Naphthalan therapy is per-
formed daily, six days a week, for three consecutive
weeks (2).
MATERIAL AND METHODS
Biopsy specimens obtained from skin lesions of
10 patients with psoriasis vulgaris were analyzed
immunohistochemically (cell immunophenotyping)
before and after a 3-week treatment with naphtha-
lan oil. Study group included five women and five
men with psoriasis vulgaris. For immunohistoche-
mical staining of 3-m paraffin block sections, anti-
CD3, anti-CD4, anti-CD8, and Ki-67 antibodies
were used (Dako, Copenhagen, Denmark). Sec-
tions were incubated for 30 min at room tempera-
ture with primary antibody at a proper dilution for
each antibody. After washing, the sections were
stained with biotinylated multi-link (swine, anti-rab-
bit, mouse, and goat immunoglobulin) (Dako) at a
1:1000 dilution, followed by staining with strepta-
vidin-biotin-peroxidase complex (Dako) at a 1:1000
dilution.
Peroxidase reaction was developed with diami-
nobenzidine (DAB) as a chromogen (Dako). The
sections were contras-stained with hematoxylin
and embedded in a synthetic medium (DPX).
T cell (CD3, CD4, and CD8 subsets) quantifica-
tion was done for the epidermis and dermis of each
skin sample as total positive cell count per mm sam-
ple. Positive Ki-67 (proliferation index) was deter-
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mined as a percentage of positive cells per 100
cells in the basal layer of the epidermis.
RESULTS
The mean proliferation index value was 29.4%
(range, 12-47%) and 7.1% (range, 2-16%) before
and after naphthalan treatment, respectively (Fig.
1, Table 1).
The mean CD3 lymphocyte count before
naphthalan treatment was 11.2 (range, 3-30) in the
epidermis, and 49.2 (range, 20-110) in the dermis
(Figs. 2 and 3). After naphthalan treatment, it was
1.9 (range, 0-5) in the epidermis and 20.4 (range,
15-28) in the dermis, yielding a decrease by 83%
and 59%, respectively (Figs. 2 and 3).
The mean CD4 lymphocyte count was 35.6
(range, 21-42) in the dermis, and 6.5 in epidermis
before naphthalan treatment. After naphthalan tre-
atment, it was 1.2 (range, 0-2) in the epidermis and
9.7 (range, 0-20) in the dermis, showing a decrease
by 81% and 73%, respectively (Figs. 4 and 5).
The mean CD8 lymphocyte count before na-
phthalan treatment was 4.4 (range, 2-11) in the epi-
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Table 1. Epidermal proliferation activity and CD3, CD4, and CD8 lymphocyte counts in 10 psoriatic pa-
tients before and after the treatment with naphthalan*
Naphthalan therapy
before after
No. Patient initials CD3 CD4 CD8 F8 Ki-67 (%) CD3 CD4 CD8 F8 Ki-67 (%)
1. PM E 30 E 21 E 8 20 38 E 3 E 0 E 4 10 16
D 110 D 82 D 37 7. D 15 D 0 D 20
2. GA E 23 E 12 E 5 11 29 E 0 E 2 E 1 6 5
D 58 D 42 D 21 D 21 D 20 D 9
3. SM E 6 E 5 E 2 9 36 E 2 E 2 E 1 4 8
D 31 D 28 D 15 D 16 D 12 D 8
4. ÈK E 3 E 4 E 1 10 42 E 0 E 2 E 0 7 5
D 24 D 21 D 8 D 18 D 14 D 9
5. PA E 18 E 5 E 11 13 21 E 2 E 2 E 2 7 4
D 20 D 24 D 6 D 12 D 15 D 5
6. OA E 8 E 4 E 2 25 15 E 2 E 1 E 1 12 5
D 62 D 42 D 25 D 32 D 10 D 15
7. BM E 8 E 4 E 4 12 12 E 2 E 1 E 2 5 4
D 28 D 18 D 18 D 8 D 6 D 12
8. PM E 5 E 4 E 0 19 18 E 1 E 0 E 0 8 2
D 58 D 30 D 18 D 32 D 12 D 13
9. TS E 7 E 4 E 8 22 47 E 2 E 1 E 2 5 12
D 42 D 48 D 8 D 22 D 2 D 25
10. GS E 4 E 2 E 3 10 36 E 5 E 1 E 5 6 10
D 59 D 21 D 32 D 28 D 6 D 18
*Abbreviations: CD3 – lymphocytes; CD4 – T helper lymphocytes; CD8 – suppressor/cytotoxic lymphocytes; F8=Ki-67 – proliferation index; E – epider-













Figure 1. Mean proliferation index value before and after
naphtalan therapy in psoriatic patients.
dermis and 21.8 (range, 8-37) in the dermis. After
naphthalan treatment, the respective values were
1.8 (range, 0-5) and 13.4 (range, 8-25), yielding a
decrease by 60% and 49%, respectively (Figs. 6
and 7).
The results of our investigation showed a de-
crease in CD3, CD4, and CD8 lymphocyte count
and pronounced decrease in proliferation index of
keratinocytes, Ki-67, in the basal layer of psoriatic
skin after naphthalan therapy.
DISCUSSION
Epidermal changes in psoriasis induced by an
altered differentiation program of the keratinocytes
develop along with profound hyperproliferation,
acanthosis, parakeratosis, and disappearance of
granular layer. Abnormal proliferation is the result of
an increased number of germinative keratinocytes
per skin surface area (4), accelerated cell cycle (5),
and increased recruitment of actively cycling lym-
phocytes from a resting pool (5).
Consequently, normalization of these processes
may positively influence the course of the disease.
Since both markers are up-regulated by naphtha-
lan, it can be postulated that naphthalan can induce
keratinocyte differentiation (7). Naphthalan strongly
inhibits the proliferation of keratinocytes (7).
Our results showed the decrease in the mean
CD3, CD4, and CD8 lymphocyte count as well as in
the mean proliferation index in the basal layer after
naphthalan treatment. These findings indicated an
antiproliferative activity of naphthalan in psoriatic
lesions.
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CD3 LYMPHOCYTES IN EPIDERMIS PER MM LENGTH
11.2
1.9
Figure 2. CD3 lymphocytes count in the epidermis before









CD3 LYMPHOCYTES IN DERMIS PER MM LENGTH
49.2
20.4
Figure 3. CD3 lymphocytes count in the dermis before










CD4 LYMPHOCYTES IN EPIDERMIS PER MM LENGTH
6.5
1.2
Figure 4. CD4 lymphocytes count in the epidermis before











CD4 LYMPHOCYTES IN DERMIS PER MM LENGTH
35.6
9.7
Figure 5. CD4 lymphocytes count in the dermis before
and after naphtalan therapy.
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In conclusion, the value of proliferation index
and immunocompetent cell counts after naphthalan
treatment indicated an antiproliferative activity of
naphthalan and its ability to decrease the immuno-
competent cell counts in psoriatic lesions. In this
way, naphthalan treatment reduced epidermal hy-
perplasia and decreased the rate of epidermopoi-
esis in patients with vulgar psoriasis.
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Figure 6. CD8 lymphocytes count in the epidermis before








CD8 LYMPHOCYTES IN DERMIS PER MM LENGTH
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Figure 7. CD8 lymphocytes count in the dermis before
and after naphtalan therapy.
Correlation of Clinical Symptoms and Laboratory Findings in
Children With Milk Allergy
Ana Votava-Raiæ, Duška Tješiæ-Drinkoviæ, Sven Seiwerth, Lana Maðerèiæ, Vladimir
Krajinoviæ
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SUMMARY Food hypersensitivities can be divided into toxic and non-
toxic, and the latter can further be subdivided into immune and
nonimmune hypersensitivities. Cow’s milk allergy or intolerance occurs
in 5-15% of infants, mostly during the first year of life, or occasionally
later. The symptoms may involve different organ systems, especially
the gastrointestinal system, skin, and respiratory system. For the diag-
nosis of cow’s milk protein allergy/intolerance, double-blind, pla-
cebo-controlled food challenge has been used as a gold standard.
Since the test suffers from some drawbacks, many reports have
pointed to the need for novel and simpler diagnostic procedures and cri-
teria. In our study, clinical symptoms and laboratory findings of patients
with cow’s milk protein allergy were compared to assess the possible
correlation between particular laboratory findings, clinical picture, and
the organ system predominantly involved. There were no significant dif-
ferences in the levels of IgE, cow’s milk protein specific IgE,
eosinophilia, prick test results, rectal mucosa biopsy histology, and
atopy incidence in patient families among the children with gastrointes-
tinal, cutaneous, and combined gastrointestinal and cutaneous symp-
toms. Improvement in the symptoms with dietary therapy irrespective of
clinical presentation and type of hypersensitivity underlying the symp-
toms in all these patients strongly suggests that clinical response
should be a basic criterion for the diagnosis of cow’s milk protein al-
lergy.
KEY WORDS allergens; diet therapy; double-blind method; immunoglobulin
E; infant; infant, newborn; milk hypersensitivity
INTRODUCTION
According to the latest classifications, food
hypersensitivities are divided into toxic and non-
toxic (1). Toxic hypersensitivity occurs consequen-
tially to the action of food ingredients or food con-
taminants, whereas nontoxic hypersensitivities de-
pend on the body’s susceptibility and can be subdi-
vided into immune (food allergy) and nonimmune
(food intolerance) hypersensitivities. Thus, cow’s
70
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milk allergy may present either as allergy or as intol-
erance. Since it is difficult to differentiate between
the two entities clinically, the diagnosis usually in-
cludes both, cow’s milk protein intolerance
(CMPI)/cow’s milk protein allergy (CMPA). It is
known that cow’s milk contains many antigenic
components. Some allergenic proteins, especially
-lactoglobulin, -lactalbulmin, and some fractions
of casein (as major allergenic proteins of cow’s
milk) are responsible for symptoms of cow’s milk al-
lergy (2). The symptoms of CMPA occur in 5-15% of
infants. However, if diagnostic criteria are strictly
followed, the real incidence is 2-3% (3). Cow’s milk
allergy usually occurs in the first year of life, with a
median age at diagnosis of seven months (4). The
symptoms may vary, primarily involving the gastro-
intestinal system, skin, and respiratory system
(2,5). It is evident that 30-60% of infants involved
have skin manifestations – labial edema (so-called
oral allergic syndrome), perianal edema and ery-
thema, and many different skin eruptions (urticaria
or rush) (6). About 20-30% of children with cow’s
milk allergy have some respiratory symptoms (e.g.,
asthma). It is estimated that 30-50% of children
have gastrointestinal symptoms (e.g., enteroco-
litis). Immune food reactions that may be mediated
exclusively by class E immunoglobulins (IgE), par-
tially IgE mediated, or cell mediated without immu-
noglobulin involvement seem to be most intriguing
for clinicians (7,8). The symptoms are identical or
nearly identical irrespective of the underlying im-
mune mechanism, although the time from chal-
lenge to onset varies. Thus, the IgE-mediated reac-
tions are characterized by a rapid onset (up to 40
minutes from challenge), mixed reactions occur be-
tween one and 20 hours from challenge, whereas
those mediated by the cellular immunity mecha-
nisms develop after more than 20 hours from the
contact with allergen (1,2,9).
A double-blind, placebo-controlled food chal-
lenge is the gold standard for diagnosing cow’s milk
allergy (2,7,8,10). However, many other parame-
ters and tests can be used as a help in making the
diagnosis and will possibly allow the double-blind,
placebo-controlled food challenge to be avoided in
the future. The findings that need to be obtained for
diagnosis include history data, peripheral blood
eosinophil count, IgE and specific IgE (RAST), skin
tests (skin prick test and patch test), and gastroin-
testinal system mucosal biopsy.
METHOD AND RESULTS
We analyzed the findings in 39 patients aged 20
days to 3 years (median, 7 months), who were hos-
pitalized at our Department because of cow’s milk
protein hypersensitivity between 1999 and 2002.
Skin symptoms were recorded in eight, gastrointes-
tinal symptoms in 16, and both skin and gastroin-
testinal symptoms in 15 out of 39 patients. Study
patients were divided into three groups: one with
the skin manifestations only, one with gastrointesti-
nal manifestations only, and one with both skin and
gastrointestinal manifestations. The values of the
following laboratory parameters of the three patient
groups were compared: eosinophilia
(>0.44×1012/L), IgE titer, RAST, eosinophil count
per high-power field (HPF) of gastrointestinal mu-
cosa biopsy specimen, skin prick test, and family
history data on atopy.
Increased peripheral blood eosinophil count
was found in 13%, 44%, and 40% (Fig. 1); in-
creased IgE titer in 63%, 56%, and 53% (Fig. 2);
positive specific antibodies to cow’s milk protein
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Figure 1. Percentage of patients with eosinophilia >0.44×












Figure 2. Percentage of patients with increased IgE titer
according to clinical manifestation of the disease.
(RAST) in 38%, 19%, and 20% (Fig. 3); increased
eosinophil count per gastrointestinal mucosa bi-
opsy HPF (>20 per HPF) in 25%, 25%, and 27%
(Fig. 4); positive skin prick test in 50%, 25%, and
20% (Fig. 5); and positive family history of atopy in
75%, 44%, and 53% (Fig. 6) of patients with cutane-
ous, gastrointestinal, and both cutaneous and gas-
trointestinal manifestations, respectively.
In all patients, a dietary regimen free from cow’s
milk protein was introduced upon clinical examina-
tion. In one patient with hypersensitivity that mani-
fested with breast-feeding, the mother excluded
cow’s milk from her diet.
Soy to cow’s milk cross-reactivity was found in
10-35% of patients, which is consistent with other
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Figure 5. Percentage of patients with positive skin prick












Figure 3. Percentage of patients with positive RAST ac-












Figure 6. Percentage of patients with positive family his-











Figure 4. Percentage of patients with increased eosino-
phil count per biopsy high-power field (HPF) according to
clinical manifestation of the disease.
Figure 7. Patient J.M. with gastrointestinal and skin mani-
festations of cow’s milk allergy. Rectal mucosa biopsy: (A)
before dietary therapy, rectal mucosa with increased eosi-
nophil count per high-power field; (B) upon introduction of




studies (4,10). In our study, nine of 37 patients in
whom soy diet was introduced showed soy hyper-
sensitivity and were switched to a protein
hydrolysate formula. Most of these patients, i.e. 7
out of 9, were under 6 months of age, which is con-
sistent with other literature reports (4). Clinical re-
mission occurred in 37 out of 39 patients and in
some of them remission was also verified by histol-
ogy of the rectal mucosa biopsy (Fig. 7) (11).
In two patients, the diagnosis was confirmed by
provocation test along with rectal mucosa biopsy,
whereby the post-challenge biopsy histology corre-
sponded to hypersensitivity.
DISCUSSION
The prevalence of skin, gastrointestinal, and
both skin and gastrointestinal symptoms in our pa-
tients was consistent with the prevalence found in
other studies (2,12). Although performed in a rela-
tively small number of patients, our study clearly
showed that there were no significant differences
among the three patient groups in any of the param-
eters examined. Since all study patients responded
well to dietary therapy irrespective of the clinical
presentation or type of hypersensitivity, and the
tests used in the study are characterized by quite a
low sensitivity, the clinical response should obvi-
ously be considered crucial for making the diagno-
sis of the disease.
Numerous studies point to the need for a new
criterion for the diagnosis of CMPA, because the
current gold standard, double-blind placebo-con-
trolled food challenge, suffers from some draw-
backs (1,8,13). The procedure is time-consuming
and exhausting, requiring hospitalization and physi-
cian’s surveillance for at least 48 hours. In addition,
allergen challenge is associated with the risk of
life-threatening anaphylactic reaction. Therefore,
we should search for a combination of laboratory
and clinical parameters that may facilitate the
diagnosis of the condition.
Our results also indicate that there is no differ-
ence in the diagnostic procedure according to clini-
cal symptomatology, i.e. to the primary organ sys-
tem of symptom manifestation. In recent literature,
the skin patch test has been described as a valu-
able diagnostic criterion, either independent or in
combination with specific IgE antibodies to cow’s
milk protein (RAST) (13,14). Since some of these
tests are not always available in our setting, we
should try to reach such results by combining some
other tests.
One of our patients developed allergic reaction
upon breast-feeding. History data showed no other
route of challenge, and the diagnosis was con-
firmed by laboratory tests, histology of gastrointesti-
nal mucosa specimens, and challenge test under
the controlled hospital conditions. The possibility of
cow’s milk protein sensitization via breast-feeding
has been reported, since particular proteins may be
small enough to be excreted in human milk (e.g.,
b-lactoglobulin) (1,2,10,15). However, it seems
more likely that a so-called “hidden nursing bottle”,
with an adequate dose of human milk for primary
challenge and antibody production, must have
crept into the maternity ward. In this case, the
haptens secreted in human milk are adequate to
cause reaction in an already sensitized child.
Therefore, if hypersensitivity is suspected, even in
breast-fed infants, the diagnosis should not be ruled
out on the basis of the absence of challenge. The
possible allergy due to a single or continuous con-
tact with a low amount of allergen should also be
taken into consideration.
The hypoallergenic infant formulas (hydroly-
sates) are used in treatment as well as prevention
of cow’s milk protein allergy (1,8,16,17).
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SUMMARY Allergic contact dermatitis is acute or chronic inflamma-
tory skin disease of allergic etiology, which develops as a result of de-
layed type of hypersensitivity, i.e. type IV reaction according to the
Gell and Coombs classification. In the retrospective study, we re-
viewed medical records of 495 patients diagnosed with allergic con-
tact dermatitis in the 1988-1998 period. The records were obtained
from the Cabinet of Allergology of the Department of Dermatology
and Venerology, Tuzla University Hospital Center. There were 312
women and 183 men, aged between 18 and 60 years. The patients
were divided into 6 groups according to their occupation. Contact
sensitization was established in 295 or 59.6% of them. The type and
frequency of causative agent in allergic contact dermatitis depended
on working environment. Potassium dichromate, a component part of
cement, caused positive reaction in 48% of construction workers
tested, which was significantly more than in the “other occupation”
group, where 14.6% of patients showed positive reaction to potas-
sium dichromate (p<0.001). Formaldehyde, used in leather process-
ing, was the most frequent among the four leading allergens in the
group of shoe workers (13.3%), whereas charcoal tar (used in the
metal processing) was the most frequent allergen in the group of
metal workers (13.9%). Nickel sulfate, potassium dichromate, cobalt
chloride, and urushiol were frequent allergens in the “other occupa-
tion” group, housewives, and textile workers. The listed allergens are
present at large in everyday life as well as in particular occupations.
KEY WORDS allergens; dermatitis, allergic contact; dermatitis,
occupational; hypersensitivity, delayed; nickel
INTRODUCTION
Allergic contact dermatitis is acute or chronic in-
flammatory skin disease of allergic etiology, which
develops as the result of delayed type of hypersen-
sitivity (type IV reaction according to the Gell and
Coombs classification). Allergens (hapten+carrier
protein), Langerhans’ cells in the epidermis, and
sensitized T lymphocytes play the main role in the
pathogenesis of the disease. CD4 lymphocytes re-
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lease cytokines that attract other lymphocytes,
macrophages, and leukocytes and activate produc-
tion of soluble factors (macrophage migration inhib-
itory factor – MIF, macrophage-activating factor –
MAF, lymphokines, and chemotactic factors) (1).
Clinical polymorphism is typical for allergic con-
tact dermatitis. In the acute allergic contact dermati-
tis, skin changes most frequently occur on the ex-
posed parts of the body, such as the face, neck,
lower arms, and back of the hands, where erythema
(redness), edema (swelling), papules (inflamma-
tory nodules), vesicles (small blisters), and some-
times bullas (blisters) develop. Chronic allergic con-
tact dermatitis is characterized by dry, slightly infil-
trated skin covered with squames and rhagades.
Itching is present in every phase of the disease.
Acute allergic contact dermatitis resolves after 1-4
weeks, whereas chronic form can last for months or
even years, with periods of relapse depending on
the frequency of skin contact with the allergen (2,3).
Most contact allergens today are chemicals.
Tuzla region is a large industrial area, with diverse
industry, and patients with allergic contact dermati-
tis are frequently seen in everyday dermatological
practice. For example, 10.5-11.5% of the patients
visiting the University Department of Dermatology
and Venerology in Tuzla in the last two years had al-
lergic contact dermatitis. Contact sensitization has
generally increased in the whole world (2-6).
The aims of the study were to determine the
most frequent causative agents in allergic contact
dermatitis and to analyze the relation between indi-
vidual allergens and the working and living environ-
ment in Tuzla area.
MATERIALS AND METHOD
In the retrospective study, we reviewed medical
records of 495 patients with allergic contact derma-
titis in the 1988-1998 period. The records were ob-
tained from the Cabinet of Allergology of the Univer-
sity Department of Dermatology and Venerology,
Tuzla University Hospital Center. There were 312
women and 183 men, aged between 18 and 60
years. The patients were divided into 6 groups ac-
cording to their occupation (Table 1).
Allergologic investigation included assessment
of skin sensitization by use of patch testing with
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Figure 1. The patient with facial allergic contact dermati-
tis in acute phase.
Table 1. Patients with allergic contact dermatitis
according to their occupation








*Other occupation includes clerks, students, teachers, unemployed,
and persons not exposed to highly potent allergens in their everyday
work and living environment.
Figure 2. The hand of the same patient (see Fig. 1).
standard series of allergens, produced by the
Zagreb Immunologic Institute, Zagreb, Croatia.
Patches were placed on the skin of the back, and
the reading was taken after 48 and 72 h; the reac-
tion was scored according to the International Con-
tact Dermatitis Research Group system (2,3). Pa-
tients in the acute phase of the disease were not
tested, but treated until the withdrawal of the symp-
toms (Figs. 1 and 2). Chi-square test was used for
data analysis.
RESULTS
Out of 495 patients with allergic contact dermati-
tis, 219 (119 women and 100 men) belonged to the
“other occupation” group, which included clerks,
students, teachers, unemployed, and other patients
not regularly exposed to highly potent allergens in
their working and living environment (Table 1). Posi-
tive reaction to patch testing with a standard series
of allergens was found in 134 (61.2%) of them. Four
most frequent allergens were nickel sulfate, potas-
sium dichromate, cobalt chloride, and urushiol (Ta-
ble 2, Fig. 3).
Out of 91 women included in the group of house-
wives, 51 (56.0%) were sensitized to the same four
contact allergens as those found in the “other occu-
pation” group (Figs. 3 and 4).
Out of 43 patients in the group of metal workers,
22 (51.2%) had positive patch test reaction. The
most frequent allergens were cobalt chloride, nickel
sulfate, urushiol, and charcoal tar. There were no
positive reactions to potassium dichromate, as op-
posed to “other occupation” group, but sensitization
to charcoal tar was confirmed, which is a frequent
professional allergen in metal workers (Fig. 5).
Out of 63 patients in the group of textile workers,
40 (63.5%) developed patch test positive reaction.
The most frequent allergens in this group of pa-
tients were potassium dichromate, nickel sulfate,
urushiol, and cobalt chloride. There were no statisti-
cally significant differences in the contact sensitiza-
tion between the group of textile workers and “other
occupation” group (Fig. 6).
In the group of 30 shoe workers, 17 (56.0%)
were positive to potassium dichromate, nickel sul-
fate, formaldehyde, and urushiol. Shoe workers are
mostly exposed to these allergens at their work
place. The hypersensitivity to potassium dichroma-
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Table 2. Patients with patch test positive reaction and the most frequent allergens per occupation group
Occupation No. (%) of patients Patch test positive (No., %) Most frequent allergen (%)
Other occupation* 219 (44.2) 134 (61.2) nickel (22.8)
Housewives 91 (18.4) 51 (56.0) nickel (19.8)
Metal workers 43 (8.6) 22 (51.2) cobalt (18.6)
Textile workers 63 (12.7) 40 (63.5) nickel (28.6)
Shoe workers 30 (6.0) 17 (56.0) nickel (30.0)
Construction workers 49 (9.8) 33 (67.3) potassium dichromate (49.0)
Total 495 (100.0) 295 (59.6)














Figure 3. Distribution of the most frequent allergens in




















Figure 4. Comparative presentation of four most frequent
allergens in the group of housewives and “other occupa-
tion” group.
te was significantly higher in the shoe workers
(7.2%) than in the “other occupation” group (Fig. 7).
Sensitization to potassium dichromate, cobalt
chloride, nickel sulfate, and urushiol was estab-
lished in 33 (67.3%) out of 49 construction workers.
There was a significant difference in sensitization to
potassium dichromate between the group of con-
struction workers and “other occupation” group
(49.0% vs. 14.6%, respectively) (Fig. 8). Potassium
dichromate and cobalt chloride can be found in ce-
ment and other construction materials, which is the
reason why construction workers were significantly
more exposed than other workers to those aller-
gens at their work place (p<0.001).
DISCUSSION
Analysis of the frequent professional allergens
yielded useful information. There is a need for con-
trol of the percentage of workers with hypersensitiv-
ity in the developed industrial area of Tuzla in order
to improve occupational safety and adequate pre-
vention of occupational allergic contact dermatitis.
Our results for the group of shoe workers (13.3%
positive to formaldehyde) point to the need for
better protection during industrial processing of
leather and other materials containing formalde-
hyde, with which shoe workers get in contact.
These findings are in accordance with other studies
(4-6). Wet cement represents a special threat to
workers in construction industry. In highly devel-
oped European countries, sensitization to potas-
sium dichromate is almost nonexistent, because
the technological process of cement production has
become completely closed and iron chloride has
been introduced (6). In Scandinavian countries, for
example, not a single construction worker with al-
lergy to potassium dichromate has been recorded
in the last 10 years. Our results – 67.3% construc-
tion workers with hypersensitivity – point to the
need for improvement of both safety measures at
work and cement production process. In our study,
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Figure 6. Comparison of four most frequent allergens in
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Figure 5. Comparison of four most frequent allergens in

























Figure 8. Comparison of four most frequent allergens in























Figure 7. Comparison of four most frequent allergens in
the group of shoe workers and “other occupation” group.
ACTA DERMATOVENEROLOGICA CROATICA 79
Sijerèiæ et al: Acta Dermatovenerol Croat
Contact Allergens in Tuzla Area 2003;11(2):75-79
nickel sulfate was the most frequent allergen in the
“other occupation” group, group of housewives, tex-
tile and shoe workers, which is in accordance with
other studies (5,6).
CONCLUSION
In the retrospective study, out of 495 patients
with allergic contact dermatitis divided into 6 occu-
pation groups, contact sensitization was estab-
lished in 295 or 59,6% of them. The type and fre-
quency of causative agent in allergic contact der-
matitis depends on working environment. Potas-
sium dichromate, a component part of cement,
caused a positive reaction in 48% of construction
workers tested, which was significantly more than in
the “other occupation” group, where 14.6% of pa-
tients showed positive reaction to potassium
dichromate (p<0.001). Formaldehyde, used in
leather processing, was frequent among the four
leading allergens in the group of shoe workers
(13.3%), whereas charcoal tar (used in metal pro-
cessing) was the most frequent allergen in the
group of metal workers (13.9%). Nickel sulfate, po-
tassium dichromate, cobalt chloride, and urueshiol
were frequent allergens in the “other occupation”
group, housewives, and textile workers. The listed
allergens are present at large in everyday life as
well as in particular occupations. Our results show
that the continuous monitoring and diagnosis of
contact allergenic dermatitis, especially in occupa-
tions at risk, would provide useful information
indicating the need for change in technological
process of work, as well as for improvement of
safety measures at work.
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SUMMARY Emollients are agents designed to make the stratum cor-
neum softer and more pliant by increasing its hydration. A large num-
ber of preparations are available today, many of which are marketed
as cosmetic and therapeutic moisturizers. They are the most pre-
scribed products in dermatology. Their structure and function are sur-
prisingly complex and sophisticated, and many are equidistant be-
tween cosmetics and drugs. The use of the emollients corrects the
problems in scaling disorders. It is well known that the electrical prop-
erties of the stratum corneum change after application of an emol-
lient. It is also possible that they have suppressive effects on epider-
mal thickening. Emollients have an anti-inflammatory activity and
also give some transient relief from irritation. In clinical use emollients
are employed as treatments for ichthyoses, xeroderma and disorders
of keratinization, atopic dermatitis, psoriasis, and photodamaged
skin. Emollients of the new millennium include agents that mimic nat-
ural ingredients and function as botanicals, including vitamins,
hydroxy acids, and retinoids. Emollients can cause a few side effects,
such as irritant dermatitis, allergic contact dermatitis, fragrance al-
lergy or allergy to other constituents (preservatives or additives),
stinging, cosmetic acne, and pigmentary disorders. We can conclude
that emollients, continuously evolving to ever more sophisticated
products, are very important in the treatment of different dermatoses.
KEY WORDS dermatologic agents; dermatology; emollients; skin;
skin diseases
INTRODUCTION
It would be very difficult to imagine the practice
of dermatology or the world of cosmetics without
emollients. The urge to apply different kinds of oil
and grease to the skin may be as old as mankind it-
self. It is certain that the ancient Greeks, and Egyp-
tians before them, applied oils and pleasant smell-
ing fatty concoctions on the skin, but it also seems
likely that even before that early man had devel-
oped the habit of applying animal or plant oils for
protection and maybe pleasure. They were cer-
tainly in use as both medicaments and cosmetics
(1-4).
From the records from around 700 BC we
learned that the ancient Greeks used wool fat, an
agent that continued to be extensively used over
following centuries. Petrolatum (petroleum jelly) or
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white soft paraffin of “Vaseline” was originally the
subject of a patent filed by Cheseborough in 1872
(1). This semi-solid distillation derivative of crude
petroleum has been astonishingly successful over
the past 130 years as an emollient and as a constit-
uent of a wide variety of topical products. Emol-
lients, obviously, have a long and honorable history
and remain as important as ever in the manage-
ment of patients with skin disorders (1,5).
Today, emollients are formulated in quite a com-
plex manner. Moreover, it is not only their formula-
tion, but also their effect that is complex (6).
WHAT ARE EMOLLIENTS?
There are different terms for emollients to de-
scribe their different functions. The term most fre-
quently used is “emollients”, followed closely by
“moisturizers”, “lubricants”, and “vanishing creams”.
When employed to carry some active agent to the
skin surface, they are referred to as “bases” or “ve-
hicles”. When sold as cosmetics, emollients often
carry more romantic names, describing a desired
biological activity, such as “revitalizing cream” or
“regenerating milk” (4,7).
When prescribed as treatment adjuncts or, in-
deed, as the main treatment, like for xerodermatous
disorders, emollients should be used frequently
enough to obtain the optimal moisturizing effect (3).
BIOPHYSICAL ACTIONS OF
EMOLLIENTS
The main action of emollients is to occlude the
skin surface and to encourage a build-up of water
within the stratum corneum. Actually, there is an un-
even distribution of water within the stratum corne-
um, with higher concentrations in the deeper seg-
ments near the viable epidermis. The water is held
by the avidity of small molecules as well as by hy-
drogen bonding to some of the protein structures.
The lipids in the intercorneocyte space, and particu-
larly the ceramides, impede the movement of water
through the horny layer. These molecules emanate
from the lamellar bodies in the granular cell layer
and function as alternating electron-dense and
electron-lucent lamellae in the space between the
horn cells. However, the lipids themselves do not in-
fluence the mechanical function of the stratum
corneum (8). It is the water content of the skin that
controls its biomechanical properties (9).
Desquamation is a fundamental part of epider-
mal biology as it is intimately linked to epidermal cell
production. Furthermore, normal desquamation is
central to barrier function. This, if nothing else, is
the reason why emollients play so important role in
dermatopharmacology (4).
The electrical properties of the stratum corneum
change after application of an emollient due to the
increased amount of water in the corneum; they
have been popular methods for assessing the
hydration of the horny layer (10).
Emollients seem to have antimitotic properties,
anti-inflammatory activity, and antipruritic effects.
They also seem to have some therapeutic activity in
psoriasis and chronic eczematous states, which
suggests the possibility of having suppressive ef-
fect on epidermal thickening. There are two possi-
ble mechanisms of their action. The first one relates
to the observation that emollients promote the heal-
ing of a damaged stratum corneum barrier, and the
improved barrier somehow calms down the highly
active epidermis. The second possibility is that
there is a reduction in prostaglandin synthesis
caused by emollients containing a high proportion
of petrolatum, which is also in some way responsi-
ble for this effect. Whatever the mechanism, the
antimitotic activity seems to have clinical relevance
and should be investigated further (11).
Rubbing an emollient into a sore and inflamed
patch of skin gives symptomatic relief and reduces
the degree of inflammation. How an anti-inflamma-
tory action is actually effected is not clear. One
study did show that petrolatum has inhibitory effect
on prostaglandin synthetase. This bears an impor-
tant implication with regard to the synthesis of
eicosanoid compounds and their involvement in
inflammatory disease (1,12).
Emollients give some transient relief from irrita-
tion, even when the pruritus is unaccompanied by
any visible skin abnormality. At least in the case of
emulsion formulation, some of this effect may be
caused by the skin cooling due to the evaporation of
the water content of the preparation. However, not
all emollients contain water. Other actions may also
be involved, e.g., if petrolatum can inhibit prostaglan-
ACTA DERMATOVENEROLOGICA CROATICA 81
Nola et al: Acta Dermatovenerol Croat
Emollients – Sophisticated Therapy 2003;11(2):80-87




Naturally occurring skin lipids and sterols are of-
ten added to moisturizers. In the correct propor-
tions, these agents can help promote repair of cuta-
neous barrier function. In the wrong proportions,
they can delay repair. Lipids (fats, waxes, and oils)
are the essential components of emollients. They
provide an impervious layer on the skin surface and
prevent the flow of water through the skin and thus
transepidermal water loss. The water unable to
evaporate from the surface becomes trapped within
the stratum corneum and profoundly alters the
properties of that structure. The lipids used may be
derived from animal fats of one sort or another, veg-
etables, minerals, or may be entirely synthetic in or-
igin. Whatever the type of lipid use overall, lipids
usually account for 20-40% weight of the entire
formulation (13).
Animal lipids. Although animal fats were used as
emollients in the past, they now have no place in the
formulation of emollients. They consist predomi-
nantly of fully saturated triglycerides and are inele-
gant cosmetically (1).
Lanolins. Wool grease (or wax) has retained an
important place in the formulation of emollients over
the past 2 to 3 millennia. Lanolin is extremely com-
plex, composed of esters, high molecular weight
diesters, hydroxyesters, lanolin alcohols, and lano-
lin acids as well as hydrocarbons. Physically, it is a
two-phase system with a liquid-lanolin oil compo-
nent and a solid lanolin wax fraction. The liquid frac-
tion contains more esters of lower molecular
weight. Many studies have demonstrated that ei-
ther hydrous lanolin or creamier preparations con-
taining emulsions of lanolin are effective in the relief
of xerotic skin through the restoration of perturbed
barrier function: lanolin preparations are also help-
ful in wound healing. They are generally well
accepted as excellent lubricants for the skin (14).
Petrolatum. Petrolatum is also known as white
(or yellow when less refined) soft paraffin of Petro-
latum jelly and is obtained by the distillation of min-
eral oils. Petrolatum was introduced in the 1870s as
a wonder ingredient for the treatment of chapped
hands and became popular because of its resis-
tance to rancidity. Petrolatum is usually employed
as the “gold standard” in comparative tests of the
ability of emollients to reduce transepidermal water
loss (15). Kligman (16) showed that apart from their
emollient, soothing, and smoothing characteristics,
petrolatum-containing emollients have significant
UVR protection properties. The petrolatum prepa-
rations did have a sunscreen effect but it amounted
only to an SPF of 2 (1,16).
Vegetable lipids. These “naturals” have been in-
creasingly popular over the past two or three de-
cades, partially because of a fashionable underly-
ing premise that everything natural is good. Some
vegetable lipids may possess special and useful
properties, particularly those containing a signifi-
cant proportion of unsaturated fatty acids. Vegeta-
ble oils that have been used include sunflower seed
oil, grape seed oil, walnut oil, avocado oil, palm oil,
and corn oil. Cocoa butter, candelilla wax, and
cornuba wax are semisolid vegetable lipids that are
sometimes employed. Cocoa butter is notorious for
its propensity to cause “cosmetic acne” (17). Vege-
table oils often have a distinctive aroma, which may
be a disadvantage. Some oils contain allergens and
cause sensitization (e.g., peanut oil and arachis oil)
(1).
Synthetic lipids. Most lipid constituents used in
modern formulations are synthetic because they
have been chemically modified in some way and
can hardly be described as pure natural products.
Among the oldest of the synthetic lipids are the sili-
cone oils, such as the dimethyl, polysiloxanes, and
silicone glycol copolymers (1).
Humectants
These are substances added to emollient for-
mulations to attract water into the stratum corneum.
The humectants accumulate within the stratum
corneum and attract moisture from the dermis, not
from the environment. A major and very popular
humectant in cosmetic products is glycerin, which
has been in use for more than 50 years. Glycerin
seems to maintain the osmolarity of the intracellular
environment and liquid crystalline structure of
membranes. It is usually employed at concentra-
tions of 2-10%, but increased benefit has been
claimed for preparations containing higher concen-
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trations. Another important humectant is “Natural
Moisturizing Factor” (NMF), which consists of
amino acids, Pyrolidone Carboxylic Acid, urocanic
acid, urea, lactic acid, and citrates. NMF accounts
for 20-30% dry weight of the stratum corneum.
These materials are extremely hygroscopic and im-
portant in maintaining a watery milieu in the upper
part of the horny layer, enabling the proteases to
cleave the desmosomal contacts. Lactic acid is an
alpha-hydroxy acid and its benefits stem from its
keratolytic effects. It has been found to increase
ceramide levels within the stratum corneum. Lactic
acid-containing cream also improves skin rough-
ness, dyspigmentation, and sallowness in patients
with photodamaged skin, although these effects
could be assigned to its humectant properties (2).
Other agents classified as humectant, including
sorbitol, dibutylphthalate, and ethoxylated glucose,
are sometimes included in formulae (13).
Emulsifying Agents
The large majority of emollient formulations con-
tain emulsions – usually oil in water, sometimes wa-
ter in oil, and sometimes double and even triple
emulsions are put together by very clever formula-
tions. Emulsifying agents permit the formulation of
such emulsions and ensure their continued stability
(1). The exact emulsifier used depends on the oil in
the emulsion. A mixture of hydrophilic and hydro-
phobic surfactants in often employed, and a deter-
gent emulsifying agent that prevents aggregation
and clouding. However, they tend to irritate the skin.
A new category of surfactants that shows less ten-
dency to cause irritation is the polymeric surfacta-
nts, e.g., ethoxylated dipoly-hydroxy-stearic acid (4).
Preservatives
Preservatives are also known as biocides,
antimicrobial agents, or disinfectants. Essentially,
they are agents that kill microbes and prevent colo-
nization of topical formulations. Preservatives are
essential in any lotion or cream formulation, espe-
cially those containing water. The system must be
protected from microbiological contamination dur-
ing manufacture and after it is opened and exposed
to contamination by being used. The agents used
as preservatives are parabens (methylparaben-
propylparaben combination) formaldehyde donors
(e.g., quaternium-15 and 3’-demothoxy-3O-deme-
thylmatairesinol hydantoin), chelating agent (e.g.,
etylenediaminetetraacetic /EDTA/), methylisothia-
zolinone, and methylchloroisothiazolinone (12).
Other Ingredients
Bland agents (fillers), such as starch, gelatin,
talc, and the pectinates, alter the thickness and rhe-
ological properties of formulations and sometimes
they are added to the formulation. Sunscreens re-
duce the possibility of chronic photodamage. Fra-
grances are always added to emollient formulations
and present in all topical products to mask the natu-
ral odors of their contents. Unfortunately, they are
the most common offenders in producing an allergic
contact dermatitis. Colorants are also complex, but
not as much as fragrances, and give rise to adverse
reactions less often (1).
Active Ingredients
These include agents for the treatment of photo-
damage, such as retinol, ascorbic acid, ceramides,
hyaluronic acid, alpha hydroxy acids (AHAs), and
vitamins. Retinoids can reduce some of the stig-
mata of photodamaged skin. AHAs have been
shown to exfoliate and act as humectants. Vitamins
have a role in protection from oxygen radicals pro-
duced by exogenous (e.g., UV light) and endoge-
nous (e.g., inflammation) factors. When topically
applied, vitamins can reduce cellular injury caused
by these harmful insults (12).
EMOLLIENTS IN CLINICAL USE
The emollients have found very many uses as
monotherapies or treatment adjuncts for diseased
skin as well as prophylactic agents. They are em-
ployed for more than one purpose, like in eczema,
where they reduce itching and scaling and have the
cosmetic function of making the affected site look
better (7,18,19).
Atopic Dermatitis
Atopic dermatitis is one of the greatest thera-
peutic challenges for dermatologists. During remis-
sion periods, the regular use of topical basis ther-
apy that consists of drug-free water-in-oil moistur-
izer can decrease relapses and severity. Emollients
help these patients because of their anti-inflamma-
tory effect and give some temporary relief from the
characteristic itch (20,21).
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Psoriasis
In psoriasis, moisturizers can be used as
adjuvant therapy with corticosteroids. In photothe-
rapy, moisturizers can improve efficacy and may
have a protective component against damage by
UVA light. Whatever agents chosen, topically ap-
plied anthralin, calcipotriol, tazarotene or cortico-
steroids, or systemic therapy with methotrexate or
cyclosporine, emollients are necessary adjuvant
treatments for them all. They are especially impor-
tant when oral retinoids are given due uncomfort-
able skin dryness and itchiness (12,22). It is likely
that emollients can improve psoriasis in somewhat
more fundamental ways. Experiments have shown
that petrolatum reduces the mitotic activity of the
stimulated epidermis, but how this antimitotic
activity is mediated is still uncertain (2).
Ichthyosis, Xeroderma, and Disorders
of Keratinization
All patients with ichthyotic or xerodermatous dis-
orders need to take particular care while bathing
and where possible in modulating the humidity of
their environment. When used regularly, moisturiz-
ers make the affected skin feel less itchy and more
comfortable. In addition, scaling decreases and the
skin looks and feels smoother. The improvement
may be the result of rapid dissolution of desmo-
somal bonds by activation of the stratum corneum
chymotryptic enzyme when there is sufficient mois-
ture. The use of urea for skin disorders can be
traced back to Babylonian times. It was certainly
widely used for infected wounds and inflammatory
disorders. Inclusion of urea (5-10%) in the formula-
tion seems to improve the clinical efficacy of the
treatment of ichthyosis, xerotic disorders, and pityri-
asis rubra pilaris (23,24). Glycerin is an extremely
popular additive to emollients and has excellent
characteristics (4,25).
Other Inflammatory Disorders
Radiotherapy can result in unpleasant burns,
and adequate use of emollients can improve the
discomfort and decrease the inflammation. It
should be routinely used in patients undergoing this
treatment. Because of their generally soothing
qualities, emollients are useful after all types of in-
flammatory dermatoses (e.g., adverse reactions to
drugs or sunburns) (12).
Use of Emollients with Topical
Retinoids and Other Irritants
Topical retinoids have an unfortunate tendency
to cause skin irritation. Therefore, topical retinoids
are usually applied at night, whereas emollients
should be applied to the treated areas as often as
needed during the day. The same applies to treat-
ment with benzoyl peroxide preparations for acne,
as these can also cause significant irritation (7,26).
Wound Healing
Ointments have a beneficial effect on the pro-
cesses of epidermal migration and regeneration.
There is considerable body of evidence that the rate
of re-epithelization increases with the use of emol-
lients. Angiogenesis also seems to be increased
and scar formation is decreased (1,27).
Prevention of Dermatitis
It was shown that normal undamaged skin has
enhanced barrier function after use of emollients. A
number of studies have demonstrated that the use
of emollients reduces the severity of skin irritation
from detergents. Various moisturizers considerably
reduced the increased transepidermal water loss
from the skin exposed to dishwashing detergent in
volunteer subjects, as compared with controls
whose skin was not emollient-treated but was de-
tergent-treated. Also, prolonged hydration of the
stratum corneum may actually make it more perme-
able and susceptible to environmental trauma. This
applies both to the prolonged use of rubber gloves
and the use of moisturizers (4).
Chronic Photodamage
Judicious use of emollients will reduce the ap-
pearance of the fine lines and wrinkles of
photodamaged skin by moisturizing the upper stra-
tum corneum and making it swell and flatten. This
“irons out” the fine lines, making the skin smoother
and less “craggy” (28).
Thermal Protection
Water free ointments protect facial skin against
frostbite (29). Also, painful cracks that develop in
the brittle stratum corneum in conditions of low tem-
perature and low relative humidity can be prevented
by frequent use of emollients (30). These prepara-
tions also provide some protection for the skin
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against external environmental trauma, such as
cold wind, solar UVR, and atmospheric pollutants
(31,32).
Emollients in Newborns
Preterm infants have an immature stratum cor-
neum and relatively inefficient barrier function. Ap-
plication of emollients decreases the transepider-
mal water loss and reduces skin infection in the
newborn (33).
Extracorporeal Shock Wave Lithotripsy
Petrolatum emollient is used as a skin contact
medium for the ultrasound shock wave from an
extracorporeal lithotriptor used to fragment renal
stones (1).
Emollients as Cosmetics
Moisturizers are the basis of foundation creams,
nourishing creams, hand creams, repair creams,
night creams, cleansing creams, and numerous
other preparations. They produce some swelling in
the horny layer, resulting in flattening of the skin sur-
face features, so that the skin looks and feels
smoother (4).
ADVERSE EFFECTS FROM THE USE OF
EMOLLIENTS
Emollients are for the most part blameless and
benign agents causing few side effects. Vast
amounts of emollients are used on a daily basis
and, unlike most other therapeutic agents, are re-
sponsible for very few problems (34).
Irritant Dermatitis
Primary irritant dermatitis is the most common
type of contact dermatitis in general population. The
dermatitis occurs where the emollient is applied.
Thus, with products used as part of a treatment reg-
imen, the rash may occur predominantly on the
trunk, hands, and limbs. By definition, primary irri-
tant dermatitis affects a large proportion of the indi-
viduals who use the product. Nonetheless, it can be
difficult to recognize. Irritant responses may be the
result of several irritant substances of a low degree
of irritation working together rather than just one
major toxic substance (35).
Diagnosis will depend on good “detective work”
and identification of the irritating ingredients. In gen-
eral terms, dark skinned individuals are less often
affected by primary irritant dermatitis (36). Propyl-
ene glycol is a frequent constituent of creams be-
cause of its excellent solvent properties, but it be-
comes irritating in more than 15% in the final for-
mula. Other emulsifying agents that stabilize cream
formulation are sodium lauryl sulphate and deter-
gents. Also, wool wax alcohols, the preservative
benzalconium, chloride, some free fatty acids, e.g.,
oleic acid and polyethylene glycol stearates, are
other substances that may cause irritation (20,36).
Allergic Contact Dermatitis
Allergic contact dermatitis (ACD) is the most fre-
quent adverse side effect due to cosmetics in gen-
eral and emollients in particular. ACD may arise be-
cause of a pre-existing allergy to one of the constit-
uents or the subject may become sensitized solely
due to the use of the emollient in question. The
usual groups of chemical agents to which sensitivity
develops are fragrances, preservatives, and emul-
sifiers. Sometimes the sensitizer is a fundamental
part of the emollient, such as lanolin or propylene
glycol, but this is less common (37).
Fragrance Allergy
Fragrances are the most frequent cause of “cos-
metic allergy”. Fragrances are universal in topical
products. Even when labeled “fragrance free”, topi-
cals have recently been found to contain some fra-
grance to mask the “natural” odor of the other con-
stituents. “Fragrance mixes” containing the com-
monest fragrance allergens are much more predic-
tive (38,39).
Allergy to Other Constituents
Preservatives are sometimes responsible for al-
lergic contact dermatitis. Colorants are also occa-
sional sensitizers, although paraphenylenediamine
and azo dyes, once common culprits, are not so
much in use today (34).
Stinging
There are some substances that have the an-
noying ability to cause a sensation of stinging when
applied to the face. There is no visible sign of irrita-
tion when this happens and no changes can be de-
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tected in any of the physiological variables, such as
blood flow and transepidermal water loss (32).
Cosmetic Acne
Some substances, when applied topically, have
the unfortunate tendency to cause comedones and
sometimes the inflamed lesions of acne. They
seem to do this by irritating the epithelium at the
mouth of the follicle. This adverse side effect is
much more frequently seen in individuals in the
“acne age group”. Formulations containing tar prod-
ucts are notorious for inducing an acneiform
folliculitis, but these are not usually found in emol-
lients. The major “comedogens” or “acneigens” are
cocoa butter and its derivatives, petrolatum and
other mineral oil substances, isopalmitate, isopro-
pyl myristate, and their various analogues (17).
Miscellaneous Adverse Reactions
Pigmentary disturbances are uncommon conse-
quence of the use of cosmetics. Hyperpigmented
areas on the neck were not uncommon result of a
photosensitivity response to 5-methoxypsoralen in
Bergamot oil, which was a fragrance constituent of
“eau do cologne” (34). Depigmentation is a rare re-
sult of cosmetic usage – the cosmetic industry is
mostly looking for agents to make the skin less pig-
mented (34). Oleogranulomatous inflammatory re-
sponse can occur in lymph nodes draining areas of
skin treated with emollients in a patient with an un-
usual form of ichthyosis called Netherton syndrome
(40).
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“Creme de Noisette” made of hazelnuts and used as a dry night cream. It leaves
the skin unbelievably smooth. Sunspots and wrinkles quickly disappear.
From the collection of Stella Ferenèiæ-Fatoviæ, M.D., Ph.D.
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20,00-22,00 Welcome reception
Friday, May 30, 2003.
8,00-20,00 Registration at the Registration Desk in front of the Reception of the Hotel Jezero
MAIN CONGRESS HALL HOTEL JEZERO
1. THE ROLE OF LOCAL TREATMENT IN DERMATOLOGY
08,45-10,45
Chairpersons: H. Nakayama, M. Ramos-e-Silva, R. Wolf, V. Milavec-Puretiæ
08,45-09,00 V. Milavec-Puretiæ, I. Lakoš-Jukiæ: Optimization of the topical therapy in
dermatology (O 5)
09,00-09,15 S. Murat-Sušiæ, K. Husar: Neonatal and infant skin care (O 6)
09,15-09,30 I. Nola, K. Kostoviæ, L. Kotrulja, L. Lugoviæ: Emollients as sophisticated therapy in
dermatology (O 7)
09,30-09,50 R. Wolf, H. Matz, E. Orion: Sunscreens – the ultimate cosmetic (O 8)
09,50-10,00 J. Lipozenèiæ: What’s new in topical therapy? (O 9)
10,00-10,15 C. R. Celebi: The project of consumer attitudes on cosmetic products and
applications in Balkanian countries (O 10)
10,15-10,30 M. Ramos-e-Silva: Photoaging – myths and facts (O 11)
10,30-10,45 Discussion
10,45-11,00 Coffee break
11,00-12,00 Satellite symposium SPIRIG
Extemporaneous prescriptions
M. Gloor: Update on extemporaneous prescriptions in dermatology (S 1)
P. Huber: Quality management in extemporaneous prescriptions
12,00-14,00 Lunch time and poster viewing
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2. THERAPY OF INFLAMMATORY SKIN DISEASES
14,00-16,00
Chairpersons: J. Ring, A. Kapp, A. Pašiæ, G. Trevisan, J. Lipozenèiæ
14,00-14,20 J. Ring, U. Darsow: New approaches in treatment of atopic eczema (O 12)
14.20-14.35 I. Lawrence: Three studies in pediatric and adult patients demonstrate that tacrolimus
ointment is safe and effective in the treatment of atopic dermatitis (O 13)
14,35-14,50 F. Kokelj, G. Trevisan: UV combined therapy in psoriasis (O 14)
14,50-15,05 V. Kuzmanovska, L. Biserkoska-Atanasovska: A new combination in local
treatment for psoriasis vulgaris (O 15)
15,05-15,15 P. Vrogiæ, A. Pašiæ, T. Podobnik-Takaè, J. Lipozenèiæ: Psoriasis vulgaris et
arthritis psoriatica gravis mutilans – case report (O 16)
15,15-15,30 Z. Jukiæ, V. Barišiæ-Druško, I. Ruèeviæ, N. Šustiæ, D. Biljan, A. Ageel, R. Vukadin:
Local therapy of psoriasis vulgaris – historical review (O 17)
15,30-15,45 A. Pašiæ, R. Èeoviæ, D. Hrsan: The light in the treatment of dermatoses (O 18)
15,45-16,00 Discussion
16,00-17,00 Satellite symposium VICHY
Improving our Knowledge of Healthy Skin: UV-Induced Skin Damage
and Public Awareness of Photoprotection
I. Bartenjev: The importance of photoprotection
A. Bakija-Konsuo, Z. Bukviæ-Mokos, M. Kaštelan, L. Prpiæ-Massari, I. Sjerobabski-
Masnec, L. Stojanoviè, B. gavec: Educating people about the harmful effects of the
sun and the importance of photoprotection: Results of the “Sun Prevention Center”
campaign
17,00-17,30 Coffee break
3. TREATMENT OF VIRAL, BACTERIAL, PARASITIC DISEASES AND
SEXUALY TRANSMITTED INFECTIONS
17,30-19,00
Chairpersons: A. Horváth, A. Stary, M. Waugh, M. Šitum, V. Heghyi
17,30-17,50 A. Horváth, K. Nagy: Unusual cases of immunodermatologic diseases:
retroviral background? (O 19)
17,50-18,05 M. Waugh: Syphilis in Europe setting the scene (O 20)
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18,05-18,20 R. Wolf, H. Matz, E. Orion: Scabies: The diagnosis of atypical cases and their
treatment (O 21)
18,20-18,35 A. Stary: Antibiotic resistance in gonococcal infection (O 22)
18,35-18,45 M. Potoènik: Side effects of different treatment methods for anogenital warts (O 23)
18,45-19,00 Discussion
19,00-20,00 Satellite symposium BELUPO
Itrac 3 in Dermatology
M. Skerlev: The novel treatment strategies – significance of Itraconazole
20,30- Gala Dinner with live music
Saturday, May 31, 2003.
MAIN CONGRESS HALL HOTEL JEZERO
4. TREATMENTS AND MISTREATMENTS IN COSMETOLOGY
09,00-12,30
Chairpersons: H. P. M. Gollnick, A. Basta-Juzbašiæ, A. D. Katsambas, L. Oremoviæ, F. Gruber
09,00-09,20 H. Nakayama: Melasma : Its causation and treatment (O 24)
09,20-09,40 A. D. Katsambas: Topical corticosteroids old and new guidelines (O 25)
09,40-09,55 A. Basta-Juzbašiæ: Pro et contra topical corticosteroids on the face (O 26)
09,55-10,10 S. Ljubojeviæ, J. Lipozenèiæ, A. Basta-Juzbašiæ, V. Milavec-Puretiæ: Contact
sensitivity in facial dermatitis (O 27)
10,10-10,25 L. Oremoviæ, I. Sjerobabski-Masnec, L. Lugoviæ, G. Novak Biliæ: Cosmetics and
acne vulgaris (O 28)
10,25-10,40 N. Arslanagiæ, R. Arslanagiæ: Side effects of local glucocorticosteroid therapy on
the skin of the face (O 29)
10,40-11,00 V. Hegyi, L. Hegyiva: Laser in dermatology – past, present and future (O 30)
11,00-11,10 I. Sjerobabski Masnec, L. Oremoviæ, L. Kotrulja, I. Nola, J. Meštroviæ-Štefekov:
Mistreatment in acne therapy – a case report (O 31)
11,10-11,20 N. Puizina-Iviæ, T. Stipiæ, A. Èarija, S. Periæ-Sušak, V. Gotovac: Peelings of ageing
skin: what’s new? (O 32)
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11,20-11,35 I. Bartenjev: Laser in dermatology (O 33)
11,35-11,50 M. Šitum: Approach to dermatosurgery in Croatia (O 34)
11,50-12,10 L. E. Millikan: Surgical treatment-cosmetic (O 35)
12,10-12,20 Discussion
12,20-12,30 Coffee break
12,30-13,30 Satellite symposium URIAGE-Formasana
Atopic dermatitis and skin care
J. Lipozenèiæ: Etiopathogenesis of atopic dermatitis – the phenomenon of dry and
irritable skin
S. Murat-Sušiæ: Treatment and skin care of patients with atopic dermatitis
S. Škrinjar: URIAGE products in skincare of dry and atopic skin
13,30-14,00 ANNUAL MEETING OF THE CROATIAN DERMATOVENEROLOGICAL SOCIETY
14,00-15,00 Lunch time and poster reviewing
15,00-16,00 Satellite symposium BEIERSDORF
New Scar Reducer Therapy
B. Marinoviæ: Common scars and keloids
J. Lipozenèiæ: Hansaplast – scar reducer in prevention of keloids
5. TREATMENTS AND MISTREATMENTS IN DERMATOMYCOLOGY
16,00-17,00
Chairpersons: M. Skerlev, A. Prohiæ, V. Barišiæ-Druško, N. Arslanagiæ
16,00-16,20 M. Skerlev: The appropriate and inappropriate treatment of dermatomycoses (O 36)
16,20-16,30 A. Prohiæ, M. Kantor: Tinea incognita caused by Trichophyton verrucosum (O 37)
16,30-16,40 J. Radoš, M. Skerlev, D. Celiæ, I. Dobriæ: What do we really know about tinea
incognita? – a case report (O 38)
16,40-16,50 D. Biljan, V. Barišiæ-Druško, Z. Jukiæ, N. Šustiæ, I. Ruèeviæ, R. Vukadin, A. Ageel:
Clinical experience with promogran (O 39)
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16,50-17,00 Discussion
17,00-17,15 N. Sijerèiæ, F. Gruber, M. Šitum: Poster award for the best three posters
dedicated to topical therapy
17,15 J. Lipozenèiæ: Final Conclusion and Closing Ceremony
Closing Cocktail
Posters:
1. T. Batinac, J. Lipozenèiæ, G. Zamolo, F.
Gruber, A. Stašiæ, M. Lenkoviæ: P53 and Ki-67
in proliferative skin diseases
2. I. Kuljanac, E. Kneeviæ, H. Cvitanoviæ: Ery-
thema annulare centrifugum (a case report)
3. I. Kuljanac, E. Kneeviæ, H. Cvitanoviæ: Li-
chen planus linearis – a case report
4. J. Lipozenèiæ, D. Bobek, V. Milavec-Puretiæ,
J. Jakiæ-Razumoviæ, A. Basta-Juzbašiæ, S.
Ljubojeviæ: Expression of CD30+ and CD45+
RO in atopic dermatitis lesions
5. L. Lugoviæ, J. Lipozenèiæ: Mixed and pure
atopic dermatitis
6. I. Manola, S. Ljubojeviæ, J. Lipozenèiæ, N.
Pustišek: Nevus commedonicus – a case re-
port and review of therapeutical approach
7. S. Simeonova, V. Lazarevic, L. Biserkoska-
Anasovska, M. Nikolovska: Complications in
tattooing with different approach to healing
8. M. Šitum, . Buèan, S. Levanat: Gorlin’s syn-
drome and therapeuthical possibilities
9. M. Šitum, . Buèan, K. Kostoviæ, D. Štulhofer
Buzina: Congenital giant nevus – therapeutic
approach
10. I.Vukšiæ, N. Puizina-Iviæ, D. Marasoviæ, D.
Anðelinoviæ, T. Stipiæ, D. Pezelj, G. Pavièiæ,
V. Gotovac, A. Èarija, S. Periæ-Sušak: The ef-
ficacy of table sugar in treatment of venous ul-
cers
11. K. Kostoviæ, . Buèan, I. Nola, N. Troskot:
Vitiligo - new approaches in phototherapy
12. I. Ruèeviæ, V. Barišiæ-Druško, D. Biljan, Z.
Jukiæ, N. Šustiæ, R. Vukadin, A. Ageel:
Convatec in local therapy – a case report
13. J. Meštroviæ-Štefekov, M. Šitum, B. Marinoviæ,
G. Novak-Biliæ, L. Kotrulja, I. Nola: Therapeu-
tic difficulties in diagnosis of pemphigus folia-
ceus
14. G. Novak-Biliæ, M. Šitum, A. Soldo-Belic, J.
Meštroviæ-Štefekov, L. Kotrulja, L. Lugoviæ:
Vasculitis with mutilation: part of leprosy clinical
findings?
15. L. Kotrulja, L. Oremoviæ, I. Sjerobabski
Masnec, M. Šitum, M. Vurnek, . Buèan, M.
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Tadinac Babiæ, N. Jokiæ Begiæ, R. Gregurek:
Correlation between quality of life and psycho-
logical impact of patients in acne vulgaris
16. H. Cvitanoviæ, E. Kneeviæ, I. Kuljanac: Der-
matomycoses in Karlovac county 1995-2002
17. J. Lipozenèiæ, S. Ljubojeviæ, N. Pustišek, T.
Batinac: Erythromelalgia provoked by influ-
enza vaccine
18. A. Smeh-Skrbin, I. Dobriæ, G. Krnjeviæ-Peziæ,
P. Vrogiæ: Naphthalan in the treatment of
patients with atopic dermatitis (neurodermitis)
Main Sponsor:
Belupo – lijekovi i kozmetika d.o.o., Koprivnica, Ulica Grada Vukovara 14, 10 000 Zagreb
Sponsors:
Oktal Pharma, Utinjska 40, 10 020 Zagreb
Beiersdorf Medical d.o.o., Krina 18, 10000 Zagreb
Vichy, Stoenska 2, 1113 Ljubljana, Slovenia
Schering-Plough, Central East AG, Trg Draena Petroviæa, 10 000 Zagreb
Formasana, Ilica 100, 10000 Zagreb
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Active participants are from:
1. Austria














16. United States of America
17. Turkey
WHY PLITVICE LAKES NATIONAL PARK AS A CONGRESS VENUE?
Plitvice Lakes National Park, in the heart of Croatia,
consists of 16 beautiful blue-green lakes, linked by a se-
ries of waterfalls and cascades forming a chain through
a wooded valley. Over thousands of years, the waters
that flow through this area have passed over limestone
and chalk, creating deposits, which form natural barriers
between the lakes. The lakes range in height from
Proscansko Jezero at 636.6m (1,746 ft) above sea level,
to the lowest Kaludjerovac at 505.2m (1,386 ft), and in
surface area from 81 hectares (33 acres) to one hectare
(2.5 acres). Aside from the beauty of the Plitvice Lakes,
which offer a great opportunity for hiking, boating, and
other activities, there are deer, wild boar, wild cats, small
game, and many kinds of birds. The waters are rich in
trout. Hunting, fishing, and swimming are not allowed.
In April 1949, a Code was brought into force declar-
ing the Plitvice Lakes a Natural Park, as the area of spe-
cial natural beauty. The organization of United Nations,
ie, UNESCO office, recognized the exceptional natural
uniqueness of area and included the Plitvice Lakes in
1979 among the World’s cultural and natural inheri-
tance, as a special value not only for us, but for the whole
mankind. The Plitvice Lakes National park is a member
of the Natural parks Federation and European Parks of
Nature.
Join us at Plitvice, at the International Congress “Top-
ical procedures, innovations and mistreatments”, a sci-
entific meeting which is to be held in hotel “Jezero”. It will




How to Reach Plitvice Lakes National Park?
By air
There are frequent direct flights to all important Euro-
pean cities from Zagreb International airport “Pleso”.
The transportation from Zagreb to Plitvice will be orga-
nized on May 29, 2003, at 9 a.m, and departure on May
31, 2003, at 12 p.m.
By car
The Lakes are located in the area of Southeast Eu-
rope, in part of Croatia where we go from northern flat
land towards a bit more elevated karsted mountain area.
The road going through Zagreb and then continuing to-
wards central and southern section of the Adriatic, brings
us to the Plitvice























BASIC PRINCIPLES OF LOCAL THERAPY IN
DERMATOVENEROLOGY
I. Dobriæ, S. Murat-Sušiæ
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia
Systemic drugs are rarely used as the only form
of treatment for skin diseases. Most cases require a
combination of modalities, i.e. a kind of therapy that
includes both systemic drugs and drugs for local
application, which are usually referred to as topi-
cals. When prescribing these drugs, it is necessary
to take into account the following factors: 1) exact
indication; 2) knowledge of pharmacodynamic ef-
fects of the drug; and 3) right choice of the vehicle
into which the drug is incorporated. Our report con-
tains some essential facts concerning vehicles and
covers all forms of topicals: water solutions, baths,
compresses, alcohol solutions, dermatological tinc-
tures, varnishes, sprays, powders, mixtures, “zin-
kleim”, bandages, balms, gels, pastes, oils, oint-
ments, creams, and lotions. Furthermore, it deals
with clinical morphology, the choice of the best
dermatics, different groups of dermatics, and their
areas of indication. Also, some important facts are
pointed out about local therapy, glucocorticoids,
and basic principles concerning the tactics in the lo-
cal application of the glucocorticoids.
O 2





PATHOGENESIS AND CURRENT GLOBAL
TREATMENT STRATEGIES FOR ACNE –
RECOMMENDATIONS OF THE GLOBAL
ALLIANCE TO IMPROVE OUTCOMES IN
ACNE
H. P. M. Gollnick
University Clinic for Dermatology and Venerology, Otto-
von-Guericke University, Magdeburg, Germany
Acne is a disease of the second life decade, with
nearly 100% incidence among both women and
men. Acne has a polyetiological background com-
prised of genetic, endocrine, immunological, envi-
ronmental, and psychological factors. The polymor-
phous character of acne ranges from a very mild
‘’physiological’’ course to a severe disabling acute
or chronic inflammatory disease. In general, there
are two types of acne: an endogenous or “natural”
type and a “non-natural” type provoked by addi-
tional endogenous and/or exogenous factors. The
target organ is the pilosebaceous follicle. Acne al-
most exclusively occurs in the areas of the body in
which this type of follicle is distributed, in particular,
the face, chest, and back. At least four etiological
factors are responsible for the development and
maintenance of acne. These include increased ac-
tivity of the sebaceous glands with hyperseborrhea,
disturbed cornification within the pilosebaceous
duct, increased microbial colonization with P.
acnes, and inflammatory and immunological reac-
tions. However, one factor alone is usually not
enough for development of acne. Acne comedonica
and papulo-pustulosa can be found in more than
50% of cases.
The main part of acne treatment is going via top-
ical route. When small nodes or scarring occurs,
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systemic co-medication is indicated. Topical treat-
ment is affecting at least three of the four main
pathogenetic factors responsible for the develop-
ment of acne. Topical agents currently available in-
fluence at least one of these factors, but often have
additional effects. Topicals that act comedolytically
and anticomedogenically are retinoids, tretinoin,
isotretinoin, adapalene, tazarotene, and azelaic
acid. Some of the retinoids have additional anti-in-
flammatory potency. Adapalene is known from ex-
perimental and clinical studies as a potent anti-in-
flammatory retinoid. Unfortunately, the bacterial re-
sistance is emerging as a significant problem. P.
acnes resistance to the commonly used erythro-
mycin can also be transferred to clindamycin. BPO
has a strong antibacterial potency without inducing
bacterial resistance. Azelaic acid has similar effect,
but does not work as fast as BPO. Furthermore, ef-
fective combinations of antibiotics with retinoids or
benzoylperoxide are available. The Global Alliance
recommends the use of effective combinations of
topical retinoids plus topical antibiotics or other
antimicrobial drugs, i.e. benzoylperoxide, from the
very beginning. For systemic treatment of acne, an-
tibiotics, isotretinoin, and oral antiandrogenic ste-
roid hormones can be used. Tetracyclines, such as
doxycycline and minocycline, are the most fre-
quently used antibiotics for this indication. The du-
ration of treatment investigated in controlled studies
usually lasted 3 or more months. However, in prac-
tice, it is often necessary to maintain the treatment
for a longer period of time. A combination with local
treatment, e.g., benzoylperoxide, a topical retinoid,
or azelaic acid, is often advisable. The introduction
of oral isotretinoin has indeed revolutionized the
treatment of severe forms of acne. This drug affects
all pathogenic factors of acne and is still the most
potent of medications available on the market. As
long as topical antiandrogens are not fully working,
the oral use of cyproterone acetate or chlormadinon
acetate composed with etinylestradiol or spirono-
lactone remains preferred treatment in women.
Combination with a topical retinoid or azelaic acid is
advised, or a combination of an oral antiandrogen
and oral tetracyclin. This type of therapy affects the
inflammatory lesions in earlier phase. Hopefully, our
better understanding of cellular and molecular
events in acne development will lead to more effi-
cient treatments.
O 4
ETHNIC SKINS AND THEIR MANAGEMENT
M. Ramos-e-Silva, F. Addor
Sector of Dermatology and Postgraduation Course -
HUCFF-UFRJ and School of Medicine, Universidade Fed-
eral do Rio de Janeiro, Rio de Janeiro; and Medcin, São
Paulo, Brazil
Different color skins do not differ in color only.
Each type of skin has specific characteristics, such
as different responses in skin reparation, seba-
ceous secretion, skin width, fat distribution, and
hydration. Common skin diseases and their histolo-
gical features differ between Brazilian Blacks and
Whites. The knowledge of these differences is use-
ful for the correct diagnosis and treatment of prob-
lems like melasma, post-inflammatory hyperpig-
mentation, acne, or pseudofolliculitis barbae. Fur-
thermore, hair shows many interesting variations.
For example, white people tend to be more hirsute
on the arms and legs and have greater tendency to
baldness. On the other hand, curly and black hair in
Blacks entails pseudofolliculitis barbae or acne
cosmetica, which are in some aspects different
from those found in people with fair skin. These
variations should always be evaluated before any
type of therapy is applied. There are also many so-
cial and cultural aspects that should be taken into
account, beside the different evolution and scar for-
mation.
1. THE ROLE OF LOCAL TREATMENT
IN DERMATOLOGY
O 5
OPTIMIZATION OF THE TOPICAL
THERAPY IN DERMATOLOGY
V. Milavec-Puretiæ, I. Lakoš Jukiæ
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia
In the treatment of skin diseases, the advantage
of topical dermatological medications over oral
drugs is that high drug concentrations can be
achieved at the site of pathology without prior sys-
temic distribution. Many safe topical agents would
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be toxic or lethal if oral or systemic routes were
used to achieve the effective drug levels in the skin.
Dermatological preparations may be used in the
treatment of a wide range of conditions, including
eczema, inflammatory diseases, viral diseases,
fungal diseases, skin carcinomas, alopecia, burns,
acne, and local pain. In addition, they may offer ad-
vantages in terms of easy application and patient
compliance, and may provide additional advan-
tages, such as cooling and abatement of localized
inflammation and itching, and improved hydration.
Optimization of topical therapy in dermatology re-
quires knowledge of the various vehicles and when
to employ them, understanding of the active ingre-
dients, including their mechanism of action, and
clear appreciation of the appropriate indications for
the various products.
O 6
NEONATAL AND INFANT SKIN CARE
S. Murat-Sušiæ, K. Husar
Department of Dermatology and Venerology, Clinical Hospi-
tal Zagreb and University School of Medicine, Zagreb
Baby’s skin is a source of admiration to the
adults. The aims of optimal skin care are to maintain
its smoothness and to decrease the chance of vari-
ous skin diseases. Although there are some differ-
ences between the skin of neonates and infants
and the skin of adults, these are not reflected in ma-
jor functions of the organ. The skin acts as an inter-
face between the child and the environment; it gives
protection from dehydration, excessive water influx,
and electrolyte losses. It is important in thermo-
regulation and antimicrobial defense and gives pro-
tection from environmental toxins, trauma, and ul-
traviolet radiation. It is also a tactile sensor organ.
Infant’s skin is subjected to different environmental
conditions, particularly in the skin folds or the diaper
area. The ratio of body surface area to weight in in-
fants is up to 5 times that of adults. This is the major
reason that places infants at increased risk of skin
injury, percutaneous toxicity from topically applied
agents, and percutaneous infection. The cosmetic
market for children has developed enormously. Ac-
cording to statistical data, 8 skin care products are
used on average for every-day skin care of infants
in the USA. We present every-day skin care prac-
tices, including bathing, diapering, umbilical cord
care, emolliation, as well as prevention and man-




I. Nola, K. Kostoviæ, L. Kotrulja, L. Lugoviæ
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, Zagreb, Croatia
Emollients are agents designed to make the
stratum corneum softer and more pliant, increasing
its hydration. A large number of preparations are
available, many of which are marketed as cosmetic
and therapeutic moisturizers. They are the most
prescribed products in dermatology. Their structure
and function are surprisingly complex and sophisti-
cated; many are equidistant between cosmetics
and drugs. The use of the emollients corrects the
problems in scaling disorders. Also, it is well known
that the electrical properties of the stratum corneum
are changed after application of an emollient. Liter-
ature data support the possibility of their suppres-
sive effects on epidermal thickening. Emollients
have an anti-inflammatory activity and also give
some transient relief from irritation. In clinical use,
emollients are employed as treatments for the
ichthyoses, xeroderma, and other disorders of
keratinization, atopic dermatitis, psoriasis, and
photodamaged skin. Emollients of the new millen-
nium include agents that mimic natural ingredients
and function as botanicals, including vitamins,
hydroxy acids, and retinoids. Emollients can cause
a few side effects, such as irritant dermatitis, aller-
gic contact dermatitis, fragrance allergy or allergy to
other constituents (preservatives or additives),
stinging, cosmetic acne, and pigmentary disorders.
We can conclude that emollients are very important
in the treatment of different dermatoses, and are
evolving to ever more sophisticated products.
O 8
SUNSCREENS – THE ULTIMATE COSMETIC
R. Wolf1, H. Matz1,2, E. Orion1
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1Kaplan Medical Center, Rechovot, 2Tel-Aviv Sourasky Med-
ical Center, Tel-Aviv, Israel
In spite of the sunscreen-melanoma controversy
that has prevailed over recent years, sunscreens
are and will remain the “ultimate” cosmetic. The es-
sential properties of sunscreens, which include ab-
sorption spectrum, extinction coefficient, sun pro-
tection factor, and substantiveness, will be dis-
cussed, as well as some of the misunderstandings
and confusion about the mode of action of physical
(i.e. particulate and inorganic) sunscreens. For ex-
ample, the inorganic metal oxides (ZnO and TiO2)
neither act as pure scatterers nor are they inert ma-
terials that do not undergo any chemical change
while attenuating UV light. Rather, they mobilize
electrons within their atomic structure and emit the
energy in lower magnitude, and do so in exactly the
same manner as organic sunscreens. However, al-
though metal oxides can photocatalyze a number of
functional changes and cause damage to cellular
RNA, DNA, and proteins, the likelihood of the oc-
currence of these reactions is almost none when
sunscreens are used. The reason is that metallic
oxides do not penetrate the stratum corneum and
thus do not come in contact with any living cells of
the epidermis. Moreover, metallic oxides are coated
by inorganic oxides (e.g., SiO2 or Al2O3) and thus
can not react with their surroundings, such as other
components of the sunscreen itself and living tis-
sues.
O 9
WHAT’S NEW IN TOPICAL THERAPY?
J. Lipozenèiæ
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia
There is a paucity of laboratory research in com-
monly used local treatments, whereas particular at-
tention is given to new local therapy options. New
formulations, such as pimecrolimus, are being de-
veloped and implemented in the treatment of
dermatological conditions. Pimecrolimus (0.2%;
0.6%; or 1% vehicle cream Eldiel®; ASK 981) may
be used in the treatment of atopic dermatitis. This
newer calcineurin inhibitor has an anti-inflammatory
potential and has not been shown to induce skin at-
rophy. Pimecrolimus is closely related to tacrolimus.
Tacrolimus and pimecrolimus share the same cellu-
lar binding targets and mechanism of action. Tacro-
limus ointment (0.03% or 0.1% Protopic®), a topical
inhibitor of the phosphatase calcineurin, has re-
cently been approved in the USA for use in the
treatment of moderate to severe forms of atopic
dermatitis. It is the first non-steroid topical immune
suppressant. Unlike glucocorticoids, tacrolimus
cannot penetrate thick skin and does not cause der-
mal atrophy, which is an important advantage.
Tacrolimus ointment for facial lesions of chronic ac-
tinic dermatitis seems to be effective and well-toler-
ated treatment. Because of its safety, tacrolimus will
become generally preferred therapeutical agent in
the treatment of facial dermatoses (psoriasis,
seborrheic dermatitis, allergic contact dermatitis,
and rosacea), alopecia areata, and lichen planus.
However, topical steroids will remain more econom-
ical than tacrolimus because they are usually avail-
able as generics.
Lactic Care lotion (1% and 2%), the original
Alphy Hydroxy lotion with a consistency of a cream,
contains recognized humectants, lactic acid, and
sodium PCA. It is a soothing emollient and moistur-
izer, excellent for dry skin care and for large body
areas, where body hair is present. Although Lactic
Care®-HC Lotion (1% and 2%) contains hydrocorti-
sone, it is intended for patients of any age and safe
for use even in children. It is ideal for the treatment
of chronic conditions where a low potency steroid is
indicated.
A fresh approach to actinic keratoses therapy –
0.5% fluoruracil cream, with 0.35% incorporated
into a patented porus microsphere (Microspoun-
ge®-Pick CaracTM) – effectively reduces actinic ke-
ratoses and leads to rapid recovery of treatment-re-
lated irritation. It is also convenient because of
once-a-day application. Carac® is contraindicated
in women of fertile age, in patients with dihydro-
pyrimidine dehydrogenase (DPD) enzyme defi-
ciency, and in patients with known hypersensibility
to any of its components. Diclofenac sodium-3%
w/w topical gel (Salaraze® gel) is the first prepara-
tion of the new class of therapeuticals for actinic
keratoses, used for complete lesion clearance.
A skin care product for medium depth treatment
of sun damaged or unevenly pigmented skin is a
patented new formula containing 20% TCA, 10%
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L-Lactic polymer bleaching formula. It simulta-
neously inhibits pigmentation, bleaches melanin,
and exfoliates the skin. It is applied in a layering
technique (Ultra Peel® Forte, prescription only).
First tretinoin cream proven to reduce signs of
photodamage, hyperpigmentation, and roughness
of facial skin is tretinoin emollient cream 0.05%
(Renova®), appropriate for use before and after
cosmetic procedures. Tretinoin cream 0.02% (Re-
nova®) is also available for patients with fine facial
wrinkles, who use compressive skin care, avoid
sunlight, and have lightly pigmented skin.
Anti-aging skin solution with 4% hydroquinone
and 10% glycolic acid, stabilized with antioxidants
L-ascorbic acid (vitamin C) and tocopherol (vitamin
E), and broad-spectrum SPF 15 is cosmetically ele-
gant formulation (Glyquin® cream) used for the
gradual bleaching of hyperpigmented skin and con-
ditions, such as chloasma, melasma, freckles, se-
nile lentigines and other unwanted melanin hyper-
pigmentation.
Acne treatment fluid, the first product of the inno-
vative care line for skin prone to acne, belongs to a
new generation of keratolytic skin therapeuticals
(Effaclar K®). Formulated by pharmaceutical labo-
ratory, it contains natural thermal spring water and
1.5% salicylic acid, both intended for oily skin care
and gentle enough for everyday use. It leaves
pleasant, non-oily feel on the skin. Benzoyl perox-
ide in concentrations of 2-5% is still the gold stan-
dard in the treatment of mild-to-moderate papu-
lar-pustular acne. Azelaic acid is an alternative
agent with anticomedonic effect and antibacterial
activity that does not induce resistance. Physical re-
moval of multiple, densely packed, closed comedo-
nes can be done by electrocautery or CO2 laser. In
the group of topical antimicrobials in an aqueous-
based gel for acne treatment, a combination of
clindamycin 1% and benzoyl peroxide 5% (Ben-
zallinTM topical gel) works better than either clin-
damycin or benzoyl peroxide alone. It is convenient
and the only FDA-approved combination for the
topical treatment of acne. Tazarotene 0.1% cream
(Tazorac®) is indicated for the 4-week topical treat-
ment of acne vulgaris; it significantly reduces open
and closed comedones as well as inflammatory
acne, and has effects comparable to those of Diffe-
rin® gel 0.1%, as shown in a 4-week study in
healthy volunteers. Adapalene (Differin®), available
in the form of gel, cream, solution, or pledgets 0.1%,
is a topical retinoid of proven tolerability in a broad
range of patients. Multiple formulations provide a
full range of therapeutic options.
For external genital and perianal warts
(condylomata), the first and only self-applied im-
mune response modifier is imiquimod-5% Aldara®
cream. It increases cytokine (interferon ) produc-
tion and reduces DNA of human papilloma virus,
e.g., 6 and 11, which are the subtypes most com-
monly associated with external genital warts. It is
used at bedtime every other day (3 times per week)
and needs to be washed off in the morning. The av-
erage patient may need a few treatments to clear
genital warts. However, despite the treatment,
warts may recur.
Metronidazole (Metrogel®) topical gel 0.75% is a
fast-acting and powerful agent for treatment of
rosacea, and clinically proven to provide long-term
control. Three formulations are available to meet
the treatment goals: Metrogel®, a soothing, wa-
ter-based formula; Metro Cream®, a moisturizing
formula; and Metro Lotio®, an elegant easy-to-apply
lotion indicated for topical application in the treat-
ment of rosacea inflammatory papules and pus-
tules.
Fluocinolone acetonide topical shampoo 0.01%
(CapexTM shampoo) is a unique steroid treatment in
a shampoo delivery system for seborrheic dermati-
tis of the scalp. It reduces inflammatory and pruritic
components of seborrheic dermatitis. It should be
applied once a week for maintenance therapy. So-
dium sulfacetamide 10% wash (Ovace wash) is an
effective prescription treatment for skin cleansing,
applied daily or once or twice a week to prevent re-
currence of seborrheic dermatitis.
Ciclopirox topical solution 8% (PenlacTM nail lac-
quer) for nail infection is the first and only FDA-ap-
proved topical prescription treatment for treatment
of mild and moderate onychomycosis in a conve-
nient brush-on option. PenlacTM is indicated in im-
munocompetent patients with onychomycosis of
fingernails and toenails due to Trychophyton spp.
Physical sunscreens (zinc oxyde, titanium dio-
xyde, and magnesium silicate) are made in micro-
nised forms and block ultraviolet radiation. Chemi-
cal sunscreens, such as paraaminobenzoic acid
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(PABA), PABA esters, salicylates, cinnamates, anth-
ranilates, and benzophenones, act by absorbing
UVB and UVA.
Synthetic detergents (syndet) in bars are com-
posed of synthetic detergents and filters that con-
tain less than 10% soap and have an adjusted pH at
5.5-7. Syndets have distinct advantages over alka-
line soaps because they are suitable for skin with
weakened alkali-reducing capacity.
O 10
THE PROJECT OF CONSUMER ATTITUDES
TOWARD COSMETIC PRODUCTS AND
THEIR APPLICATIONS IN BALKANIAN
COUNTRIES
C. R. Celebi
Consultant Dermatologist, Ankara, Turkey
The Balkan States are potentially important mar-
ket for cosmetic industry. However, consumer atti-
tudes toward cosmetic products have never been
investigated and documented in this region. This re-
search aims at assessing the profile of consumers
in each Balkan State with respect to cosmetic prod-
ucts by use of a standard survey. The data are still
being collected.
O 11
PHOTOAGING – MYTHS AND FACTS
M. Ramos-e-Silva
Sector of Dermatology and Postgraduation Course –
HUCFF-UFRJ and School of Medicine, Universidade Fed-
eral do Rio de Janeiro, Rio de Janeiro, Brazil
Myths and facts related to photoaging are some-
times confusing, so this presentation will deal with
what we know and what we suspect about it. Some
controversial aspects about the pathogenesis, clin-
ics, histology, prevention, and treatment of photo-
aging will be discussed. Because sun exposure can
cause acute and long-term consequences, the
characteristics of the solar spectrum, its various de-
gree of penetration, and beneficial and harmful ef-
fects will be considered. For both photoaging and
photocarcinogenesis, it is sometimes necessary to
prescribe topical, oral, and/or surgical measures,
after weighing the advantages and disadvantages
of each method of treatment. There are important
differences between photoaging and chronological
skin aging. The fact that more than 80% of the
changes result from excessive sun exposure





Spirig Pharma, Karlsruhe Department of Dermatology,
Karlsruhe, Germany
Extemporaneous prescriptions should be pre-
ferred over ready-made preparations only when the
targeted therapeutic purpose cannot be achieved
with a speciality. This is often the case in daily prac-
tice: frequently the application of extemporaneous
prescriptions is necessary because the vehicle of
the ready-made preparation is not suited for the
corresponding indication. This is particularly true for
atopic eczema, with its impaired stratum corneum
barrier. Because of the barrier damaging effect of oil
in water emulsions, only water in oil emulsions or oil
in water emulsions with a moisturizer may be used.
Another important reason for the use of extempora-
neous prescriptions may be the fact that the
ready-made preparation might only be available
with an active in one or maybe two concentrations.
On the other hand, the penetration of the active at
different localization of the body and depending on
the state of the horny layer barrier can differ by a
factor of 100. For dermocorticosteroids, for exam-
ple, the concentration of the active should be
strongly individualized accordingly. Some actives or
active combinations necessary to the dermatolo-
gists are not available in suited vehicles or are not
available at all. This is particularly true for classical
actives like tar, liquor carbonis detergents, and sul-
fur, but also the antibiotic Polymycin B sulphate that
cannot be replaced because of its outstanding ac-
tion against Gram negative bacteria, particularly
Pseudomonas. Another example is retinoid acid
used by the dermatologist in case of prematurely
aged skin, lichen ruber, and psoriasis. Here, water
in oil emulsion is needed. The speciality, on the
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other hand, is only available in hydrophilic vehicles
adjusted to the acne therapy.
Some important modern principles of therapy
may not be realized with ready-made preparations.
Examples are the application of antiseptics like
chlorhexidindigluconat and particularly triclosan as
a replacement for antibiotics. A therapy with anti-
septics has large advantages because of the lack of
induction of resistance. This is in particular true for
the well-established coloring agents, Fuchsin and
Gentianaviolet (methylrosaniliumchlorid). These
actives show an extremely broad antimicrobial
spectrum not only against Gram positive and Gram
negative germs, but also against fungi. They are
thus necessary in case of mixed infections (e.g.,
Gram negative infection of the foot, so-called ath-
lete’s foot).
In some cases, the pricing might be another rea-
son to prefer extemporaneous prescriptions, e.g., in
Germany, topical minoxidil or shampoos containing
ketoconazole.
In many countries, well-documented vehicles
from industrial companies are available aside the
official standard bases. Due to such a wide choice
of differentiated products, various clinical situations
can be adequately targeted. In the context of quality
assurance of extemporaneous prescriptions, the
following requirements should be met: 1) documen-
tation of the galenical compatibility with appropriate
actives over 8 weeks; 2) documentation of the
chemical stability of the active over the same pe-
riod; 3) information about the skin physiological
properties of the different vehicles; and 4) high mi-
crobiological resistance (risk of contamination while
preparing the mixture in the pharmacy). In selected
cases, there should be documentation available on
the liberation and the penetration into the skin, as
well as on the clinical efficacy. These requirements
are met for many prescriptions by the vehicles in the
range of excipients.
2. THERAPY OF INFLAMMATORY SKIN
DISEASES
O 12
NEW APPROACHES IN TREATMENT OF
ATOPIC ECZEMA
J. Ring, U. Darsow
Department of Dermatology and Allergy, Biederstein, Tech-
nical University Munich, Germany
Atopic eczema is a chronic inflammatory skin
disease characterized by recurrent intense pruritus,
typical age-related distribution of the changes, and
skin morphology. Therapy is based on a combina-
tion of appropriate topical anti-inflammatory, anti-
bacterial, and emollient treatment as well as patient
education (“patient management”). The develop-
ment of topical corticosteroids with improved risk/
benefit ratio (e.g., prednicarbate, momethasone
furoate or methylprednisolone aceponate) has led
to significantly better results in the long-term man-
agement of atopic eczema. A progress in UV-ther-
apy of atopic eczema has been achieved with long-
wave UVA-1 (“cold light”). A new group of anti-in-
flammatory drugs for topical use are calcineurin-in-
hibitors, such as tacrolimus and pimecrolimus.
They inhibit the T cell-dependent inflammatory re-
sponse and the release of cytokines without caus-
ing skin atrophy or systemic side effects. Different
lipophilic characteristics of these compounds are
responsible for their different affinity to the skin and
distinct therapeutical affects. However, further clini-
cal studies on the long-term safety of these drugs
are necessary. The role of allergy in eliciting and
maintaining the eczematous skin lesions is still con-
troversial, but the observation of IgE on Langer-
hans’ cells of patients with atopic eczema, the ben-
efit from allergen avoidance, and the eczematous
lesions that can be induced in such patients with the
atopy patch test (APT) give rise to a reappraisal of
allergen-specific approaches to treatment. Aller-
gen-specific immunotherapy (hyposensitization)
may be used as a therapy for atopic eczema, but
there is still not enough evidence for a general rec-
ommendation. Immunomodulatory approaches may
prove effective, including anti-IgE, soluble interleu-
kin-4 receptor, and antibodies to adhesion mole-
cules or co-stimulatory molecules. Furthermore, the
development is expected of new antagonists and
synthesis inhibitors of mediators of inflammation.
O 13
THREE STUDIES IN PEDIATRIC AND
ADULT PATIENTS DEMONSTRATE THAT
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TACROLIMUS OINTMENT IS SAFE AND
EFFECTIVE IN THE TREATMENT OF ATOPIC
DERMATITIS
I. Lawrence
Fujisawa Healthcare, Inc., Deerfield, IL, USA
Data from two trials involving 8,722 adult and
pediatric patients with atopic dermatitis who applied
0.03% or 0.1% tacrolimus ointment twice daily, con-
tinuously or intermittently for up to 4 years, were
combined and analyzed. Additionally, the potential
effect of tacrolimus ointment on the immune system
was evaluated in 23 eczematous children 2 to 12
years of age who applied 0.03% tacrolimus oint-
ment twice daily for a total of 7 weeks. Patients
were vaccinated with Pneumovax® (pneumococcal
vaccine) during the third week of treatment. In the
7-week study, there were no clinically significant
changes in CBC, lymphocyte subsets, CD4/CD8
ratio, immunoglobulin levels, or tetanus and H.
influenzae antibody titers. All patients developed a
protective antibody response to at least one pneu-
mococcal serotype. Significant improvement was
observed early in treatment (p<0.001) and contin-
ued throughout the long-term studies. The risk of
adverse events, including infections, did not in-
crease with long-term use of tacrolimus ointment.
Tacrolimus ointment has no systemic immuno-
suppressive effect; its immunomodulatory effect is
limited to the skin. Tacrolimus ointment monothe-
rapy is safe, and its effectiveness is maintained
even with long-term use. It may be a drug of choice
for long-term treatment of atopic dermatitis.
O 14
UV COMBINED THERAPY OF PSORIASIS
F. Kokelj, G. Trevisan
Institute of Dermatology, University of Trieste, Trieste, Italy
Most clinical studies on the treatment of psoria-
sis concern a monotherapeutical approach, which
is of interest to pharmaceutical companies. On the
other hand, it is well known that the best clinical re-
sults in the treatment of this disease are usually ob-
tained through the combination of different meth-
ods: topical-topical, systemic-topical, and UV-topi-
cal. In recent years, numerous studies have em-
phasized the importance of the different treatment
combinations. We report on our experience with
UVB and PUVA combined with different topical
(calciportiol and tacalcitol) and systemic (retinoids
and cyclosporine) drugs.
O 15
A NEW COMBINATION IN LOCAL
TREATMENT FOR PSORIASIS VULGARIS
V. Kuzmanovska, L. Biserkoska-Atanasovska1
Medical Center, Kumanovo, 1Health Care Center, Skopje,
Former Yugoslav Republic of Macedonia
We present positive effects of a topical combina-
tion treatment for psoriasis vulgaris in outpatient
settings. Forty-six patients who visited our outpa-
tient clinics in a one-year period were included in
the study. They underwent the combination treat-
ment that involved application of a keratolytic agent
in the morning and a preparation by Galenik labora-
tory in the evening. The keratolytic treatment con-
sisted of fluorinized corticosteroid (bethametha-
son-dipropionat) combined with salicylic acid, i.e.
Belosalic® ointment. For the evening treatment, the
preparation made by Galenik laboratory was used,
consisting of Garamycin® (antibiotic), Plivit AD® so-
lution (vitamins A and D), lanolin, and vaseline (D3).
All 46 patients were treated with the combination
therapy for 14 days. After that, the treatment was
continued as a D3 monotherapy for three more
weeks. First effects were visible after 7-10 days of
treatment. After one month of therapy, scratching
and hyperkeratosis diminished, and the ill skin be-
came softer, remaining only slightly hyperpigmen-
ted in comparison with healthy skin. The attitude
that ”psoriasis never heals, but never kills, either”
should further be challenged and the development
of new therapy combinations that could give satis-
factory results in the treatment of psoriasis vulgaris
should be pursued.
O 16
PSORIASIS VULGARIS ET ARTHRITIS
PSORIATICA GRAVIS MUTILANS – CASE
REPORT
P. Vrogiæ, A. Pašiæ1, T. Podobnik-Takaè, J.
Lipozenèiæ1
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Naftalan Special Hospital for Medical Rehabilitation, Ivaniæ
Grad, 1Department of Dermatology and Venerology, Zagreb
University Hospital Center, Zagreb, Croatia
We present a case of a patient with psoriasis
vulgaris type I and very early development of
psoriatic arthritis to point to the need for locomotor
system screening in patients with either type I or
type II psoriasis. Family history revealed that the
patient’s mother also suffered from psoriasis and
was operated on for carcinoma of the uterus. The
patient’s father was an alcoholic. Younger brother
was healthy. The patient had no severe disease in
his personal history. His disease started at age 23,
with the appearance of typical psoriatic lesions on
the scalp. After 2-3 months, he developed swelling
of the interphalangeal finger joints, interphalangeal
foot joints, ankle joint, and knee joint, with fever of
up to 38°C. The cutaneous and joint lesions wors-
ened over the years, resulting in generalized psori-
asis and mutilating arthritis. The onset of vulgar
psoriasis type I in our patient was associated with
HLA DR7 and DR6. The disease assumed a very
severe course, with skin lesions paralleled by joint
alterations. During the 10-year period, the values of
ESR ranged from 80 to 110. The patient was admin-
istered various drug therapies, which could be
properly traced from his medical records. The pa-
tient did not comply with therapeutic recommenda-
tions (potus in initial history). Eventually, Metho-
trexate® (methotrexate) 7.5 mg/week was applied,
with transaminase, ESR, and CBC control every 2
weeks. He used Lubor® (piroxicam) 20 mg 1×1,
Praxiten® 15 2×1 tbl daily, and Tramal® as needed.
This case points to the importance of early diag-
nosis of joint involvement in psoriasis vulgaris and
its timely treatment, with individualized approach
along with proper education of these patients to
prevent permanent debilitating lesions. Unfortu-
nately, unfavorable personality profile of our patient
contributed to the poor outcome of his disease.
O 17
LOCAL THERAPY OF PSORIASIS VULGARIS
– HISTORICAL REVIEW
Z. Jukiæ, V. Barišiæ-Druško, I. Ruèeviæ, N. Šustiæ,
D. Biljan, A. Ageel, R. Vukadin
Department of Dermatology, Osijek University Hospital Cen-
ter, Osijek, Croatia
Topical therapy is the first line treatment for pso-
riasis and important part of the treatment of psoria-
sis in general. It is still a topic of great interest to der-
matologists. We present a historical review of topi-
cals used in the treatment of psoriasis vulgaris up to
the present times, including emollients, keratolytics,
corticosteroids, coal tar, anthralin, calcipotriene,
and tazarotene.
O 18
THE LIGHT IN THE TREATMENT OF
DERMATOSES
A. Pašiæ, R. Èeoviæ, D. Hrsan
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia
During the past 25 years, phototherapy has
greatly influenced treatment concepts in dermatol-
ogy. Photomedicine has developed from empiri-
cism into one of the most exciting fields in biomedi-
cal research. Phototherapy may be regarded as a
prime example of applied skin biology. UV radiation
has been used for decades in the treatment of com-
mon skin diseases, such as psoriasis and atopic
dermatitis. The introduction of PUVA in the mid-
1970s was a driving force for a whole new series of
discoveries during the following two decades. The
introduction of a selective spectrum in the UVB and
UVA range, such as narrow-band UVB and UVA1
phototherapy, as well as the inclusion a new indica-
tions, has stimulated the interest in photoderma-
tology. Visible light in combination with photosensi-
tizers is currently in use for diagnosis and treatment
of some types of tumors. Extracorporeal pho-
totherapy is effective in the treatment of skin lym-
phomas as well as in transplantation medicine. As
professor Fitzpatrick said, present day photo-
therapy is comparable to the use of X-radiation
therapy in dermatology, with special hardware, se-
lection of patients, and need for careful and precise
dosimetry.
3. TREATMENT OF VIRAL, BACTERIAL,






A. Horváth, K. Nagy
National Institute of Dermatovenerology, Budapest, Hungary
Exogenous infection by human retroviruses in-
duces local and/or systemic eosinophilia, with vari-
ous forms of dermatoses and immunological disor-
ders as a consequence of either direct or indirect
(cytokine promoter) expression of viral genetic ele-
ments. Human T-cell lymphotrophic virus (HTLV-1)
has been etiologically associated with adult T-cell
lymphoma/leukemia (ATL), tropical spastic para-
paresis (TSP), dermatomyositis, and infective der-
matitis (ID), all accompanied with abnormalities of
immune function. The role of HTLV-1 in the devel-
opment and progression of cutaneous T-cell lym-
phoma, mycosis fungoides, and Sezary syndrome
has not been clearly established. We investigated
the possibility of HTLV infection in patients with vari-
ous dermatoses and eosinophilia. We screened
440 patients with cell-proliferative diseases and/or
dermatoses and healthy donors for serum antibody
to HTLV, using IIF and ELISA. DNA samples of skin
lesions and lymphocytes from 50 patients were an-
alyzed by polymerase chain reaction (PCR) ampli-
fying 158 bp segment of 3’ tax and 210 bp
(1323-1442) conserved fragment of gag of HTLV-1.
Amplified PCR products were inserted in a pGEM
vector and cloned in E. coli XLI-Blue strain.
GM-CSF, IL-3, IL-5, and Eotaxin in the sera of pa-
tients were quantitatively determined by use of
ELISA. T-cell receptor gene rearrangement was an-
alyzed by Vg and Jg primers. Antibodies to HTLV-1
in patients with various malignancies and derma-
tological disorders were analyzed by IIF. No con-
firmed exogenous infection was found. However,
molecular detection by PCR indicated the presence
of HTLV-related DNA sequences in patients with
dermatoses and eosinophilia. HTLV-related DNA
sequences were detected in lymphoreticular prolif-
erations more frequently (62%) than in bullous
dermatoses (17%) and inflammatory diseases
(16%). DNA hybridization data as well as nucleotide
sequence analysis identified retroviral elements ho-
mologous (>95%) to HTLV-1 gag. We found no
homology higher than 5% to related sequences, in-
cluding several known endogenous human retro-
viruses. Among the eosinophil chemotactic factors,
GM-CSF was increased in cultured lymphocytes
stimulated by IL-2 in 4% of patients. Increased se-
rum concentrations of IL-5 and Eotaxin could be de-
tected in 50% and 32% of patients, respectively. No
increase in IL-3 was observed. It is assumed that in
Hungary, where direct evidence of exogenous
HTLV infection has not yet been confirmed, re-
stricted expression of HTLV-related retroviral se-
quences or defective HTLV-1 proviruses with inter-
nal deletions are involved in the progression of dis-
eases with altered immunological responsiveness.
Moreover, HTLV-1 tax could transactivate gene(s)
of various eosinophilic chemotactic factors (GM-
CSF, IL-5, or Eotaxin), which might result in reactive
local and/or systemic eosinophilia.
(Study supported by OTKA Grant T 034804)
O 20
SYPHILIS IN EUROPE SETTING THE SCENE
M. Waugh
General Infirmary, Leeds, England
Croatia was known for areas of endemic syphilis
in the past. Our teachers F. Gruber and Z. Zupanec
Slavec have reported and written extensively about
Skerljevo disease around Inner Carniola, the Karst,
and in Fiume (Rijeka) in the 18th and 19th centuries.
It is only just over 50 years ago that the last great
public health effort on endemic syphilis in Europe
was finished. Endemic syphilis had occurred in the
Balkans since the Ottoman incursions and although
the public health authorities of Austria-Hungary and
the subsequent kingdom of Yugoslavia provided
epidemiological data, it was not until penicillin that a
cure could be offered. From 1948, the Yugoslav
health administration together with World Health
Organization developed a nation wide syphilis con-
trol program. By the end of 1952, 1,472,402 per-
sons had been examined of whom 90,235 were
treated with penicillin. Grin noted that endemic
syphilis acquired in childhood often had more seri-
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ous effects than it had been realized, not only gum-
mata, but also all forms of neurological and cardio-
vascular manifestations, which were under-re-
corded, though, as cases occurred in rural areas.
Since the fall of Soviet communism around
1990, Europe has been going through a period of
great change. After that period, there was a vast in-
crease in early infectious syphilis not only in Rus-
sia, but also in the Baltic countries, Ukraine, and
the states of the Caucasus. There was also an in-
crease in congenital syphilis. While the main part
of the epidemic has now finished, there is evi-
dence that HIV infection and tuberculosis are in-
creasingly frequent in Russia. There have been re-
ports of a small but significant rise in early syphilis
throughout eastern and central Europe, i.e. Po-
land, Hungary, Bulgaria, and Slovenia. After very
low incidence of syphilis in the Western world after
1948, there was an increase around 1970 in homo-
sexual men. However, with the advent of AIDS, the
levels dropped. In recent years after the introduc-
tion of highly active antiretroviral treatment, there
has been a rise of risky sexual practices especially
in homosexual men, many of whom HIV-infected.
A rise in early syphilis in this group has been re-
ported from England, Germany, Amsterdam, and
Paris. There has probably been a rise in early
syphilis in heterosexuals as well, often due to pros-
titution. There is an increase in syphilis seen in im-
migrants from Africa, their public health concerns
being of large impact into Europe. Regarding the
limitations of the variety of serologic tests for syph-
ilis, FTA-ABS is still being the gold standard. One
of the greats in venereal diseases, Thomas
Turner, who died in 2002, stated that ”with AIDS in-
fection burgeoning all round the world, its suppres-
sion of immunity, and tissue reaction often permits
Treponema to swarm in scarcely noticeable le-
sions.” There has been much controversy since
the advent of HIV that regimens for treatment of
syphilis are enough. Some hold that the evidence
is contradictory and most physicians would still
recommend the same treatment as in non-HIV
cases, but with more assiduous follow-up. Syphilis
remains a challenge in its basic molecular biology,
immunological responses, affects on population,
treatment, and control.
O 21
SCABIES: THE DIAGNOSIS OF ATYPICAL
CASES AND THEIR TREATMENT
R. Wolf1, H. Matz1,2, E. Orion1
1Kaplan Medical Center, Rechovot, 2Tel-Aviv Sourasky Med-
ical Center, Tel-Aviv, Israel
Scabies, an ancient disease of mankind, is be-
lieved to occur in 30-year cycles and is currently
pandemic in most parts of the world. Contemporary
scabies outbreaks are characterized by a higher
proportion of atypical cases and the development of
drug resistance. We present a collection of atypical
cases and discuss the various diagnostic methods
for this condition to provide the clinicians at the
“frontline” with some effective tools to cope better





Outpatient Center for Diagnosis of Infectious Veneroderma-
tological Diseases, Graz, Austria
Key trends in the epidemiology of sexually trans-
mitted infections (STI) in Europe and the USA show
an increase in rates of reportable bacterial infec-
tions, such as gonorrhea, syphilis, and chlamydial
infections. In addition, the number of antibiotic-re-
sistant gonorrhea has increased in many countries,
leading to a change in the management strategy for
gonococcal infections. Recent data have shown
that quinolone-resistant N. gonorrheae (QRNG)
continues to spread not only in Asia and the Pacific,
but also in parts of the United States (West Coast)
and many European countries. Penicillin resistance
is widespread and increasingly observed in Asian,
Caribbean, and African countries as well as Eu-
rope, with a percentage of up to 30%. Elevated
MICs to azithromycin raise concerns about its rec-
ommendation for gonococcal treatment. An in-
crease of gonococcal infections has also been ob-
served in Austria in the 1999-2002 period. In three
main Centers for Diagnosis of Sexually Transmitted
Infections (STI), a 3.7-fold increase from 123 cases
in 1999 up to 575 infections in 2002 was observed
in patients screened for gonorrhea and other STIs.
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During this period, almost a 10-fold increase of
QRNG was observed from 3.9% to 33.6%, followed
by a 5-fold increase of penicillin resistant strains. In
contrast, resistance against cephalosporines and
macrolides was found only in few cases. The in-
creasing resistance of N. gonorrheae to quinolones
and other antibiotics emphasizes the need for the
performance of gonococcal culture, to examine the
resistance profile of these microorganisms before
treatment. Furthermore, recommended manage-
ment guidelines for gonococcal infections in the
USA, Europe, and Austria have to be changed ac-
cording to the resistance proof.
O 23
SIDE EFFECTS OF DIFFERENT TREATMENT
METHODS FOR ANOGENITAL WARTS
M. Potoènik
Department of Dermatovenerology, Ljubljana University
Medical Center, Ljubljana, Slovenia
Genital infections with human papilloma virus
(HPV) are the most frequent viral sexually transmit-
ted disease. In most cases, the infection takes a la-
tent course without clinical manifestations. Epide-
miological data from the United States show that
only 1% of the sexually active population presents
with anogenital warts, whereas as many as 5-20%
are infected with HPV. The epidemiological data for
Slovenia are not quite reliable, but an increasing
trend is observed. Most anogenital warts are seen
in young adults, with the highest prevalence in
women under 25 years of age. External anogenital
warts in men are mainly located on the penile shaft
and the perianal area. An effective treatment of the
disease is of great importance from the medical,
psychological, and economic point of view. To date,
none of the common treatments have been proven
to be curative. A wide range of therapies is available
for the treatment of anogenital warts (electrocoagu-
lation, cryotherapy, excision, lasers, trichloroacetic
acid, podophyllin, podophyllotoxin, interferon, and
imiquimod). Both ablative methods and drug treat-
ments may remove anogenital warts in high per-
centage of cases, but recurrences may be ex-
pected in about 30-60%, requiring retreatment. We
observed and compared the side effects of all men-
tioned methods. Electrocoagulation, excision, and
laser method are accompanied with pain and aller-
gic reaction to local anesthetics. Cryotherapy is
also accompanied with pain; trichloroacetic acid
produces ulcers and scarring; podophyllin causes
itching, burning, pain, swelling, and ulcers; podo-
phyllotoxin causes burning, tenderness, erythema,
and erosions; intralesional interferon is accompa-
nied with pain, and imiquimod with burning, pruri-
tus, irritation, and pain. None of the treatment meth-
ods eradicates the virus, none is completely effec-
tive, and none is free of side effects. The choice of
therapy depends on the morphology and extent of
the warts, available resources, the experience of





MELASMA: ITS CAUSATION AND
TREATMENT
H. Nakayama
Nakayama Dermatology Clinic, Tokyo, Japan
Facial pigmentary disorders among middle-
aged women include melasma, pigmented cos-
metic dermatitis (PCD), solar lentigo, and nevus of
Ota. Today, solar lentigo and nevus of Ota can be
cured by laser surgery, as opposed to melasma and
PCD for which other treatment approaches are re-
quired. Melasma is non-inflammatory, brown hyper-
pigmentation of the facial skin, caused by hyper-
production and accumulation of melanin pigments
in the basal cell layer of the epidermis. The prolifer-
ation of melanocytes is not remarkable. When
abundant incontinentia pigmenti histologica is pres-
ent, the possibility of PCD should be considered, as
the destruction of basal layer cells by cosmetic al-
lergy results in this type of reaction. The causative
allergens can be determined by patch testing with
cosmetic series patch test allergens, and PCD can
be cured completely by the long-term usage of cos-
metics and soaps that do not contain the allergens
responsible for the patient’s problem. This treat-
ment is called allergen control.
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Melasma, on the other hand, does not develop
due to an allergic process but rather to hyperexcre-
tion of progesterone in the luteal phases. Based on
the results of analysis of various female hormones
in the ovarial and luteal phases in patients with
melasma and their age- and sex-matched controls,
only progesterone showed remarkable and statisti-
cally significant differences between the two
groups. As many as 20% of melasma patients
showed remarkable UVB hypersensitivity, with
long-lasting brown hyperpigmentation resulting
from a single irradiation of MQD in normal persons.
No increase in porphyrins or effects of medica-
ments were exhibited. Long-term application of
whitening cream is a recommendable treatment.
The effectiveness of 1-% kojic acid cream was 85%
during one- to two-year follow-up, without any sys-
temic side effects.
O 25
TOPICAL CORTICOSTEROIDS: OLD AND
NEW GUIDELINES
A. D. Katsambas
University of Athens, Athens, Greece
Treatment with topical corticosteroids has im-
proved enormously in the past few years. The vari-
ety of new formulations and the differences in their
properties offer a wide choice of compounds for
better results. Moreover, the demands placed on
new topical corticosteroids are very high. At the
same time, public fear of the use and abuse of
corticosteroids has increased greatly. To meet the
dermatological needs, corticosteroids should have
high local potency and no systematic and local side
effect. If the physician carefully monitors the use of
corticosteroids, the systemic unwanted effects are
almost non-existing and the local side effects, espe-
cially thinning of the skin, are minimal. Treatment
with topical corticosteroids can be successful and
safe if the following points have been considered
before the treatment: diagnosis, age of the patient,
anatomical site of the disease, skin condition, fre-
quency of application, amount of application, dura-
tion of treatment, appropriate vehicle, and potential
adverse reactions. When large areas are treated,
systemic side effects must be considered. Finally,
corticophobia must be addressed by careful discus-
sion to maximize compliance.
O 26
PRO ET CONTRA TOPICAL
CORTICOSTEROIDS ON THE FACE
A. Basta-Juzbašiæ
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia
Topical corticosteroids are effective in many skin
diseases because of their anti-inflammatory and
immunosuppressive action. These therapeutical ef-
fects result from vasoconstriction, reduction of
membrane permeability, suppression of mitotic ac-
tivity, and immune response. Application of topical
corticosteroids on the face is indicated as a short-
term treatment for non-infectious dermatoses, in-
cluding contact allergic and non allergic dermatitis,
atopic dermatitis, phototoxic reactions (including
polymorphic light eruptions), insect stings, mild to
moderate psoriasis of the face, pemphigus vulgaris,
pemphigoid bullosus as well as discoid and sys-
temic erythematodes and sarcoidosis. When the fa-
vorable response occurs, the frequency of applica-
tion should be reduced to the minimum necessary,
and the treatment should be stopped as soon as
possible to avoid possible side effects. However,
topical corticosteroids are mainly applied for sebor-
rheic dermatitis and rosacea, but also for acne
vulgaris, unrecognized dermatomycosis, cosmetic
and other reasons sometimes uncontrolled for
many months or even years. This long-term use
causes many side effects resulting in facial dermati-
tis resembling rosacea, with diffuse erythema,
teleangiectasias, papules, and pustules developing
in three type of distribution: perioral, centrofacial,
and diffuse. The majority of patients are women, but
there are also more and more men and children
among the patients. Treatment of choice in these
patients is neutral topical therapy, combined with
peroral tetracycline in severe cases.
O 27
CONTACT SENSITIVITY IN FACIAL
DERMATITIS
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S. Ljubojeviæ, J. Lipozenèiæ. A. Basta-Juzbašiæ,
V. Milavec-Puretiæ
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, Zagreb, Croatia
Facial dermatitis may result from allergic or irri-
tant contact dermatitis to cosmetics, local creams,
and ointments, as well as from endogenous condi-
tions, such as atopic or seborrheic dermatitis, or
combinations of many other factors. The aim of our
study was to determine the frequency of positive
patch test reactions in patients with facial dermati-
tis. Patch testing to standard series was performed
on 322 patients according to recommendations of
the International Contact Dermatitis Research
Group (ICDRG). All patients were tested in the Al-
lergy outpatient clinic of Department of Dermatol-
ogy and Venerology, Zagreb University Hospital
Center, between 1999 and 2002. We included 4 pa-
tients with acne vulgaris, 13 with blepharoconjuncti-
vitis, 82 with allergic contact dermatitis, 15 with irri-
tant contact dermatitis, 13 with lip and 21 with
perioral involvement, 20 patients with atopic derma-
titis, 91 with seborrheic dermatitis, 11 with rosa-
ceiform steroid dermatitis, and 4 patients with
rosacea. There were 60 (19%) men and 262 (81%)
women. The mean age of the patients was 41
years. Of the 322 patch-tested patients, 131 (41%)
were negative, whereas 191 (59%) were positive,
mainly to nickel sulphate (77 or 24%), cobalt chlo-
ride (60 or 19%), carba mix (49 or 15%), fragrance
mix (41 or 13%), neomycin-sulphate (31 or 10%),
and detergents (31 or 11%). Allergic contact derma-
titis is a frequent cause of facial dermatitis. Per-
sonal care products, preservatives, and fragrances
represent the most common allergens in patients
diagnosed with allergic contact dermatitis. Our rec-
ommendation is to perform patch test to all patients
with facial dermatitis who have constantly eczema-
tous skin that shows no improvement or even dete-
riorates during conventional therapy. A significant
number of relevant allergic reactions would be
missed if patch test to standard series were not per-
formed.
O 28
COSMETICS AND ACNE VULGARIS
L. Oremoviæ, I. Sjerobabski Masnec, L. Lugoviæ,
G. Novak Biliæ
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, Zagreb, Croatia
Acne vulgaris is a multifactorial disease and the
most frequent reason of consultations in dermatol-
ogy. Three main factors are responsible for appear-
ance of acne: hyperseborrhea, infundibular kera-
tinization disorders with the formation of a come-
dos, and inflammatory disorders. Patients turn to
dermatologists not only for therapy, but also for help
in choosing cosmetics products that would be most
appropriate for their skin and for instructions on how
to use them. Cosmetics and skin care products
have become integral and even essential part of
daily care in acne patients. Cosmetics appropriate
for use in patients with acne must be non-come-
dogenic, non-acnegenic, nonirritating, and hypoal-
lergenic.
The products at the borderline between drugs
and cosmetics are called cosmeceuticals. They are
generally topical, innovative, bio-active skin care
products containing pharmacologically active ingre-
dients which can penetrate the stratum corneum
and be delivered in sufficient concentrations to the
intended target in the epidermis and dermis. They
improve cosmetic appearance of the skin and influ-
ence functional processes by providing pharma-
ceutical benefits. Skin hygiene and care is a
modulatory component to any effective acne thera-
peutic regimen. Cosmeceuticals include keratoly-
tics, antimicrobial agents, moisturizers, camouflage
products, and sunscreen agents. Cosmetic prod-
ucts are an important supplement in the anti-acne
therapy. They can reduce the predisposition to the
development of comedones as well as shiny ap-
pearance and acne lesions. The quantity of product
used and cleansing regimen should be adjusted to
the needs of individual patient.
O 29
SIDE EFFECTS OF LOCAL
GLUOCORTICOSTEROID THERAPY ON THE
SKIN OF THE FACE
N. Arslanagiæ, R. Arslanagiæ
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Dermatovenereological Clinic, Sarajevo, Bosnia and
Herzegovina
Glucocorticosteroids have revolutionized topical
therapy of many dermatoses. Today, there are
many different topical preparations containing glu-
cocorticosteroids at our disposal. Although mecha-
nisms of action of corticosteroids are symptomatic,
which implies they cannot cure the disease, they
greatly diminish or totally eliminate morphological
symptoms of disease if indications for their use are
followed. Caution with topical glucocorticosteroids
is augmented when facial skin is treated due to ex-
ternal weather factors, with cosmetic and other ap-
plied hygienic products. Long-term usage causes
side effects, such as erythema, papular or papu-
lopustular eruptions, teleangiectasia, and epider-
mal thinning. Most common mycotic superinfec-
tions are caused by Candida species. As our over-
view of inadequate application of corticosteroids
has shown, complications are mostly due to inade-
quate indications, misuse of therapy, ignorance of
side effects by the therapist, or self-medication by
some patients. Our patients applied steroids from
several weeks to several years. The majority were
women. Glucocorticosteroids were applied mainly
for seborrheic dermatitis, dermatitis perioralis,
rosacea, but also for unrecognized dermatosis, and
even dermatomycosis. We believe that most com-
plications could have been avoided if corticosteroid
preparations were not easily available as over the
counter (OTC) drugs. To prevent these unfortunate
conditions, corticosteroids should be administered
by a professional following exact guidelines for their
use.
O 30
LASERS IN DERMATOLOGY – PAST,
PRESENT AND FUTURE
V. Hegyi, L. Hegyiova
Department of Pediatric Dermatovenerology, Comenius Uni-
versity School of Medicine and Medicina Correctiva,
Bratislava, Slovak Republic
Lasers are capable of producing intense mono-
chromatic light in a very short time. Light produced
by low-power lasers may stimulate the tissue,
whereas light produced by high-power lasers may
cause tissue destruction. Introduction of new types
of lasers has allowed dermatological surgeons to
treat previously untreatable diseases. First lasers
used in dermatology were CO2 and argon lasers in
the early 1980s. Today, dermatological surgeons
use advanced laser systems under strict precau-
tions to achieve the best therapeutic and cosmetic
results. Among these laser systems, ultrapulse CO2
laser, Er-YAG laser, Nd-YAG laser, and diode laser
are often used. A universal laser capable of treating
different skin conditions still does not exist. Only ad-
vanced and powerful lasers operated by skilled pro-
fessionals allow us to achieve the best possible
therapeutic results. By increasing the knowledge of
skin optics, dermatologists can more clearly under-
stand the light-tissue interaction and cooperate in
the development of new laser systems.
O 31
MISTREATMENT IN ACNE THERAPY – A
CASE REPORT
I. Sjerobabski-Masnec, L. Oremoviæ, L. Kotrulja,
I. Nola, J. Meštroviæ-Štefekov
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, Zagreb, Croatia
Acne vulgaris is a very common dermatosis,
which mainly affects teenagers. There is a variety of
established therapies to treat acne. The therapy is
based mainly upon a good understanding of the
pathophysiology of acne and acne grade, and in-
cludes treatment of hyperseborrhea, keratolytics or
comedolytics, and treatment of inflammation. For
the treatment of mild form of acne, particularly
comedonal acne and low-grade inflammatory acne,
topical retinoids with or without benzoyl peroxide
and topical antibiotic are the mainstay of therapy.
For acne with a greater inflammatory component,
topical retinoids are combined with topical or oral
antibiotics, and in women antiandrogenic hormonal
therapy can also be introduced. In the most severe
cases of acne, such as conglobata acne, isotreti-
noin is the mainstay of therapy.
We present a case of a 19-year-old woman with
severe form of acne papulopustulosa on the face,
back, buttocks, thighs, and chest. A year before her
first visit to our Clinic, after gynecologist and derma-
tologist recommendation, she has been treated
with medium doses of peroral steroids (predni-
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solone 25 mg daily) and different topical therapy
with inadequate therapy response. In November
2002, she was admitted to day hospital. Clinical and
laboratory evaluation revealed low estradiol, pro-
gesterone, and free testosterone, normal DHEAS,
and high testosterone. Ultrasound examination of
ovaries was normal. Peroral steroids were ex-
cluded from therapy, and isotretinoin and etinile-
stradiol+ciproteron acetat were introduced, along
with the topical therapy.
O 32
PEELINGS OF AGEING SKIN: WHAT’S
NEW?
N. Puizina-Iviæ, T. Stipiæ, A. Èarija, S. Periæ-
Sušak, V. Gotovac
Split University Hospital Center, Split, Croatia
Although most topical preparations are devel-
oped for the treatment of “aged skin”, it is now well
established that clinical features attributed to aging
are those of photoaging, i.e. wrinkles, age spots,
and actinic keratoses. We have many different
methods of skin resurfacing at our disposal, includ-
ing a wide variety of chemical peels. The selection
of the peel will depend upon the skin condition, i.e.
the Glogau photoaging classification as well as
Fitzpatrick’s skin typing. Among the chemical peels
currently used are glycolic acid, salicylic acid, res-
orcinol, Jessner’s solution, TCA, and phenol. Com-
bination of different ingredients enhances the bene-
fits of single peeling agent. At the end, the results of




Ljubljana University School of Medicine, Ljubljana, Slovenia
For many years, the scarless and painless re-
moval of different skin changes seemed to remain
out of reach. However, through the development of
different modern high-energy laser systems, these
aspirations turned into daily practice. Is it really so?
Various vascular as well as epidermal and der-
mal skin changes and malformations represent the
majority of indications for the use of different laser
systems in dermatology. We have had a generally
good experience with therapeutic effects of different
lasers for treatment of vascular neoplasms (nevus
flammeus, hemangiomas, and teleangiectasias),
and for epithelial benign skin lesions (lentigines,
warts, hidradenoma, milia, epidermal nevi, xanthe-
lasma, rhynophym, and elastosis actinica). How-
ever, we do not believe that laser represents the
best and especially not the only treatment option in
all these cases. Possible side effects are scars,
depigmentations, hyperpigmentations, bleeding,
delayed healing, and secondary microbial infection.
Independent from all these limitations, laser sur-
gery nowadays represents an interesting, modern
treatment possibility in dermatology, where devel-
opment of new laser systems for new indications is
faster than in any other field of dermatotherapy.
O 34
APPROACH TO DERMATOSURGERY IN
CROATIA
M. Šitum
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, Zagreb, Croatia
The acquisition of basic dermatological surgery
skills is an important component of dermatological
training in Croatia. Dermatology is both, a medical
and a surgical specialty. A broad knowledge of the
biology and function of the skin and pathology of
dermatological disorders enables the dermatologist
to choose the best treatment modalities, either
medical or surgical or combination of both. Opera-
tive dermatology follows the same rules and re-
sponsibilities as all other branches of surgery, in-
cluding the pre-, intra-, and postoperative care. The
general condition of the patient must be taken into
account when the surgical procedure is planned.
Since nearly all procedures in dermatologic surgery
are elective, one should consider the noninvasive
technique available when surgical treatment carries
risk for the patient. A major part of dermatologic sur-
gery in Croatia consists of the removal of malignant
and premalignant tumors. In addition, many benign
tumors and malformations are removed for esthetic
reasons and for prophylaxis to avoid malignant
change. Another indication for surgery is the treat-
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ment of inflammatory and postinflammatory condi-
tions, e.g., acne inversa, acne scars, rhynophyma,
and posttraumatic scars. However, these indica-
tions are rare in Croatian dermatosurgery. Except
therapeutic and prophylactic excisions, we perform
a great deal of skin biopsy for diagnosing inflamma-
tory dermatosis. Three types of biopsies are gener-
ally performed: punch biopsy, the spindle shaped or
elliptical incisional biopsy, and tangential incisional
(shaved) biopsy. Due to the lack of technical and
anesthesiologic support, we do not provide lymph
node and sentinel lymph node biopsy. The choice of
anesthetic technique for most dermatologic surgery
cases is a matter of individual preference. We use
local, topical, regional anesthesia, and cryoanes-
thesia. Tumescence technique for locoregional an-
esthesia for liposuction, phlebectomy, and derma-
brasion is not performed, because these operations
are done by plastic and vascular surgeons. Also,
due to the lack of anesthesiologists in dermato-
surgery, we do not operate under general anesthe-
sia. In Croatian dermatosurgery, we do basic opera-
tive techniques, which include subcutaneous su-
ture, skin suture and suture removal, curettage, tan-
gential excision, and scissors excision. When a de-
fect cannot be closed by use of simple techniques,
some sort of classic surgical repair must be under-
taken. Flaps and grafts are most frequently used in
repairing the defects.
O 35







THE APPROPRIATE AND INAPPROPRIATE
TREATMENT OF DERMATOMYCOSES
M. Skerlev
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital and School of Medicine, Zagreb, Croatia
Dermatomycology is one of the most traditional
and fundamental fields of Dermatology and Vene-
rology; it is ever changing science, especially due to
the significant changes in epidemiology worldwide
and novel treatment strategies. So far, the
antimycotics for oral use have been quite often in
our focus. In this report, we shall concentrate to the
specificity of the topical treatment of fungal skin in-
fections. An appropriate topical therapy is some-
times state-of-the-art. The most important clue to
the successful management of dermatomycoses is
the exact diagnosis confirmed by culture. The clini-
cal features of fungal skin infections these days
might sometimes be quite different from the routine
we have been used to. For example, the clinical ap-
pearance of mycotic lesions of the face may simu-
late other dermatologic entities (e.g., nummular ec-
zema, erythema annulare, and lupus erythema-
tosus), making the diagnosis difficult. The clinical
pattern of the fungal infection of the face might be
either “classical” dermatomycosis (oval or round
erythematous lesion with scaly border) or have
“tinea incognita” pattern, which seems to be more
frequent during the last years due to the inappropri-
ate diagnosis and treatment. There should be
greater awareness of the possibility of such mycotic
infection to avoid missing the true etiology and inap-
propriate and prolonged use of topical steroids. A
special attention should be given to the Malassezia
species-related disorders, which are typically local-
ized on the scalp and central facial region. Further-
more, there has been an epidemic outbreak of
Microsporum (M.) canis infection in Croatia in the
last 25 years, from one positive culture in 1978 up to
414 positive isolates in 2002, according to the data
obtained in the Central Mycological Laboratory of
our Department. Some atypical and unusual varia-
tions of tinea capitis due to Microsporum species
are presented. For example, introducing only topi-
cal antimycotic therapy is not sufficient to obtain a
good therapeutic result in these cases. We refer to
the 34 cases of typical Kerion Celsi due to Micro-
sporum species (and not due to Trichophyton
mentagrophytes, which is a typical pathogen in
such cases) observed during the last five years.
The clinical features consisted of painful inflamma-
tory mass on the scalp, with loss of hair, pustular
discharge, sinus formation, mycetoma-like grains,
and thick crusting. M. canis and M. gypseum were
isolated by culture in 28 and 6 cases, respectively.
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In the first stage of the treatment, the antipyo-
dermatic agents should be topically applied in the
thick layer. Otherwise, using only topical antimy-
cotic therapy in Kerion Celsi, the course of disease
may be prolonged and the therapeutic result may
be poor. The antimycotis for oral use should be ad-
ministered, as well. However, tinea capitis due to M.
canis represents a greater therapeutic problem
than tinea caused by T. mentagrophytes. Moreover,
the new or previously very sporadic etiologic agents
have been recently observed in Croatia, such as T.
tonsurans causing a deep form of tinea capitis,
mostly in wrestlers. All the above-mentioned
changes in etiology, epidemiology, and clinical pat-
tern of fungal skin infections certainly require corre-
sponding evolution in treatment strategies.
O 37
TINEA INCOGNITA CAUSED BY
TRICHOPHYTON VERRUCOSUM
A. Prohiæ, M. Kantor
Department of Dermatology and Venerology, Sarajevo Uni-
versity Hospital Center, Sarajevo, Bosnia and Herzegovina
Tinea faciei is uncommon site of fungal infection.
It often has an unusual presentation that mimics
other skin conditions, such as discoid lupus erythe-
matosus, psoriasis, rosacea, contact allergic der-
matitis, and photodermatoses. Misdiagnosis is par-
ticularly common in those tinea infections whose
appearance has been modified by inappropriate
treatment, usually by application of topical steroid
preparations. Topical steroids suppress the local
immune response and reduce the inflammation, re-
sulting in exacerbation of the skin lesions that be-
come bizarrely shaped (“tinea incognita”). A 24-
year-old woman, a veterinary student, presented
with broad erythematous, scaling patches spread-
ing over her face. She was misdiagnosed with dis-
coid lupus erythematosus and treated with topical
steroids. Although the erythema and symptoms im-
proved, the patches continued to enlarge, showing
the loss of scaling and annular rim. Based on myco-
logical findings, a diagnosis of Trichophyton ver-
rucosum was made. The lesions completely
cleared with oral and topical terbinafine therapy.
O 38
WHAT DO WE REALLY NOW ABOUT
TINEA INCOGNITA? – CASE REPORT
J. Radoš, M. Skerlev, D. Celiæ1, I. Dobriæ
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center, 1Medikol Outpatient Department,
Zagreb, Croatia
The term “tinea incognita” is consistent with di-
verse clinical presentations of mycotic infections
modified by the inappropriate administration of
corticosteroids or other topical modalities. There
has been an increasing number of such cases de-
scribed during the last five years. Thus, we present
a case of a 67-year-old man with a five-year history
of widespread lesions consisting of multiple ery-
thematous plaques involving the trunk and extremi-
ties, all the time treated with potent topical steroids.
The clinical features were thus largely modified.
Some of these lesions had a psoriasis-like presen-
tation, and some of them had an eczema-like and a
folliculitis-like aspect. Repeated potassium hydrox-
ide (KOH) preparation missed showing fungal ele-
ments. The crucial role for diagnosis was the cul-
ture where Trichophyton mentagrophytes var. inter-
digitalis was revealed. The lesions have completely
resolved after two months of oral and topical anti-
mycotic treatment. Thus, the mycotic etiology
should always be in our focus when thinking of atyp-
ical, long-lasting, and recalcitrant skin lesions pre-




D. Biljan, V. Barišiæ-Druško, Z. Jukiæ, N. Šustiæ, I.
Ruèeviæ, R. Vukadin, A. Ageel
Department of Dermatology, Osijek University Hospital Cen-
ter, Osijek, Croatia
Promogran matrix is a new topically applied in-
teractive wound therapy. The product is a sterile,
freeze-dried composite of oxidized regenerated
cellulose (ORC) and collagen. In the presence of
exudate, the Promogran matrix transforms into a
soft and conformable, biodegradable gel; this al-
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lows contact with all areas of the chronic wound.
Saline or Ringer’s solution should be used to hy-
drate Promogran matrix on dry wounds. Promogran
matrix is indicated for the management of all
chronic wounds clear of necrotic tissue and visible
signs of infection, including diabetic ulcers, venous
ulcers, pressure ulcers, and ulcers caused by
mixed vascular etiologies. It has demonstrated
hemostatic properties and can be used under com-
pression therapy. At the Department of Dermatol-
ogy, Clinical Hospital Osijek, we apply Promogran
in case of chronic venous ulcers and in this report,




p53 AND Ki-67 IN PROLIFERATIVE SKIN
DISEASES
T. Batinac, J. Lipozenèiæ1, G. Zamolo2, F.
Gruber, A. Stašiæ, M. Lenkoviæ
Department of Dermatology, Rijeka University Hospital Cen-
ter, Rijeka; 1Department of Dermatology and Venerology,
Zagreb University Hospital Center, Zagreb; 2Department of
Pathology, Rijeka University School of Medicine, Rijeka,
Croatia
P53 protein is essential for the regulation of cell
proliferation and its aberrant accumulation is usu-
ally seen in malignant tumors. It also occurs in
squamous epithelium of inflammatory skin dis-
eases characterized by hyperproliferation. The aim
of this study was to elucidate the role of the p53 tu-
mor-suppressor protein in the pathogenesis of dif-
ferent hyperproliferative, non-malignant, and malig-
nant skin diseases, and association between p53
overexpression and cell proliferation. To assess
p53 and Ki-67 protein expression, we examined
immunohistochemicaly a total of 150 skin speci-
mens consisting of 5 groups of 30 specimens each:
normal skin, psoriatic skin, keratoacanthomas, ba-
sal cell carcinomas, and squamous cell carcino-
mas. P53 immunostaining of normal skin, psoriatic
skin, keratoacanthomas, basal cell carcinomas,
and squamous cell carcinomas was positive in
39.0%, 46.7%, 66.7%, 80%, and 86.7% of the
cases, respectively. P53 and Ki-67 positive cells
were present in basal (normal skin) and suprabasal
layers (psoriatic skin), in cancer nests of kerato-
acanthomas, basal cell carcinomas, and squamous
cell carcinomas as well as in dysplastic and even
morphologically normal epidermis adjoining can-
cers. The positivity of p53 and Ki-67 protein differed
significantly among the groups. Our findings sug-
gest that p53 overexpression occurs widely in neo-
plastic and non-neoplastic skin lesions. It is associ-
ated with the cell proliferation in normal as well as in
changed epithelium.
P 2
ERYTHEMA ANNULARE CENTRIFUGUM –
A CASE REPORT
I. Kuljanac, E. Kneeviæ, H. Cvitanoviæ
Department of Dermatology, Karlovac General Hospital,
Karlovac, Croatia
Erythema annulare centrifugum (EAC) is annu-
lar erythema with raised scaly borders. Most cases
of EAC remain unexplained. It has been associated
with infections, such as ascariasis, tuberculosis,
Candida albicans, and Epstein-Barr virus, and even
with malignant neoplasms. After a variable period of
time, the lesions disappear spontaneously, but new
lesions appear after months or years. Systemic ste-
roid or antipruritic agents may help, but topical ther-
apy has little effect. We present a case of a 56-
years-old man with erythematous, annular lesions
with scaly borders that lasted for a few months.
Most of the lesions were distributed in femoral re-
gion and trunk. Histological finding confirmed the di-
agnosis. Laboratory findings were normal. A search
for causative factors was negative. Systemic anti-
histaminics and local steroid therapy were recom-
mended.
P 3
LICHEN PLANUS LINEARIS – A CASE
REPORT
I. Kuljanac, E. Kneeviæ, H. Cvitanoviæ
Department of Dermatology, Karlovac General Hospital,
Karlovac, Croatia
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Clinically and histologically, lichen planus (LP) is
a very typical, papular skin disease. Morbidity in the
population is about 0.02%. The cause of LP re-
mains unknown. In the linear type (an uncommon
pattern), papule are seen in linear or zosteriform
configuration, such as along the path of the nerve or
at the site of healed herpes zoster. We present a
case of lichen linearis in a 54-year-old woman with
10-month history of pruritic violaceus papules. The
papules were distributed on distal parts of the upper
arms and on the right hand thumb (dorsal part). The
nail of the thumb was also affected. The size of lin-
ear distribution was about 12 x 1-2 cm. Personal
and family history was normal. Laboratory findings,
including allergological tests, were also normal. Lo-
cal steroid therapy was recommended.
P 4
EXPRESSION OF CD30+ AND CD45+RO IN
ATOPIC DERMATITIS LESIONS
J. Lipozenèiæ, D. Bobek, V. Milavec-Puretiæ, J.
Jakiæ-Razumoviæ1, A. Basta-Juzbašiæ, S.
Ljubojeviæ
Department of Dermatology and Venerology and 1Depart-
ment of Pathology, Zagreb University Hospital Center,
Zagreb, Croatia
Atopic dermatitis has cellular imunohistoche-
mical features similar to those of allergic contact
dermatitis (ACD). There is plenty of evidence of
T-cell activation in this disease. The involvement of
CD30+ T cells in acute stages of atopic dermatitis
might establish CD30 as a helpful marker in differ-
entiating these two diseases. Tissue sections from
the skin of 12 patients with acute atopic dermatitis
and 13 with allergic contact dermatitis (nickel-in-
duced) were examined immunohistochemically to
determine cell-surface antigens, including CD30,
CD3, CD4, and CD45RO. The severity of atopic
dermatitis was graded by the SCORAD clinical
scoring system. The analysis of CD30+, CD45RO+,
CD3+, and CD4+ cells in the dermis and epidermis
showed a much wider range of values and statisti-
cally higher median (p<0.01) in the inflammatory in-
filtrate of acute atopic dermatitis than in allergic
contact dermatitis. Our results showed an associa-
tion of CD30 expression with atopic dermatitis, but
not with allergic contact dermatitis. CD30 expres-
sion in atopic dermatitis might be helpful in
histologic differentiation of these two disorders as
well as in further characterization of atopy patch
testing. The results suggested that a specific regu-
latory function of CD30+ T cells was provoked in
acute atopic dermatitis. Abundant CD45R0+ cells
were detected both in atopic dermatitis and allergic
contact dermatitis lesions.
P 5
MIXED AND PURE ATOPIC DERMATITIS
L. Lugoviæ, J. Lipozenèiæ1
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, 1Department of Dermatology and
Venerology, Zagreb University Hospital Center, Zagreb,
Croatia
Atopic dermatitis may be expressed as an aller-
gic rhinoconjunctivitis (AR) or atopic dermatitis (AD)
and in only a small proportion as allergic bronchial
extrinsic asthma (AB). Patients with AD often have
concomitant symptoms of respiratory allergy (RA),
with or without AR and AB (“mixed” vs. “pure” AD).
The aim of our study was to examine the aller-
gologic status in “mixed” and “pure” AD, using dif-
ferent test parameters. The study included 30 pa-
tients with AD hospitalized or treated in Outpatient
Allergy Unit, Department of Dermatology and Vene-
rology, Zagreb University Hospital Center, and 10
healthy controls. The patients were divided into two
groups: “mixed” AD (n=20) and “pure” AD (n=10).
Hanfin & Rajka criteria were used for AD diagnosis.
The parameters for monitoring included personal
and family history of disease, results of cutaneous
tests, and laboratory findings. Cutaneous tests in-
cluded skin prick test for inhalant and food aller-
gens, scratch test to preservatives and additives
(supplied by the Institute of Immunology Zagreb),
and epicutaneous (patch) test to contact allergens
(according to ICDRG). Laboratory findings included
values of serum immunoglobulin E (total IgE deter-
mined by the radioimmunosorbent test [RIST],
Pharmacia, Uppsala, Sweden; and ELISA), mark-
ers on B lymphocytes (CD21 and CD23) and T lym-
phocytes (HLA-DR) in peripheral blood (three-color
immunofluorescence analyses on a flow cytome-
ter-immunofenotyping). Out of 30 patients, 15 de-
veloped the disease when under the age of two, 17
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had one coexisting allergic disease, and 3 had two
coexistent conditions (AR and AB). Skin prick tests
on food and aeroallergens were positive in 9 out of
10 patients with “pure” AD, and in 15 out of 20 pa-
tients with “mixed” AD. Scratch test reactions were
positive in 4 out of 10 patients with “pure” AD and 12
out of 20 with “mixed” AD. Patch test reactions were
positive in 5 out of 10 patients with “pure” AD and 14
out of 20 with “mixed” AD. Serum IgE titer was in-
creased in 21 out of 30 patients with AD. Determi-
nation of CD23 markers on B lymphocytes showed
increased values in 6 patients with “pure” and in 4
with “mixed” AD. The values of CD21 were de-
creased in 16 AD patients. HLA-DR expression was
normal in almost all patients. The results showed
differences between the two AD groups only for
younger age in “mixed” AD. We conclude that AD
can be used as an indicator of increased suscepti-
bility to development of RA later in life.
P 6
NEVUS COMMEDONICUS – A CASE
REPORT AND REVIEW OF THERAPEUTICAL
APPROACH
I. Manola, S. Ljubojeviæ1, J. Lipozenèiæ1, N.
Pustišek2
”Polanèec” Polyclinic for Dermatology and Gynecology,
Donja Stubica; 1Department of Dermatology and Venero-
logy, Zagreb University Hospital Center, 2Children’s Hospi-
tal, Zagreb University School of Medicine, Zagreb, Croatia
Nevus comedonicus (NC) is uncommon abnor-
mality of pilosebaceous unit, clinically character-
ized by confluent clusters of dilated follicular orifices
plugged with pigmented keratinous material that re-
sembles open comedones. The undifferentiated
epithelium of the hair follicles produces keratin
which, packed in laminated layers, forms keratin
plug. The condition is usually asymptomatic, but it
may be complicated by infection and scarring.
A 19-year-old woman visited Outpatient Allergy
Unit at Department of Dermatology and Venerology,
Zagreb University Hospital Center, because of a
skin condition present since birth, with a tendency
to worsening after the beginning of puberty, espe-
cially in the previous few months. The skin lesions
were characterized by numerous 1-3 mm, darkly
pigmented, keratotic plugs clustered in linear, uni-
lateral patches on the left side of abdomen. Several
papules and crusts were seen around umbilicus,
especially around the area in contact with metal
button. The standard epicutaneous tests gave posi-
tive reaction to nickel sulfate and carba mix. Previ-
ous treatments included keratolytics, local antibi-
otic, manual extraction, and were either ineffective
or had minimal effects. Our treatment consisted of
daily application of 0.1% tretinoin cream. After only
4 weeks of local therapy, cosmetic result was evi-
dent, with slight resolution of keratin plugs. The indi-
cations for treatment are recurrent infections and
cosmetic reasons. Therapeutic approaches include
topical keratolytic agents (salicylic, lactic, d-tartaric
and a-hydroxy acid, and benzoyl peroxid), ammo-
nium lactate, topical retinoic acid, manual extrac-
tion of comedones, pore strip pack, dermabrasion,
excision of smaller lesions, tissue expansion in ex-
tensive NC lesions, hormonal (estrogen and pro-
gesterone) therapy, and peroral isotretinoin. Topical
and systemic antibiotics are indicated to control in-
fection in inflammatory, cystic, and scarring type of
NC. Our patient with coexisting NC and contact al-
lergy responded well to combined retinoid and
corticosteroid local therapy. Application of retinoid
acid usually accelerates the exfoliation of the epi-
thelium and the expulsion of the keratin layers, but
does not eliminate the crypts and pits in the skin. To
date, there is no single treatment of choice.
P 7
COMPLICATIONS IN TATTOOING WITH
DIFFERENT APPROACH TO HEALING
S. Simeonova, V. Lazarevic, L. Biserkoska-
Anasovska, M. Nikolovska
Department of Dermatology and Venerology, Health Care
Center, Skopje, Former Republic of Macedonia
We present two patients with warts as a compli-
cation of tattooing. One of them was a 28-year-old
man with decorative tattoo on his chest and both
upper forearms. The second one was a 20-year-old
man with decorative tattoo on his right forearm. In
both cases, small verruciform changes developed
along the tattooed lines few years after tattooing.
The changes were not accompanied with subjec-
tive difficulties. Both patients were healthy, with un-
remarkable medical history. The first patient
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thought about removing the whole tattoo and was
referred to a surgeon for esthetic surgical treat-
ment. The warts have been surgically removed
along with the tattoo. Histological examination con-
firmed the viral infection of the tattooed skin. In the
second case, the treatment with cryotherapy was
successful in removing the warts. Tattooing, as a
fashion trend, increasingly becomes a dermatologi-
cal issue. It brings rare potentially dangerous and
odd medical complications. The warts are probably





M. Šitum, . Buèan, S. Levanat1
Department of Dermatology, Sisters of Mercy University
Hospital; 1Division of Molecular Medicine, Ruðer Boškoviæ
Institute, Zagreb, Croatia
Gorlyn’s syndrome, or nevoid basal cell carci-
noma syndrome, is a genetically determined auto-
somal dominant disorder responsible for predispo-
sition to basal cell carcinomas of the skin as well as
other developmental disorders and defects. The
syndrome is very rare, with the prevalence of 1 per
56,000 population. It is characterized by the child-
hood onset of multiple basal cell carcinomas and
several other tumors, such as ovarian fibroma and
medulloblastoma. Developmental disorders, as an-
other prominent hallmark of the syndrome, include
pits of palms and soles, jaw keratocysts, abnormali-
ties of the vertebrae, bifid ribs, and short metacarp-
als. The most common neurologic malformations
are midline brain malformations, retardation, ele-
ctroencephalographic abnormalities, strabismus,
ectopic calcification of the dura, and macrocephaly.
The genes involved in cancerogenesis often play a
critical role in the normal development and cellular
regulation, and mutations of these genes contribute
to cancerogenesis. PTCH gene, responsible for this
disorder, a human homologue of the Drosophilla
segment polarity gene patched, is mapped to chro-
mosome 9q22.3. The loss of heterozygosity at this
site in both sporadic and hereditary basal cell carci-
nomas suggests that it functions as a tumor sup-
pressor. Drosophilla patched is a part of the
patched signaling pathway, important in determin-
ing embryonic pattering and cell fate in multiple
structures of developing embryo. Human patched is
mutated in both hereditary and sporadic Gorlin’s
syndrome and inactivation of the gene is probably a
necessary step for the disease to develop. Clinical
findings of the basal cell carcinomas as part of
Gorlin’s syndrome are different from the classic
ones. Initially, changes appear as small pink or
light-brown papules. The lesions are painless.
Commonly, the changes are benign in early child-
hood, but during the puberty, they assume their ma-
lignant form. They are slow growing tumors, which
rarely produce metastases, but can cause the local
destruction of the tissue. The most common sites of
appearance are the face, neck, and upper part of
the trunk (back and chest). Surgery is the treatment
of choice, but since tumors may be very numerous,
surgical treatment is not always practical. Further-
more, tumor recurrences are common due to diffi-
cult defining of the skin margins. Recent studies us-
ing photodynamic therapy with a systemic or topical
photosensitizer and appropriate laser or non-laser
light source have shown good early results, and
cryotherapy has been useful for small, early le-
sions. Intralesional interferon- has been reported
useful in a small number of cases. Radiotherapy
should not be used, since the rate of appearance of
new lesions is accelerated after the irradiation in the
irradiated field. However, the follow-up due to early
detection of basal cell carcinoma is very mportant.
P 9
CONGENITAL GIANT NEVUS –
THERAPEUTIC APPROACH
M. Šitum, . Buèan, K. Kostoviæ, D. Štulhofer
Buzina1
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, 1Department of Dermatology and
Venerology, Zagreb University Hospital Center, Zagreb,
Croatia
Congenital giant nevus (congenital hairy nevus,
or bathing trunk nevus) is an extensive pigmented
nevus with a tendency to spread within a derma-
toma. The incidence is extremely low, ranging from
1/5,000 to 1/20,000 births. The cause of congenital
melanocytic nevi is unknown. They presumably
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represent a significant defect in the migration of
melanocytes from the neural crest. Although there
are reports of familial congenital melanocytic nevi,
most cases are sporadic. There is a great variation
in the clinical appearance of congenital nevi: they
can take a shape of a bathing trunk, vest, pelerine,
coat sleeve, or socks. Affected area is a dark,
brown pigmented, hairy, weakly infiltrated, and of-
ten verrucous. Except on the trunk and extremities,
the nevus can be found in scalp, brain, spinal cord,
and meninges. Due to the affection of the central
nervous system, one can have disturbances that
represent neurocutaneous syndroma, so-called
melanosis neurocutanea. Regarding the extension
of skin changes, these nevi are great therapeutic
problem. The basic treatment of congenital melano-
cytic nevi is surgical excision. The stimulus towards
therapy is to prevent the later development of ma-
lignant melanoma and to provide cosmetic im-
provement for this often extremely distressing prob-
lem. The patient should be followed-up every six
months to check for a change in color, shape, satel-
lite lesions, and nodules. Since the large congenital
melanocytic nevi may evolve into malignant mela-
noma in the first year of life, excision should be un-
dertaken as soon as the risks associated with anes-
thesia are acceptable. Often several staged exci-
sions (partial surgical excision), combined with tis-
sue expanders or skin grafting, are needed. The
propensity of congenital melanocytic nevi to extend
quite deep implies that some melanocytes are often
left behind. Sometimes, extremely superficial, pale
congenital melanocytic nevi are treated early in life
with dermabrasion; this offers an easier and safer
way to treat larger areas in a small child, but also
leaves behind melanocytes in deeper layers of the
skin. Smaller lesions can be excised later, perhaps
after a patient is 8-10 years old and when local an-
esthesia usually suffices.
P 10
THE EFFICACY OF TABLE SUGAR IN
TREATMENT OF VENOUS ULCERS
I. Vukšiæ, N. Puizina-Iviæ, D. Marasoviæ, D.
Anðelinoviæ, T. Stipiæ, D. Pezelj, G. Pavièiæ, V.
Gotovac, A. Èarija, S. Periæ-Sušak
Split University Hospital Center, Split, Croatia
There is no ideal therapy for ulcers infected with
Pseudomonas aeruginosa. The idea of using a ta-
ble sugar for these infections came from South
America, where this technique has been used for
centuries. We used the table sugar as the first-line
defense in ulcers infected with P. aeruginosa after
obtaining of ulcer’s swab for bacterial culture. The
preliminary results showed that sugar could be con-
ventional therapy aid in the management of venous
ulcers infected with these gram-negative bacteria.
The possible mode of inhibition of P. aeruginosa
growth is discussed according to the recent litera-
ture data.
P 11
VITILIGO – NEW APPROACHES IN
PHOTOTHERAPY
K. Kostoviæ, . Buèan, I. Nola, N. Troskot
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, Zagreb, Croatia
Vitilgo is a depigmenting disorder characterized
by amelanotic maculae resulting from a loss of
melanocytes. Its prevalence in the worldwide popu-
lation is approximately 2%. There are several hy-
potheses on the pathogenesis of the disease, but
none is fully explanatory. Vitiligo can be treated in
many ways, but not all the patients respond to cur-
rent treatment modalities. Phototherapy with
psoralen and UVA (PUVA) is the most useful for ex-
tensive vitiligo. Psoralen is used as a bath prepara-
tion or orally with 8-methoxypsoralen (8-MOP)
taken two hours before exposure to UVA lamps.
The treatment is given two to three times a week. If
there is no response within three months, the treat-
ment should be stopped. The recommended upper
limit for the total number of treatments is 100-150.
The areas that respond most favorably are the face
and the trunk. Since 8-MOP can cause a number of
adverse effects, including gastrointestinal side ef-
fects, such as nausea and vomiting, and skin side
effects, such as erythema and pruritus, new treat-
ments may include the use of 5-methoxypsoralen
(5-MOP) and narrow-band UVB therapy. Since
5-MOP is less phototoxic agent, the incidence and
severity of adverse effects, such as nausea, vomit-
ing, erythema, and pruritus, are 2-11-fold less fre-
quent than with 8-MOP. 5-MOP has similar re-
sponse rate as 8-MOP in repigmenting vitiligo. Sev-
eral studies suggested that narrow-band UVB can
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be more effective than oral PUVA, with response
rates ranging between 30% and 67%. Where other
forms of phototherapy are concerned, the face and
the trunk have better regimentation than distal parts
of extremities. In addition, narrow-band UVB have
no gastrointestinal side effects and erythema is
milder. It must be pointed out that this is the most ef-
fective treatment modality for children with vitiligo.
P 12
CONVATEC IN LOCAL THERAPY – CASE
REPORT
I. Ruèeviæ, V. Barišiæ-Druško, D. Biljan, Z. Jukiæ,
N. Šustiæ, R. Vukadin, A. Ageel
Department of Dermatology, Osijek University Hospital Cen-
ter, Osijek, Croatia
We present a case of a woman with diabetes
mellitus and unusual necrosis of the toes followed
by sepsis. The patient‘s medical history revealed
that wet gangrene involving the great toe and the
second toe of the right foot developed after she had
bathed in the Adriatic Sea. Soon after the appear-
ance of foot gangrene, the patient developed sep-
sis, agranulocytosis, and gangrene of both fore-
arms (gangrena antebrachii utriusquae). We de-
scribe the results of dermatological therapy of gan-
grene in our patient using Convatec® products.
P 13
THERAPEUTIC DIFFICULTIES IN
DIAGNOSIS OF PEMPHIGUS FOLIACEUS
J. Meštroviæ-Štefekov, M. Šitum, B. Marinoviæ1,
G. Novak-Biliæ, L. Kotrulja, I. Nola
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, 1Department of Dermatology and
Venerology, Zagreb University Hospital Center, Zagreb,
Croatia
We present a case of pemphigus foliaceus in a
77-year-old female patient with intercellular IgG
and IgA deposits and a 10-year history of bullous
disease. First skin lesions appeared on the scalp 10
years ago, and six months later on the trunk in the
form of small blisters and erosions, histologically
assigned to Grover disease. Three years ago, dur-
ing the episode of bullous eruption, erythematous
patches appeared on the face. Direct immuno-
fluorescence showed intercellular IgA deposits and
linear deposition of C3 and C1q along the base-
ment membrane; diagnosis of IgA pemphigus was
made. In August 2001, clinical examination re-
vealed scaly erythematous plaques on the face and
annular lesions with a scaly margin on the trunk and
extremities. Cutaneus biopsy specimens showed
intraepidermal blisters with acantholysis in the up-
per epidermis, without neutrophilic infiltration. Di-
rect immunofluorescence revealed intercellular IgG
and IgA deposits, whereas indirect immunofluores-
cence showed circulating IgG and IgA antibodies
directed against intercellular spaces of the epider-
mis. Antibodies showed specific reactivity with
desmoglein-1 antigen (DSG-1 202,5 ind), but no
specific reactivity with desmoglein-3 (DSG-3 0.9
ind). Diagnosis of pemphigus foliaceus was made.
After six weeks of treatment with methylpredni-
solone and azathyoprine, the skin lesions withdrew,
but corticosteroid side effects remained quite visi-
ble. After a short, three-month period of remission,
skin lesions reappeared: erythematous plaques on
the face and scaly, annular lesions on the trunk and
extremities, which were more pronounced then be-
fore. We started Dapsone 100 mg daily and after an
initial good recovery, the patient developed a most
unusual side effect of this therapy – increased val-
ues of methemoglobin. Thereafter, the dose was
decreased to 50 mg daily. The patient is still being
followed-up. The question is what other treatment
options will be left to use if this and other side ef-
fects continue to appear.
P 14
VASCULITIS WITH MUTILATION: PART OF
LEPROSY CLINICAL FINDINGS?
G. Novak-Biliæ, M. Šitum, A. Soldo-Belic, J.
Meštroviæ-Štefekov, L. Kotrulja, L. Lugoviæ
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital, Zagreb, Croatia
We present a case of a 57-year-old man who is
still without a definite diagnosis. The patient was re-
ferred to our Department in September 2002 from
the ENT Department, where he was observed for
hearing loss, skin changes, and primary destruction
of the left nasal region (alae nasi) under suspicion
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of skin tumor. However, skin biopsy did not reveal
any tumor cells. Patient has had diabetes mellitus
and hypertension for many years. A year ago, he
had cerebrovascular insult (CVI), which resulted in
mild left-side hemiparesis, but caused no other
complications. First skin lesions appeared on his
nose, forehead, and dorsum of the right hand a year
ago, after CVI. The changes were most expressive
in the nasal region, with destruction of tissue, pro-
gressive tissue loss, erythema, and edema around
the defect. Atrophic, anesthetized areas of the skin
could be seen on the forehead and dorsum of the
right hand. Simultaneously with skin changes, eye-
sight weakening, double visions, and a hearing loss
started to appear, but patient was generally in good
condition.
The differential diagnosis included systemic in-
fective (leprosy or TBC), systemic autoimmune (lu-
pus mutilans profundus or vasculitis), and other
systemic diseases (complications of diabetes mel-
litus). History data and clinical findings (travelling to
countries with endemic leprosy, sensory disorders,
and nasal destruction) primary referred to leprosy;
therefore, extensive clinical, laboratory, and histo-
pathologic examinations were made in that direc-
tion, but specific tests to M. leprae were negative.
Skin biopsy of the nose lesion showed “small vessel
neutrophilic” vasculitis. Ziehl-Nilsen, Giemsa, and
PAS staining were negative. NMR showed ele-
ments of vasculitis in distal parts of the posterior
and medial cerebral arteries.
Multidisciplinary consultations of specialists in
infectious diseases, neurology, ENT, internal medi-
cine, and pathology led to the conclusion that the
pathological process is primary autoimmune vascu-
litic disease of unknown etiology. However, based
on the clinical findings, the diagnosis of borderline
leprosy still cannot be definitely excluded. As the
disease has been advancing, it had to be decided
what therapy to apply. Systemic corticosteroid ther-
apy has been started with high-dose methylpredni-
solone (80 mg; Medrol® tbl). There has been no sig-
nificant clinical improvement, but it seems that pro-
gressive course of disease has slowed down. The
patient is still under observation.
P 15
CORRELATION BETWEEN QUALITY OF
LIFE AND PSYCHOLOGICAL IMPACT IN
PATIENTS WITH ACNE VULGARIS
L. Kotrulja, L. Oremoviæ, I. Sjerobabski-Masnec,
M. Šitum, M. Vurnek1, . Buèan, M. Tadinac
Babiæ1, N. Jokiæ Begiæ2, R. Gregurek2
Department of Dermatology and Venerology, Sisters of
Mercy University Hospital; 1Department of Psychology, Fac-
ulty of Philosophy; and 2Clinic for Psychological Medicine,
Zagreb University Hospital Center, Zagreb, Croatia
Acne vulgaris is a common inflammatory derma-
tosis that can produce psychological and physical
scarring. It is common for the patient to develop
psychological problems as a consequence of the
condition, such as those related to low self-esteem,
social phobias, depression, anxiety, suicidal
thoughts, and lowered quality of life. Self-assess-
ment of acne severity is often more severe than
clinical dermatological evaluation, which is impor-
tant for understanding the necessity of individual
approach to the patient. Isotretinoin is indicated in
the treatment of severe form of the disease, al-
though its application has also been suggested
lately in moderate form of acne with prominent
cicatricial liability or when the disease has a strong
psychological impact on patient’s life. In the last 15
years, there has been evidence of possible associ-
ation of isotretinoin therapy with depression and
suicidal tendency during the treatment. The aim of
our clinical trial, conducted at two Dermatological
Departments in Croatia, was to determine how pa-
tients with acne vulgaris cope with their disease and
what is the influence of isotretinoin therapy on psy-
chological status of the patient. Acne severity was
determined by a dermatologist using validation
grading system. Patients were asked to self-rate
their condition. Quality of life was measured by Der-
matology-Specific Quality of Life Questionnaire
(DSQL). Subjects also completed Assessments of
the Psychological and Social Effects of Acne
(APSEA), Beck’s Depression Inventory (BDI),
State-Trait Anxiety Inventory (STAI), and the Mea-
sure of Psychological Stress (MSP). The results
showed that patients with acne suffered from
psychosocial problems induced by their disease.
The disability associated with acne correlated in-
consistently with clinical grading of acne severity,
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but showed a good correlation with self-rated se-
verity of the condition. It seems that the impairment
caused by acne does not correlate with the objec-
tive clinical assessment of acne severity. The most
important factor is the patient’s perception of their
condition. Therefore, it is important for the future re-





H. Cvitanoviæ, E. Kneeviæ, I. Kuljanac
General Hospital Karlovac, Karlovac, Croatia
We investigated the frequency of dermatomy-
coses in the Karlovac area during 1995-2002. The
study included a total of 1,182 cases of clinically
suspected dermatomycoses. In all patients, the
identification of fungi was performed by direct mi-
croscopic preparation with 20% KOH and culture
on Sabouraud medium at the Central Mycologic
Laboratory of Croatia, Department of Dermatology
and Venerology, Zagreb University School of Medi-
cine. Positive results were obtained in 354 (29.9%)
out of 1,182 patients; 169 (47.7%) were men, and
185 (52.2%) were women. The average age of the
patients was 39 years. Distribution of dermatomy-
coses was as follows: trunk 9 (2.5%), arms 72
(20.3%), legs 83 (23.4%), finger nails 23 (6.6%), toe
nails 48 (13.6%), face 40 (11.2%), and scalp 79
(22.3%). The results showed that Trichophyton
mentagrophytes was the most common etiologic
agent, found in 154 (43.5%) cases, followed by
Microsporum canis in 110 (31.1%) cases. Candida
spp. was isolated in 70 (19.8%), Trichophyton rub-
rum in 14 (3.9%), Epidermophyton floccosum in 4
(1.1%) Trichophyton violaceum in 1 (0.3% ), and
Microsporum gypseum in 1 (0.3%) patient. In 150
(42.4%) cases, we administered oral antifungal
therapy, mostly terbinafine. In 254 (57.6%) patients,





J. Lipozenèiæ, S. Ljubojeviæ, N. Pustišek1, T.
Batinac2
Department of Dermatology and Venerology, Zagreb Univer-
sity Hospital Center; 1Children’s Hospital Zagreb, Zagreb
University School of Medicine, Zagreb; 2Department of Der-
matology and Venerology, Rijeka University Hospital,
Rijeka, Croatia
Erythromelalgia is a rare and unusual clinical
syndrome characterized by erythema and swelling
of the skin due to vasodilatation, increased temper-
ature of the affected skin, burning, and pain in acral
parts of the extremities, aggravated by warming
and relived by cooling. Women are affected 2.5-fold
more frequently than men. We present a case of a
22-year-old woman who has suffered from painful
bilateral erythema, swelling, and warmth of hands
and feet for a year. A month before she developed
the symptoms, she had received influenza vaccine
because of recurrent respiratory infection. There
was no unusual immediate reaction to vaccination.
Clinical picture was characterized with symmetri-
cal, pronounced redness, swelling, and warmth of
the skin of distal limbs accompanied by severe
burning pain that could be relieved by cold com-
presses. Her mother suffered from chronic throm-
bocytopenia. Patient’s routine blood tests, including
platelet count, were within the normal ranges. Diag-
nosis of erythromelalgia was established on the ba-
sis of clinical and laboratory findings (hematologi-
cal, biochemical, microbiological, and immunologi-
cal), indicating no systemic organ involvement.
Histological finding revealed arteriolar endothelial
cell swelling, thickening of vessel walls, and peri-
vascular inflammatory infiltration of lymphocytes
and plasma cells. Thermography showed incre-
ased skin temperature in the affected areas and
thermal amputation of the fingers on both hands.
Treatment was very difficult. Multidisciplinary ap-
proach was necessary, including patient education
(learning to avoid episodes, controlling secondary
and underlying factors, and use of drugs). In the be-
ginning, the patient was administered aspirin, but
she developed an allergic drug eruption, which was
proven by testing. She refused taking corticostero-
ids. Oral prostaglandin (misoprostol) 800 mg daily
was introduced after 8 months of illness, with 10%
capsaicin cream for topical therapy, which showed
limited effect. Cyproheptadine (Periactin 3 tbl daily;
followed by 2 tbl daily) during 1 month with cold
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compresses during 2 months led to improvement
and showed to be a treatment of choice in our pa-
tient.
The pathogenesis of the disease is still unclear.
In our patient, influenza vaccination given 30 days
before the development of the symptoms suggests
an immune-mediated injury probably induced by
the vaccine. Despite recent progress in under-
standing and treating erythromelalgia, this vascular
disorder remains painful and life-altering disease
for many patients. The use of high dosage oral
prostaglandin produces good results and, some-
times, dramatic improvement. However, it showed
relative effect in our patient, in whom cyprohepta-
dine and cold compresses proved to be the therapy
of choice.
P18
NAPHTHALAN IN THE TREATMENT OF
PATIENTS WITH ATOPIC DERMATITIS
(NEURODERMITIS)
A. Smeh-Skrbin, I. Dobriæ1, G. Krnjeviæ-Peziæ, P.
Vrogiæ
Naftalan Special Hospital for Rehabilitation, Ivaniæ Grad,
and 1Department of Dermatology and Venerology, Zagreb
University Hospital Center, Zagreb, Croatia
Our aim was to examine the efficacy of naphtha-
lan in the treatment of patients with atopic dermati-
tis – a chronic, usually pruritic, and clinically vari-
able skin disease associated with atopy. Naphtha-
lan therapy has been used in the treatment of pa-
tients with various forms of psoriasis for 14 years,
due to the anti-inflammatory and antiproliferative ef-
fect of natural mineral oil, naphthalan. Our study in-
cluded 15 patients aged 15 years and above, who
underwent a 3-week naphthalan therapy that con-
sisted of taking a 12-minute bath in a tub filled with
naphthalan oil at temperature of 34°-38°C every
day. Patients took 18 baths during the study. Neu-
tral cream and antihistaminic medications were
also administered. SCORAD index was determined
and a photographic record made of each patient at
the beginning and at the end of the 3-week therapy.
Naphthalan therapy resulted in the improvement of
clinical picture and reduction of subjective symp-
toms, such as itching and sleeping disorders. The
average SCORAD index was 71.92 before the ther-
apy and 25.66 after the therapy. Our results show
that naphthalan therapy alleviates the signs and
symptoms of atopic dermatitis and can be used in
the treatment of such patients.
BELUPO – THE GRAND GLOBAL TROPHY AWARD
«DON’T WORRY BE HEALTHY!
ZDRAVO BUDI»
The New York Festivals has awarded the main
prize Grand Global – The Best in Healthcare Com-
munication Worldwide for 2002 to the BELUPO
pharmaceutical company for the project of «Don’t
Worry Be Healthy! Zdravo budi!» exhibition.
The Global Award is presented for Best Con-
sumer Public Relations Materials in the area of
health care. In 2002, there were 1,300 candidates
from all over the worlds. In the category of Grand
Global – Social Commitment, Belupo exhibition
was assessed as the most original and most suc-
cessful, socially useful project in the world. This is
the first time that a firm from this part of Europe has
been honored with such an award, which is even
more rewarding.
«Don’t worry be healthy! Zdravo budi» was
opened to the Croatian public in October 2001, in
the Museum of Arts and Crafts, Zagreb. The project
was realized by Ante Rašiæ and Oleg Hriæ from
Studio Rašiæ, in cooperation with the experts from
Belupo-Marketing (Renata Tomerlin-Juzbašiæ).
This multimedia exhibition presented a new vi-
sual identity of packaging of Belupo non-prescrip-
tion pharmaceuticals. Artistic illustrations served as
a basis for the attractive new image: simple, easy-
to-remember, and recognizable motifs that refer the
user to the effects of the drug.
This unique economic, cultural, and marketing
project introduced Belupo as an innovative and
modern firm, whereas the project itself wan every
contest it entered.
The honor to receive one of the five greatest
awards – Grand Global Trophy at The New York
Festivals – fell to the Croatian firm, Belupo. Grand
Global – The Best in Healthcare Communication
Worldwide for the «Zdravo budi!» exhibition was
presented by the representative of The New York
Festivals at the presentation ceremony that took
place on Thursday, April 24, 2003, at 5:00 p.m. in
the Museum of Arts and Crafts, Trg maršala Tita 10,
Zagreb. The event was attended by the President of
the Republic of Croatia and other leading eco-
nomic, cultural, public, and political figures in the
country. There was a complete atmosphere of the
ceremony of award presentation to Belupo and the
artistic team behind the project.
Cordial congratulations to Belupo-Marketing,
Zagreb.
Prof. Jasna Lipozenèiæ, M.D., Ph.D.
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The Croatian Dermatovenerological Society of the Croatian Medical Association, Zagreb
and
“Naftalan” Special Hospital for Rehabilitation, Ivaniæ Grad, Croatia
organize
International Symposium
Current State on Psoriasis and Naphthalanotherapy
Ivaniæ Grad, Croatia
September 19, 2003.
Bus transportation from Zagreb to Ivaniæ Grad will be organized for all participants of the Symposium.
Continuing Medical Education Course on
Sexually Transmitted Diseases and Infections
Zagreb, Croatia
November 21-22, 2003
The Continuing Medical Education Course is organized by the Chair of Dermatovenerology, University School of
Medicine Zagreb and the Croatian Dermatovenerological Society of the Croatian Medical Association under the aus-
pices of Academy of Medical Sciences of Croatia.
There has been a resurgence of sexually transmitted infections (STIs) in all age groups, which makes diagnostic proce-
dures in venerology ever more important. Great efforts are needed in service provision, health promotion, and research
to identify the interventions most likely to succeed. The prevalence of the most frequent STIs will be discusses on the
Course.
World known expert in the field of STIs, Prof. James Bingham will also participate in Course.
Contact:
Prof. Jasna Lipozenèiæ
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Main topics:
• New aspects in etiopathogenesis of psoriasis
• Immunohistopathologic diagnosis in prognosis of
psoriasis
• Antiproliferative effect of naphthalan combined ul-
traviolet B (UVB) light and naphthalan therapy
• Other therapeutic options in treatment of psoriasis.
Contact:
Prof. Jasna Lipozenèiæ






On the First Spring Symposium of the European Academy of Dermatovenerology in Hotel Intercontinen-
tal, Malta, on March 1, 2003, Stella Fatoviæ-Ferenèiæ (Croatia) and Karl Holubar (Austria) were awarded
the Lupus Malta Prize for the best poster submission on Lupus Erythematosus: History of Lupus Erythema-
tosus.
Congratulations to the authors and Croatia, too.
Prof. Jasna Lipozenèiæ, M.D., Ph.D.
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Severe Acute Respiratory Syndrome (SARS)
S. Ljubojeviæ
Department of Dermatology and Venerology, Zagreb University Hospital Center, Zagreb,
Croatia
Severe acute respiratory syndrome (SARS) is a
respiratory illness of unknown etiology that has
been spreading since February 1, 2003. The diag-
nosis of the disease can be made on the following
criteria: 1) fever >38°C; 2) one or more clinical find-
ings of respiratory illness (e.g., cough, shortness of
breath, difficulty breathing, hypoxia, or radiographic
findings of either pneumonia or acute respiratory
distress syndrome); 3) travel within 10 days of on-
set of symptoms to an area with documented or
suspected community transmission of SARS
(World Health Organization has received reports of
the syndrome from China, Singapore, Vietnam,
Thailand, Indonesia, Taiwan, and Philippines, as
well as Canada, the United States, and Germany);
and 4) close contact within 10 days of onset of
symptoms with either a person with a respiratory ill-
ness who traveled to a SARS area or a person
known to be a suspect SARS case. Travel includes
transit in an airport in an area with documented or
suspected community transmission of SARS. Close
contact is defined as having cared for, having lived
with, or having direct contact with respiratory secre-
tions and/or body fluids of a patient known to be a
suspect SARS case.
The outbreak in the area mentioned above has
continued to grow in magnitude and has affected
groups outside the initial risk groups of hospital
workers, their families, and other close person-
to-person contacts, although all the cases reported
have identified links to known SARS cases. In addi-
tion, a small number of persons with SARS, now in
other countries in the world, appear to have ac-
quired the infection while in Toronto. On the basis of
this information, World Health Organization is also
including Toronto in the extension of its SARS-re-
lated travel advice.*
SARS is a new disease, first recognized in late
February 2003, that has spread along the routes of
international air travel. The disease originated in
Guangdong at the end of last year and has affected
over 300 people and killed five. The outbreak in
Hong Kong started when a doctor from southern
China arrived on February 21, 2003, and stayed in a
local hotel. He had been unwell for a few days be-
fore the trip but now became seriously ill and died in
a local hospital. However, he had infected his
brother-in-law, two nurses in the hospital, and
seven guests who had stayed on the same floor of
the hotel. One of these hotel guests was admitted
into a major public hospital on February 24 and was
responsible for the outbreak there, affecting at least
88 healthcare workers and 18 medical students.
Another major outbreak affecting 237 residents (at
the time of writing) in a housing estate was traced
back to a patient discharged from the same ward of
the public hospital.
As of April 22, 2003, a cumulative total of 3,947
cases had been reported from 25 countries on five
continents. The outbreak started with a visitor from
southern China on February 21. At the hospitals
where the first cases were treated, the disease
spread quickly among healthcare workers, and
then out into the community as family members be-
came infected. On March 27, the Department of
Health announced drastic measures, including vig-
orous contact tracing and examination, quarantine
of contacts in their homes, and closure of all
schools and universities.
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*Source: http://www.health.ri.gov/disease/communicable/
sars/han35.htm.
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Precautionary measures aim to reduce the im-
pact of SARS and contain the disease while it is still
in a relatively early stage. There is strong evidence
that a novel coronavirus is the pathogen. Precau-
tions for droplet infection should be instituted, in-
cluding the wearing of masks, and rigorous disin-
fection measures and hygiene procedures.
The SARS situation is assessed on a daily basis
to determine whether other areas need to be in-
cluded in the travel advice and if additional precau-
tionary measures are required.
The rapidity of the spread of the disease and the
morbidity indicate that the agent responsible is
highly infectious and virulent. Strict infection control
measures for droplet and contact transmission by
healthcare workers, a vigilant healthcare profes-
sion, and public education are essential for disease
prevention.
For more detailed information visit the following
websites:
• World Health Organization. Severe acute re-
spiratory syndrome (SARS). Available from:
www.who.int/csr/2003_03_12/en. Accessed:
March 12, 2003.
• Government of Hong Kong Special Adminis-
trative Region Department of Health. Atypical
pneumonia. Available from: www.info.gov.hk/
info/infection-c.htm. Accessed: April 7, 2003.
• Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T,
Chan-Yeung M, et al. A cluster of cases of se-
vere acute respiratory syndrome in Hong
Kong. N Engl J Med 2003 Apr 1 [epub ahead
of print]. Available from: http://content.nejm.
org/cgi/reprint/NEJMoa030666v2.pdf. Acces-
sed: April 7, 2003.
• Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam
LYC, Lim W, et al. Coronavirus as a possible
cause of severe acute respiratory syndrome.
The Lancet 2003 Apr 8 (published online).
Available from: http://image.thelancet.com/ex
tras/03art3477web.pdf. Accessed: April 8,
2003.
• Hospital Authority. Severe acute respiratory
syndrome: clinical guidelines (revised 27 Mar
2003). Available from: www.ha.org.hk/hes
d/nsapi/?MIval=ha_view_template&group=
PRS&Area=CGL. Accessed: April 7, 2003.
• Lee N, Hui D, Wu A, Chan P, Cameron P,
Joynt GM, et al. A Major outbreak of severe
acute respiratory syndrome in Hong Kong. N
Engl J Med 2003 April 7. Available from:
www.nejm.org. Accessed: April 7, 2003.
• Centers for Disease Control and Prevention.
Severe acute respiratory syndrome (SARS):
information for clinicians. Available from:
www.cdc.gov/ncidod/sars/clinicians.htm. Ac-
cessed: April 7, 2003.
• Peiris JS, Lai ST, Poon LL. Coronavirus as a
possible cause of severe acute respiratory
syndrome. The Lancet 2003 Apr 8 (published
online). Avaliable from: http://image.thelanc
et.com/extras/03art3477web.pdf. Accessed:
April 8, 2003.
Three Studies in Pediatric and Adult Patients Demonstrate
that Tacrolimus Ointment is Safe and Effective in the
Treatment of Atopic Dermatitis
Ira Lawrence
Fujisawa Healthcare, Inc., Deerfield, IL, USA
INTRODUCTION
Tacrolimus ointment (Protopic®), a topical calci-
neurin inhibitor, is approved in many countries
around the world for the treatment of atopic derma-
titis in adult and pediatric patients (1-3). This article
summarizes results from 3 recent clinical studies in
adults and children with atopic dermatitis treated
with tacrolimus ointment. Immune parameters were
evaluated in 23 children 2 to 12 years of age with
atopic dermatitis who applied 0.03% tacrolimus
ointment twice daily for a total of 7 weeks. Patients
were vaccinated with Pneumovax® (pneumococcal
vaccine) during the third week of treatment. Data
from two large multi-center trials involving 8,722 pa-
tients with atopic dermatitis who applied tacrolimus
ointment continuously or intermittently for up to 4
years were combined and analyzed. Patients ap-
plied 0.03% or 0.1% tacrolimus ointment twice daily
during episodes of atopic dermatitis and for 1 week
after clearing of lesions.
Seven-week Study
There were an equal percentage of male and fe-
male patients and those with moderate or severe
disease. The majority of patients were white, but
there was a good representation of African Ameri-
cans. There were no clinically significant changes
over time for CBC, lymphocyte subsets (CD3, CD4,
CD8, and CD 19 cell counts) and CD4/CD8 ratio.
There was no clinically significant change in immu-
noglobulin (IgG, IgA, IgM, IgE) levels observed over
time, or in the tetanus and H. influenzae antibody
titers. All patients developed a protective antibody
response to at least one pneumococcal serotype.
Long-term Studies
The demographics and baseline characteristics
for the two long-term trials are summarized in Table
1. Rapid improvement of atopic dermatitis was ob-
served during the first few weeks of treatment
(p<0.001) and improvement continued throughout
these long-term studies. There was no loss of effec-
tiveness. Transient, mild, local application site reac-
tions (pruritus and burning/stinging) were observed
early in treatment, but were of short duration and
rarely led to discontinuation. Patients with severe
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Table 1. Demographics and baseline characteris-
tics of patients with atopic dermatitis (1-4)
Patients
Characteristics pediatric (n=4,350) adult (n=4,372)
Male sex (%) 46.5 42.5
White (%) 69.5 74.9
African American (%) 17.0 13.7
Other (%) 13.5 11.5
Mean (±SD) age (years) 6.6±3.8 41.3±15.6




Body surface area affected
(%, mean±SD) 36.3±27.8 30.1±27.2
†Severity of atopic dermatitis based on Rajka and Langeland Criteria (4).
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disease reported these application site events more
frequently. The risk of adverse events including in-
fections did not increase with long-term use of
tacrolimus ointment. There were no reports of skin
atrophy at the application site, even with treatment
for up to 4 years.
CONCLUSION
Tacrolimus ointment does not affect levels of
immunoglobulins, antibodies, lymphocyte subsets,
nor does it interfere with the antibody response to
pneumococcal vaccine in children with atopic der-
matitis. Tacrolimus ointment has no systemic immu-
nosuppressive effect and its immunomodulatory ef-
fect is limited to the skin. Tacrolimus ointment mo-
notherapy is safe, and its effectiveness is main-
tained, even with long-term use. Tacrolimus oint-
ment monotherapy may be a drug of choice for
long-term treatment of atopic dermatitis.
References
1 Tacrolimus ointment: Advancing the treatment of
atopic dermatitis. J Am Acad Dermatol 2001;44:S1-72.
2 Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R,
Ruzicka T, et al. Safety and efficacy of 1 year of tacro-
limus ointment monotherapy in adults with atopic der-
matitis. The European Tacrolimus Ointment Study
Group. Arch Dermatol 2000;136:999-1006.
3 Rico MJ, Lawrence I. Tacrolimus ointment for the treat-
ment of atopic dermatitis: clinical and pharmacologic
effects. Allergy Asthma Proc 2002;23:191-7.
4 Rajka G, Langeland T. Grading of the severity of atopic
dermatitis. Acta Derm Vereol Suppl (Stockh) 1989;
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“Eau de cologne 4711” offered at fair prices (packaging and shipment
expenses not included) in the form of cologne or soap.
From the collection of Stella Ferenèiæ-Fatoviæ, M.D., Ph.D.
The First European Academy of Dermatology and
Venerology Spring Symposium
The First European Academy of Dermatology
and Venerology (EADV) International Spring Sym-
posium, organized by Prof. Joseph Pace, was held
in St. Julius Bay, Malta, from February 27 to March
1, 2003. The EADV Spring Symposium was held in
cooperation with Internal Skin Care Nursing Group
(ISNG) and Patients Associations represented in
Malta, the EUROPSO, the Malta Psoriasis Associa-
tion, ELEF European Group of Lupus Patients and
Lupus Malta. There were 1,000 participants coming
from 55 countries. The program included three Ple-
nary focus sessions, six Plenary lectures, six work-
shops, 48 free communications, 170 posters, eight
meetings of sister societies, and three satellite sym-
posia about new therapies for eczema and psoria-
sis (Fig. 1).
The EADV provides continuing medical educa-
tion (CME) in the fields of Dermatology and Vene-
rology and helps maintaining high professional
standards within our specialty, related professions,
and health services. The CME Committee of the
EADV developed an active evaluation program to
optimize the practical and scientific content of the
EADV Congress. Sessions in History of Medicine
were organized on February 26, 2003, as a pre-
congress activity. As an additional option for those
interested in the History of Medicine, the Local Or-
ganizing Committee in cooperation with the Univer-
sity of Malta arranged a day’s program that will be
remembered as very successful.
Morning sessions were held in Fort St. Angelo,
now sovereign territory of the Order of St. John.
Several experts talked on the history of medicine in
Malta, from the period before 1530, through the
years of the Order in the 1530-1798 period, to the
later period between 1800 and 1964 (a lecture titled
“British connection”). The sessions were very suc-
cessful. After a short guided tour of the castle, once
a famous bastion in the stand against the Turkish
Armada during the Great Siege in 1565, we were
taken to Sacra Infermeria across the Grand Harbor
in Valetta. Sacra Infermeria was once considered
the best hospital in Europe and often referred to as
«the real splendor of Malta». Today, it is the Medi-
terranean Conference Center, where the History of
Dermatology meeting took place under the co-cha-
irmanship of some of the most eminent experts in
the field of History of Medicine: Prof. Karl Holubar
from Vienna, Austria (President of European Soci-
ety of History of Dermatovenerology), Prof. Law-
rence Charles Parish from Philadelphia, USA
(President of American Society of Dermato-
lovenerology), and Prof. Marcia Ramos-e-Silva
from Rio de Janeiro, Brasil.
The Eponyms of Dermatology
How and why some skin disease was named af-
ter a person was the main topic of the afternoon
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Figure 1. The First Spring Symposium of the European
Academy of Dermatology and Venerology.
sessions. Dermatologists are often faced with the
nomenclature that includes the name of an impor-
tant person associated with the cutaneous entity.
These sessions aimed at reminding the clinicians of
the contributions made by physicians whose names
have become eponyms. Stella Fatoviæ-Ferenèiæ
from Croatia presented Kogoj’s pustule; Michael
Skerlev described Buschke-Löwenstein tumor, and
Jasna Lipozenèiæ talked about Scleredema of
Buschke. The following skin diseases was also pre-
sented: Gunter’s disease, Bowen’s disease,
neurofibromatosis, anetoderma and atrophoderma
psoriasis, urticaria, Hailey-Hailey disease, dermati-
tis herpetiformis, blastomycosis, Bourneville’s dis-
ease, acrodermatitis, and pityriasis rosea (Fig. 2).
On February 25, 2003, Professor Alfredo
Rebora gave the Evening Dinner lecture on Lichen
Planus and the liver (Fig. 3).
Lupus Malta Prize for the best submission on
Lupus erythematosus went to Stella Fatoviæ-
Ferenèiæ and Karl Holubar for the “History of lupus
erythematosus” poster. Congratulations to the au-
thors and Croatia. Other prizes were Shiseido Prize
for the best submission on skin aging and Bank of
Valetta Malta Prize for the best submission from a
Mediterranean country.
For the first time, the Organizing Committee has
accepted all lectures without compulsory registra-
tion. Thus, all submitted abstracts were published in
the Journal of European Academy for Dermatology
and Venerology although some of the authors could
not join us in person at the Congress.
The Venue took place in Intercontinental Hotel
Malta, bowling alley, a cinema complex, and a
Heath Club in St. Julian’s, Malta.
The Opening Ceremony on February 27, 2003,
took place in the world famous St. John’s Cathedral
in Valetta, a home to the Caravaggio’s famous Be-
heading of St. John. The event was preceded by a
Choral/Organ Concert by courtesy of the Metropoli-
tan Cathedral Chapter and St. John’s Co-Cathedral
Foundation. Prof. Guido de Marco, Patron of the
Symposium, kindly offered the reception at the
President’s Palace. On March 1, 2003, a masked
carnival ball was organized in Sacra Infermeria.
The oral communications in workshops covered
the field of dermatopathology (inflammatory disor-
ders; and nevi and neoplastic diseases); cosmetic
dermatology (live transmission – office procedures;
the AHA’s historic development; and “How to do it”
cosmetic dermatological surgical talks); approach
to the patient with sexually transmitted infections;
pediatric dermatology; photodynamic therapy; vitili-
go; Internal Skin Care Nursing Group (ISNG). Ple-
nary Sessions included Inflammatory Dermatoses;
Sun Care; Skin Cancer; and Skin and Internal Dis-
eases. Short presentations were as follows: Gen-
eral, Epidemiology, Quality of Life, Research, Can-
cer, Infection, and Treatment 1 and 2. The session
on Atopic Dermatitis was organized by Lipozenèiæ
and Ring.
Prof. A. Kapp from Hannover chaired the Fuji-
sawa Satellite Symposium, “A New Therapeutic
Paradigm in Atopic Dermatitis Management”,
where a 10-year experience in monotherapy with
Protopic® was presented, as well as guidelines for
its use in everyday practice.
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Figure 3. Prof. Alfredo Rebora gave the Evening Dinner
lecture Lichen Planus and the Liver: so old that it is some-
how historical.
Figure 2. History of Dermatovenerology Meeting, Malta,
March 26, 2003.
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Serono organized “The promise of biological
therapies: new approaches in psoriasis”, which was
co-chaired by J. H. Saurat and J. Pace. Moder-
ate-to-severe psoriasis could be efficiently treated
with efalizumab, a therapy that has every potential
to bring about the improvement in the quality of life
of such patients.
The First EADV International Spring Sympo-
sium held on Malta, February 27 – March 1, 2003,
was successful in scientific as well as social as-
pects. The colleagues from Croatia participated
with six posters and three lectures.
Prof. Jasna Lipozenèiæ, MD, PhD
What is the Significance of Dermatovenerology?
Report from the 5th Symposium of Sexually Transmitted Diseases with
International Participation, Opatija, Croatia, April 14-16, 2003
The 5th Symposium on Sexually Transmitted
Diseases with international participation was held in
Opatija, April, 14-16, 2003 under the auspices of
Ministry of Health of Republic of Croatia and Cro-
atian Academy of Medical Sciences and the patron-
age of the 11 Societies of the Croatian Medical As-
sociation, including Dermatovenerological, Infecto-
logical, Epidemiological, Gynaecological, Primary
Health Medicine, School Medicine, Urological,
Society for Chemotherapy, and others.
Since the First Symposium in Dubrovnik five
years ago, the Organizing Committee has been
headed by Prof. Slavko Schoenwald, M.D., Ph.D.,
from the Department of Infectology, Zagreb Univer-
sity School of Medicine. Unfortunately, Prof.
Schoenwald has passed away just a week before
this year’s Symposium, which has been therefore
dedicated to him. We believe that the values Prof.
Schoenwald has built in these yearly meetings and
his spirit will continue to live through all of us during
the following years. Prof. Višnja Škerk, M.D., Ph.D,
from the Department of Infectology, Zagreb Univer-
sity School of Medicine, has become the President
of the Symposium this year, and Prof. Vesna
Jureša, M.D., Ph.D., from the Department for
School Medicine of the Zagreb University School of
Medicine, and Assistent Prof. Mihael Skerlev, M.D.,
Ph.D., from the Department of Dermatology and
Venerology of the Zagreb University Hospital Cen-
ter and School of Medicine, have been appointed
the Vice-Presidents of the Organizing Committee
this year. The main topics of the Symposium were
the following: HIV-infection/AIDS; Virus Hepatitis as
STI; Prevention of Sexually Transmitted Infections
(STIs); HPV-genital Infections; Association be-
tween STIs and Women with Genital Malignancies;
Chronic Prostatitis as STI; Pelvic Inflammatory Dis-
ease; Genital Infections Caused by Chlamydia and
Ureaplasma; and Free Communications. Two Sat-
ellite Symposia were also held, sponsored by Phar-
maceutical Companies. GlaxoSmithKline spon-
sored the Symposium dedicated to the significance
Figure 1. 5th Symposium on STD with International
Particitipation; Opatija, April 14-16, 2003.
of valacyclovir in the treatment of genital herpes;
whereas Belupo sponsored the Symposium dedi-
cated to the antibacterial drugs for the treatment of
STIs. There were about 320 registered participants
from different medical specialties, such as Infecto-
logy, Dermatovenerology, Gynecology, Medical Mi-
crobiology, School and University Medicine, General
Medicine, Family Medicine, Urology, Epidemiology,
and other.
Epidemiology, modern diagnostics, and therapy
as well as some psychological aspects (Prof.
Gruden, Department for Psychiatry, Zagreb Univer-
sity School of Medicine) of Sexually Transmitted
Diseases (STD) were reported during plenary lec-
tures. Sexually Transmitted Diseases are one of the
major public health problems in the world, and the
participants of the Symposium would like to make
the Health authorities in Croatia also aware of that
fact. The concept of this Symposium was multidisci-
plinary, as usual. However, we would like to report
briefly on the active part of dermatovenerologists.
The Section on HPV-genital infections was co-
chaired and the plenary lectures dedicated to this
topic presented by Assist. Prof. Mihael Skerlev from
Zagreb and Dr. Marko Potoènik from the Depart-
ment of Dermatology and Venerology of Ljubljana
University School of Medicine, Slovenia. M. Skerlev
draw attention to the HPV-genital infections today
ranging from almost invisible, “subclinical” lesions
harboring high-risk HPV types to the giant condy-
lomata of Buschke-Löwenstein type. Dr Potoènik
discussed the positive findings of HPV types on the
apparently healthy skin of the genital area. Dr
Hrvoje Cvitanoviæ from Karlovac Medical Center
presented interesting data on the epidemiology of
genital warts in the Karlovac region. The Free Com-
munications Section was co-chaired by Dr Branka
Marinoviæ, M.Sc., from the Department of Dermatol-
ogy and Venerology of Zagreb University School of
Medicine, and Assist. Prof. Mirna Šitum, M.D.,
Ph.D., from the Department of Dermatology and
Venerology of Zagreb University Dentistry School,
Sisters of Mercy University Hospital, Zagreb, Cro-
atia. Dr Marinoviæ presented a lecture dedicated to
neurosyphilis, emphasizing (again) the traditionally
high level of laboratory diagnostics of syphilis in the
Serological Laboratory of the Department of Der-
matology and Venerology of Zagreb University
School of Medicine and the need for more active
approach to the prevention and treatment of syphi-
lis in Croatia. Assist. Prof. Šitum presented posters
dedicated to the resolutive phase of syphilis and to
the treatment of STIs.
There is a long list of interesting lectures pre-
sented at this year’s Symposium by our colleagues
belonging to different medical specialties. The
multidisciplinary approach is important in the field of
STIs. However, we would like to point out the inter-
esting data regarding HPV-genital infections in
women and pelvic inflammatory disease presented
by Assist. Prof. Hrvoje Vrèiæ from the Department of
Gynecology and Obstetrics of Zagreb University
School of Medicine, as well as the lectures dedi-
cated to the association between STIs and malig-
nancies held by Dr. Zekan and Dr. Vujiæ from the
same Department. The interesting data were also
presented by Prof. Asim Kurjak and Assist. Prof.
Sanja Kupešiæ from the Department of Gynecology
and Obstetrics of Zagreb University School of Medi-
cine and Holy Ghost Hospital. The lectures held by
Prof. Škerk, Prof. Krhen, and Prof. Kraus (the last
two from the Departments of Urology of Zagreb Uni-
versity School of Medicine and Dentistry School, re-
spectively) were related to the role of Chlamydia
trachomatis in the etiopathogenesis of prostatitis.
The importance of the preventive strategies for
STIs in the adolescent age was pointed out by Prof.
Jureša, Dr. Kuzman, and Dr. Depina, specialists in
School Medicine. The significance of oral antibiot-
ics used for treatment of STIs was presented by
Prof. Francetiæ from the Department of Clinical
Pharmacology, Zagreb University School of Medi-
cine. The current aspects of hepatitis B and C diag-
nostics were presented by Dr. Adrijana Vince,
Ph.D., whereas the antiretroviral drugs used for
treatment of HIV-infection were summarized by
Prof. Josip Begovac (both from the Department of
Infectology, Zagreb University School of Medicine).
During this Symposium it soon became clear
that the ever changing scientific knowledge regard-
ing STIs has especially changed during the last 10
years due to the progress in molecular diagnosis
and the development of rational pharmacotherapy,
which have had a great impact on the current STD
concept. The significant changes in epidemiology
of STIs, their modified etiology, atypical clinical vari-
ations, and different treatment strategies were em-
phasized. All the participants were cordially invited
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to attend the next Symposium, which is to be held in
2004 in Opatija, Croatia. It has been concluded at
this year’s Symposium that there is a strong need to
constitute the STD Society of the Croatian Medical
Association in order to raise the level of conscious-
ness of STIs in Croatia, among many other tasks. In
spite of the logical multidisciplinary spirit, we be-
lieve that our colleagues dermatovenereologists
will participate more actively and in greater num-
bers in the years to come. We also believe that this
is the best way for Dermatovenerology to maintain
its significance and position!
Assist. Prof. Mihael Skerlev, M.D., Ph.D.
Branka Marinoviæ, M.D., M.Sc.
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“I am always healthy and happy” – Hofer baby powder. Available at the pharmacy next door.
From the collection of Stella Ferenèiæ-Fatoviæ, M.D., Ph.D.
Marko Polo´s Diary
Stella Fatoviæ-Ferenèiæ, ESHDV representative of Croatia
Malta: The First EADV International Spring
Symposium, February 27 to March 1, 2003.
The EADV was founded as a non- profit associa-
tion in Luxemburg in 1987 and has been growing
ever since. The last EADV Congress shifted its
venue more toward East, to Prague, thereby em-
bracing the countries of the previous eastern block.
This spring the EADV´s dynamics was broadened
even more by the introduction of the Spring Sympo-
sia. The Mediterranean, the cradle of Western civili-
zation, was almost symbolically chosen as a place
of venue and the Maltese archipelago became its
birthplace. Spring was not really on its way to warm
me up when I arrived on February 25
th
at the Mal-
tese airport, and a cold and sharp wind was chasing
clouds across the sky. On the way to the hotel I no-
ticed a lot of brownish yellow colors in the scenery
and architecture. Certainly spring had not arrived
here yet and for a while I felt sorry that the sympo-
sium was not organized a few weeks later, when the
landscape would be painted in more vivid colors.
However, there was no rain and I could easily take a
refreshing walk along Spinola Bay before the His-
tory Dinner, which took part later in the evening. The
dinner went by in pleasant conversations among
friends and colleagues of both History societies.
This time I was not the only participant from Croatia.
Jasna Lipozenèiæ and Mihael Skerlev joined us as
invited speakers at the Symposium. As always, a
special lecture was given, this time by Alfredo
Rebora from the University of Genoa, who spoke
about Lichen Planus and the Liver: so old that it is
somehow historical.
The following day, the traditional History Day,
started with the History of Medicine Meeting at Fort
St Angelo, which is official territory of the Order of
Saint John. We were welcomed by the Resident
Knight, and afterwards had the pleasure to gain
knowledge about Malta’s history and history of
medicine. Superbly prepared lectures were deliv-
ered within the castle, the famous bastion and
stand against the Turkish Armada in the Great
Siege of 1565. The whole event was unique and ex-
traordinary. In this regard, the main organizer Jo
Pace must be congratulated. The afternoon ses-
sion proceeded at the Sacra Infermeria, now the
Mediterranean Conference Centre, across the
Grand Harbor in Valetta. In older times, many con-
sidered it the best hospital in Europe, and we were
pleased to be shown the long wards, where the sick
were treated, the famous majolica collection, and
the medical museum. After lunch, the Eponyms of
Dermatology session started under the co-chair-
manship of Karl Holubar, Marcia Ramos-e-Silva,
and Larry Parish. In an era when the number of
eponyms is increasing and a lot of controversy is
taking place on that subject, the pioneers in the clin-
ical art of disease recognition were enlivened be-
fore us and we all enjoyed their presence. As a mat-
ter of fact, the session attracted an exceptional high
number of people and I could feel a delicate stream
forming and flowing from past to present. The very
first descriptions of diseases were associated to re-
cent view points or clinical cases. We were all
merged into an almost spiritual atmosphere, a
space where original ideas and ingenious minds
where exposed, and where all of a sudden a
designation of past or present was irrelevant.
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The following day, I attended a cosmetic derma-
tology live-session. I was really impressed. Strap-
ped to my seat by curiosity, I could not restrain my-
self from thinking how the desire for physical beauty
triumphs over all the risks, as it always has since
the rise of mankind. Who would win, vanity or na-
ture, science or our limitations, no one can tell. Yet –
physical beauty seems to be imperative despite our
constant claims that the real beauty is not skin
deep.
The first day ended with a stylish opening cere-
mony at a Choral/Organ Concert at St John’s Co-
Cathedral, followed by the reception hosted by the
President of Malta, under whose patronage the en-
tire event of the first EADV Spring Symposium was
held.
The following days went by quickly, packed with
meetings, workshops, and late dinners. The war
with Iraq was the top issue in the corridors and
could not be avoided even during pleasant talks on
literature, which I had with Jeffrey Bernard, the edi-
tor of the Blue Journal. The closing event crowned
by a carnival party was arranged on Saturday eve-
ning. Ladies were dressed in black and gold; men in
black. Masks were available right at the entrance. A
delicious dinner with live music and candles fol-
lowed. Indeed, what made me happy more that
anything was the Malta Lupus Prize for the best
submission on Lupus erythematosus, which Karl
Holubar and I won as co-authors for our poster.
By the next morning, candles burnt out, the
masks were down, and the first Spring Symposium
of the EADV was over.
***********************************************
The world is waiting, sretan vam put!
stella@hazu.hr
***********************************************
“Rubber guard” – condom packaging.




Ljudevit Jurak International Symposium on Comparative Pathology, Zagreb, Croatia, June 6-7, 2003. Contact:
Prof. Mladen Belicza, M.D., Ph.D., Department of Pathology, Sisters of Mercy University Hospital, Vinogradska cesta
29, 10000 Zagreb, Croatia; www.kbms.hr/Jurak/symposium.htm; e-mail: juraks@kbsm.hr
XXII Congress of the European Academy of Allergology and Clinical Immunology, Paris, France, June 7-11, 2003.




International Psoriasis Symposium, New York, USA, June 17-22, 2003. Contact: Skin Disease Education Founda-
tion, 233 East Erie Street, Suite 700, Chicago, Illinois 60611; e-mail: sdef@sdefmail.com; www.sdefderm.com
Second Dermatology Update, National Skin Centre Singapore, Singapore, June 28-29, 2003. Contact: www.ilds.org
First World Congress on Work-Related and Environmental Allergy (1
st
WOREAL) & Fourth International Sympo-
sium on Irritant Contact Dermatitis, Helsinki, Finland, July 9-12, 2003. Contact: secretariat@woreal.org;
www.woreal.org
International short course in dermoscopy, Graz, Austria, July 15-19, 2003. Contact: Lorenzo Cerroni, Department of
Dermatology, University of Graz, Auenbruggerplatz 8, A-8036 Graz.
Summer Academy of Dermatopathology, Graz, Austria, July 21-25, 2003. Contact: Lorenzo Cerroni, Department of
Dermatology, University of Graz, Auenbruggerplatz 8, A-8036 Graz.
15
th
Biennial Congress of the International Society for Sexually Transmitted Diseases Research (ISSTDR), Ot-
tawa, Canada, July 27-30, 2003. Contact: 2003 ISSTDR Congress Secretariat, 251 Bank Street, Suite 401, Ottawa,
Canada; e-mail: information@isstdr.org; www.confersense.ca
International Symposium on Atopic Dermatitis, Rome, Italy, August 29-31, 2003. Contact: Alberto Giannetti,
giannett@unimore.it; Giampiero Girolomini, giro@idi.it
XVIII World Allergy Organization Congress ICACI, Vancouver, Canada, September 7-12, 2003. Contact: Sally Kolf,
611 East Wells Street, Milwaukee, WI 53202, USA; e-mail: congress@worldallergy.org; www.worldallergy.org
Current State on Psoriasis and Naphtalanotherapy, Symposium on Croatian Dermatovenerological Society of the
Croatian Medical Association, Ivaniæ Grad, Croatia, September 19, 2003. Contact: Prof. Jasna Lipozenèiæ, Šalata 4,
10000 Zagreb, Croatia. Tel./Fax: +385-1-4920-014; e-mail: jasna.lipozenèiæ@zg.tel.hr
12
th
Congress of European Academy of Dermatology and Venerology, Barcelona, Spain, October 15-18, 2003.
Contact: Unicongress, Calvet, 55, Baixos, 08021 Barcelona, Spain; e-mail: eadv2003@unicongress.com; www.
eadv.org
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6
th
Tergestinum Symposium on Psoriasis and 2
nd
Alpe Adria Meeting on Psoriasis, Bibione, Italy, November 7-8,
2003. Contact: Organising Secretariat, Via San Nicolo 14, 34121 Trieste, Italy. Tel +39 40 368343, Fax: +39 40
368808
Sexually Transmitted Diseases, Continuing Medical Education. Course organized by the University School of Medi-
cine Zagreb and Croatian Dermatovenerological Society of the Croatian Medical Association, Šubiæeva 9, 10000




Alple-Adria-Danube Congress of Sexually Transmitted Diseases and Infections of the Skin, Prague, Novem-
ber 27-30, 2003. Contact: jana.hercogova@lfmotol.cuni.cz
3
rd
World Congress of the International Academy of Cosmetic Dermatology, Beijing, China, December 7-10, 2003.




World Congress of IACD, Cairo, Egypt, April 12-18, 2004.




International Congress of Dermatology, Beijing, China, May 2004. Contact: ICD2004 Secretariat, Dept. of Foreign




Congress of the European Academy of Allergology and Clinical Immunology, Amsterdam, Netherlands, June
12-16, 2004. Contact: Dept. Allergology, University Hospital Rotterdam, dr. Molewaterplein 40, NL-3015 GD Rotter-
dam, The Netherlands; e-mail: degroot@algo.azr.nl; www.congrex.com/eaaci2004
X World Congress of Pediatric Dermatology, Rome, Italy, July 7-10, 2004. Contact: Triumph Congressi, Via Lucilio,
60, 00136 Rome, Italy; e-mail: dermo@gruppotriumph.it; www.gruppotriumph.it
American Academy of Dermatology, Academy ’04, New York, USA, July 28-August 1, 2004.
13
th
Congress of the European Academy of Dermatology and Venerology, Florence, Italy, November 17-21, 2004.
Contact: e-mail: president@eadv2004.org; info@eadv2004.org
10
th
World Congress on Cancers of the Skin, Vienna, Austria, March 19-23, 2005. Contact: Elfriede Pomp, Depart-




World Congress on Melanoma, Vancouver, B.C., Canada, September 2-9, 2005. Contact: Venue West Conference
Services Ltd., Vancouver, B.C., Canada; e-mail: congress@venuewest.com
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